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The impact of randomized controlled trials is frequently diminished by disparate outcome 
reporting, precluding the comparison of results between trials or synthesis of data in meta-
analyses. This is particularly problematic in lower incidence conditions such as 
Oropharyngeal squamous cell carcinoma (OPSCC), where the need to synthesise data from 
competing trials is greater. Minimum outcome reporting standards, known as Core 
Outcome Sets (COS) have been shown to increase the consistency of outcome reporting 
between trials of comparable interventions, thus facilitating the comparison or synthesis of 
trial data.  
 
The objective of the work in this thesis was to identify outcomes of importance to patients, 
carers and healthcare professionals and define a COS for OPSCC. The methods used 
comprised a systematic review of OPSCC RCTs to identify the outcomes reported and 
establish whether there was outcomes heterogeneity as suggested by other studies; semi-
structured qualitative interviews with patients and carers to establish their outcomes of 
importance; a Delphi Study of patients, carers and healthcare professionals, to reach 
consensus on the outcomes that should be included in a COS for OPSCC.  
 
The systematic review described in chapter two identified significant heterogeneity in 
outcome reporting; 58 outcomes were reported in 43 RCTs, only three outcomes were 
measured in more than 50% of studies, and only 41% of outcomes were measured in more 
than one study. The qualitative study identified 136 outcomes. Survival and late adverse 
effects of treatment are of greatest priority to patients and carers. The Delphi study 
successfully reached consensus on eight outcomes for inclusion in the COS. 
 
There is substantial heterogeneity in the outcomes measured in contemporary RCTs in 
OPSCC. Yet, there is strong consensus between stakeholder groups in the outcomes of 
importance. Implementation of the COS will increase the consistency of outcome 
reporting thus facilitating the comparison of data from competing trials and synthesis of 
data in meta-analyses.  
 
Further consideration must be given to ways in which the uptake of COS can be 
maximised to have the highest impact. The COS is applicable to trials of interventions 
used in current clinical practice, however the advent of new treatment strategies may 
require that this is reviewed and adapted. 
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Chapter 1 
Introduction and background
 
 
1.1 Squamous cell carcinoma of the head and Neck 
 
Head and Neck Squamous cell carcinomas (SCCHN) are a biologically diverse 
group of cancers affecting the mucosal surfaces of the upper aero-digestive tract. 
Sub-sites include the oral cavity, oropharynx, nasopharynx, hypopharynx and 
larynx [1, 2]. For individual sub-sites, the incidence of these cancers is relatively 
low, however, as a group, SCCHN is the sixth most incident cancer worldwide [3].  
 
Loco-regional spread to the cervical lymph nodes at presentation is common, and 
associated with a poorer prognosis. Patients with distant metastatic spread are 
generally treated in a palliative capacity. Those with disease recurrence have a 
poor prognosis and the treatment options depend largely on the treatment already 
received for the primary tumour. The median survival of patients with recurrent or 
metastatic SCCHN in most series’ is six to nine months depending upon patient 
and disease-related factors [4]. 
 
Treatment of SCCHN relies on radiotherapy (RT), surgery +/- post-operative RT or 
cisplatin based chemoradiotherapy (CRT), CRT alone or following induction 
chemotherapy. Multimodality treatment  is usually required for disease control and, 
increasingly, small molecule adjuvants are now being used [5].  
 
The complex anatomy and functions of the upper aero-digestive tract mean that 
radical treatment to this area is associated with variable, but often significant and 
complex functional deficits. Speech and swallowing are predominantly affected but 
aesthetic changes are also a concern for many patients and consequently, treatment 
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can have a profound effect on a person’s quality of life, social interactions, 
relationships and employment [6].  
 
There are significant geographical variations in the incidence and primary site of 
SCCHN, likely reflecting the prevalence of known risk factors as well as genetic 
and ethnic predisposition amongst populations [4]. In the developed world, tobacco 
smoking and alcohol consumption are the most important risk factors, which often 
act synergistically, and, by repeated exposure, causing “field cancerization” in the 
mucosa of upper aero-digestive tract [1]. There is a dose-response relationship; 
with a higher relative risk of developing SCCHN in longer-term smokers. This 
declines upon cessation of smoking  [7, 8]. Persistent smoking increases the risk of 
early and late adverse effects of treatment and compromises long-term disease 
control and overall survival [9]. A decrease in the incidence of laryngeal SCC has 
correlated with a reduction in the prevalence of tobacco smoking, yet in the 
oropharynx subsite, SCC is increasing [10].  
 
SCCHN is more common in socio-economically disadvantaged groups [11-13]. 
This has been attributed to increased consumption of tobacco and alcohol in 
patients with lower socio-economic status (SES) [11], however other theories 
include exposure to toxic chemicals [14], increased exposure to human 
papillomavirus (HPV) [15], differences in diet [16-18] and poorer oral hygiene 
[19]. Lower SES is also associated with poorer outcomes [20-23]. Data from the 
United States have shown that those without private medical insurance are at 
increased risk of death after a diagnosis of SCCHN when compared with patients 
with private insurance, after adjustment for age, gender, race, smoking, alcohol 
use, site, socioeconomic status, treatment, and cancer stage [24]. Psychosocial 
support is extremely important in patients going through treatment for SCCHN. A 
2013 analysis of SEER (Surveillance, Epidemiology and End Results) data by 
Aizer et al. [25] of 1,260,898 patients diagnosed with lung, colorectal, breast, 
pancreatic, prostate, liver/intrahepatic bile duct, non-Hodgkin lymphoma, head and 
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neck, ovarian and oesophageal cancer showed that married patients were less likely 
to present with metastatic disease (adjusted odds ratio [OR], 0.83; 95% CI, 0.82 to 
0.84; P < .001), more likely to receive definitive therapy (adjusted OR, 1.53; 95% 
CI, 1.51 to 1.56; P < .001), and less likely to die as a result of their cancer after 
adjusting for demographics, stage, and treatment (adjusted hazard ratio, 0.80; 95% 
CI, 0.79 to 0.81; P < .001) than unmarried patients. These associations remained 
significant when each individual cancer was analyzed (P < .05 for all end points 
for each malignancy), however married patients with head and neck cancers 
displayed the greatest relative reduction in cancer death (33%). For a number of 
cancer sites including head and neck, the survival benefit associated with marriage 
was larger than the published survival benefit of chemotherapy.  There are likely to 
be many reasons for this effect; married patients are more likely to have better 
access to healthcare [26], marital status may also impact stage at diagnosis as 
patients with a spouse may be encouraged to seek medical attention for worrisome 
symptoms [25], spouses may also encourage patients to undergo definitive versus 
expectant management [27]. Psychosocial support allows patients to share the 
emotional burden of a cancer diagnosis. Patients who are married display less 
distress, depression and anxiety [28]. The spouse, family members and/or close 
friends often play a central role in the care of the patient with OPSCC. The 
morbidity associated with radical multi-modality therapy means that patients are 
often unable to carry out many of their normal activities and require assistance 
with some of the most basic functions including self-care and meal preparation. 
Those close to the patient are often the ones to seek medical assistance on behalf of 
the patient if required. Probably the most significant reason for marital status 
conferring survival advantage is that married patients have better adherence with 
prescribed treatments [29] and in SCCHN missed or delayed radiation treatment is 
associated with increased rates of loco-regional recurrence and death [30].   
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1.2 Oropharyngeal squamous cell carcinoma 
 
National cancer registries in the United Kingdom have recorded a doubling in the 
incidence of Oropharyngeal Squamous Cell Carcinoma (OPSCC) over the last 
decade, and this trend is mirrored in Northern Europe, the USA and Australasia 
[31-35]. Oncogenic human papillomavirus genotype 16 (HPV-16), has been 
attributed as the cause for this increase in incidence worldwide, with the National 
Cancer Institute in the US estimating a 225% increase in HPV-positive OPSCC 
between 1988 and 2004, and a 50% reduction in the incidence of HPV-negative 
OPSCC [36].  
 
It seems that the attractive proposition of an epidemic caused by a single 
aetiological agent may not be so simple. A recently published multicentre cross-
sectional retrospective study of archival tumour tissue blocks, aimed at 
determining the proportion of HPV-positive and HPV-negative OPSCC in the 
United Kingdom between 2002 and 2011, has shown that the proportion of HPV-
positive cases remained static, at around 50%, whilst the overall incidence of 
OPSCC doubled [37]. These results suggest that the rapidly increasing incidence of 
OPSCC in the UK cannot be solely attributed to the influence of HPV. In addition 
to smoking and alcohol consumption, HPV remains an important risk factor for 
OPSCC, although exposure to risk factors and their significance seems to vary by 
population. In the Netherlands, a nationwide study comprising all 16,480 patients 
with oral tongue SCC (OTSCC), oral cavity SCC  (OCSCC) excluding tongue and 
OPSCC, demonstrated similar increases in the incidence of OCSCC and OTSCC as 
for OPSCC [38]. This does not support the assumption that HPV is the main 
contributor to a rising incidence of OPSCC and tobacco and alcohol remain 
important risk factors. Furthermore, Dutch molecular epidemiological evidence of 
HPV DNA positive OPSCC, documented a HPV-positive incidence around 30-
40% over the last decade 26-28 [39-41]. 
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HPV-positive OPSCC occurs in a younger patient cohort than HPV-negative 
disease and confers substantial benefits in terms of survival, with a 58% reduction 
in the risk of death demonstrated by Ang et al. in their analysis of RTOG 0129 
RCT [42-45]. Whilst these patients can be reassured of a five-year survival 
likelihood of greater than 80%, the functional deficits associated with multi-
modality therapy remain substantial [2, 44]. Patients will live longer with the side-
effects of treatment, which are potentially more debilitating, and less acceptable to 
those with young families, long lives and careers ahead of them.  
 
It is likely that the outcomes prioritised by this new cohort of younger, more 
educated patients will differ from older patients with SCCHN related to tobacco 
and alcohol consumption. Prior to the advent of HPV related OPSCC, research 
conducted to establish outcome priorities in SCCHN patients showed that these 
differ between patients of different age groups, and naturally amongst individuals 
with different priorities and expectations. In a study by List et al. in which patients 
with SCCHN were asked to rank outcomes of importance prior to starting 
treatment, pain was a greater priority than cure in older patients compared with 
younger patients [46]. A systematic review published in 2016 which sought to 
establish outcome priorities for head and neck cancer patients could make no 
conclusions about the outcome priorities of OPSCC patients due to significant 
heterogeneity between studies and called for research to establish outcome 
priorities in patients with HPV-positive disease [47]. 
 
Despite the introduction of new therapeutic strategies, the five-year overall 
survival for HPV-negative cancer has remained at approximately 50-60% over the 
last three decades [45, 48]. So whilst clinical trials in HPV-positive OPSCC may 
seek to prioritise functional outcomes, a drive to improve survival remains the 
focus in HPV-negative disease. 
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1.2.1 Treatment strategies 
 
Historically, the treatment of choice for locally advanced OPSCC was open 
surgical resection involving mandibulotomy and reconstruction followed by 
conventional radiotherapy. The surgery, a major undertaking for both the patient 
and medical team, was often associated with significant short and long-term 
dysfunction in speech and swallowing, higher levels of severe complications and 
unacceptable cosmetic defects [49]. In the 1970s and 1980s a number of adverse 
pathological features associated with an increased risk of loco-regional recurrence 
following surgery for SCCHN were identified. These included inadequacy of 
surgical margins around the primary tumour, primary tumour site, advanced T-
stage, perineural invasion, lymphovascular invasion, number and location of 
malignant neck nodes and extracapsular spread [50-54]. The RTOG 73-03 trial 
demonstrated the benefits of post-operative radiotherapy in terms of loco-regional 
control [55]. A subsequent SEER population-based analysis demonstrated a 
survival gain of 10% in patients with adverse pathological features receiving 
adjuvant radiotherapy [56]. In 2005, a pooled analysis of two RCTs from the 
RTOG and EORTC which compared adjuvant post-operative radiotherapy (PORT) 
versus post-operative chemoradiotherapy (POCRT) showed a significantly 
improved survival in patients some adverse pathological features. On the basis of 
this data, POCRT became standard of care for the adjuvant treatment of patients 
with SCCHN with these high-risk pathological features. The majority of patients 
are categorised into this group. Open surgery therefore fell out of use in favour of 
‘organ-sparing’ cisplatin-based chemoradiotherapy regimens [57, 58], the benefits 
of which, over radiotherapy alone, were further demonstrated in the seminal 
MACH meta-analysis [59]. Whilst these regimens are widely considered to be the 
current standard of care for patients with locally advanced OPSCC, they have 
never been directly compared with surgical techniques in a randomized controlled 
trial [60], and a growing body of evidence suggests that long-term swallowing 
function is not necessarily optimised by this choice of treatment strategy [61-64]. 
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The incidence of severe acute toxicity doubles with the addition of chemotherapy, 
this includes treatment related deaths. Higher rates of severe late toxicity are also 
seen compared to PORT alone [65, 66]. 
 
Advances in minimally invasive surgical techniques with the use of transoral laser 
or robotic resection have challenged the status quo, with evidence suggesting that 
functional outcomes are superior, without compromise in oncological outcomes 
[67-69].  
 
The changing aetiology of the disease, improvements to survival and functional 
expectations of patients naturally drive us to question the appropriateness of 
contemporary, radical treatment strategies, and whether de-escalation may achieve 
similar survival outcomes but lower the incidence and severity of post-treatment 
functional deficits. In the UK alone, a number of trials are under way to investigate 
whether such de-escalation is possible. De-ESCALaTE HPV (Determination of 
Epidermal growth factor receptor inhibitor (cetuximab) versus Standard 
Chemotherapy (cisplatin) early And Late Toxicity Events in Human 
Papillomavirus positive oropharyngeal squamous cell carcinoma, NCT01874171) 
compares radiotherapy concomitant cetuximab, an epidermal growth factor 
receptor inhibitor, or cisplatin in patients with low-risk HPV-positive OPSCC with 
toxicity as the primary outcome. The primary outcome of PATHOS (Post-
operative Adjuvant Treatment for HPV-positive Tumours, NCT02215265) is 
patient reported swallowing, measured using the MD Anderson Dysphagia 
Inventory.  
 
The likelihood is that patient stratification and refinement of study populations in 
OPSCC clinical trials based on social, demographic and tumour characteristics will 
continue. The RTOG 0522 trial comparing radiotherapy and cisplatin plus or minus 
cetuximab showed no significant difference in progression-free survival, overall 
survival, loco-regional failure or distant metastasis between the treatment arms, 
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and so these were combined for the correlative analysis. This identified more than 
10 pack-years of cigarette smoking as an independent predictor of poor prognosis; 
other predictors were p16-negative carcinoma, N2b-3 category, T4 tumour, and 
poor performance status. The authors supported a strategy of designing future trials 
for better biologically defined HNC entities. This means, however, that the number 
of patients eligible for a given trial will decrease progressively. To overcome this 
problem, Ang et al. encourage international collaborations to complete patient 
accrual in a timely fashion [70]. 
 
Large multi-centre trials are often complex, expensive and require significant time 
for adequate recruitment, which is often not reached. Registry based RCTs (RRCT) 
have been proposed as an alternative methodological approach to increase the 
efficiency and cost-effectiveness of clinical trials [71]. Large-scale clinical 
registries initiated to assess the quality of clinical performance are, at present, 
successfully collecting data from consecutive patients in many hospitals and 
health-care organizations; Denmark, Sweden, and the UK have some of the most 
complete national databases [72]. Patients can then be randomly allocated with 
most of their required baseline medical history already recorded, minimizing the 
need for additional data collection and onsite monitoring. This concept is the 
foundation for the design of registry-based randomized trials, which may be a 
possibility in the future in SCCHN [73]. 
 
There is significant variation in the incidence and severity of post-treatment 
functional deficits in OPSCC patients, in addition to relatively small numbers, 
tumour biological heterogeneity and variable response to treatment. As such these 
cancers pose particular challenges to researchers when selecting which outcomes to 
measure in trials. However, with individualised therapies becoming more of the 
norm, and therefore the numbers of comparable patients/interventions decreasing 
there is an urgent need to ensure that results can be compared between trials and 
synthesised in meta-analyses. Currently, no outcome reporting standard exists for 
clinical trials in OPSCC to ensure that this happens [74]. 
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1.3 Clinical trials in healthcare 
 
Clinical trials are research studies undertaken for the purpose of assessing the 
safety and efficacy of interventions, treatments or care procedures. Early phase 
clinical trials are often conducted to establish the safety or efficacy of a particular 
intervention and are carried out in a small number of participants. Such efficacy or 
explanatory trials determine whether an intervention can have a beneficial effect in 
an ideal situation under optimum conditions [75]. These tend to precede 
effectiveness trials (or pragmatic trials), which measure the degree of beneficial 
effect under ‘real-world’ clinical settings, conducted following as close to clinical 
practice as possible [76]. 
 
Clinical trials establish the efficacy or effectiveness of an intervention by 
comparing its beneficial and harmful effects on a number of pre-determined 
outcomes (the outcome variables or endpoints). The selection of the most 
important outcomes is therefore essential if research is to inform the evidence base 
for a particular clinical condition or intervention and ultimately influence clinical 
practice. Clinical trial data is used to inform clinical guidelines and shared decision 
making practices and in the development of health policies such as those by The 
National Institute for Health and Clinical Excellence (NICE) [77]. 
 
Randomized controlled trials (RCTs) are seen as the gold standard  for evaluating 
the effects of treatments because they employ more robust methodological 
standards for assessing the effectiveness of interventions in healthcare [78]. RCTs 
used randomised treatment allocation to prevent selection bias by distributing the 
characteristics of patients that may influence assessment of treatment between 
groups [79]. RCTs eliminate selection bias by balancing both known and unknown 
prognostic factors, in the assignment of treatments [80]. Without randomisation, 
treatment comparisons may be prejudiced, whether consciously or not, by the 
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selection of participants of a particular kind to receive a particular treatment. 
Random assignment permits the use of probability theory to express the likelihood 
that any difference in outcome between intervention groups merely reflects chance 
[81]. The final advantage of random allocation is that in some situations it 
facilitates blinding the identity of treatments to the investigators, participants, and 
evaluators which reduces bias after assignment of treatments [82]. Of these three 
advantages, reducing selection bias at trial entry is usually the most important [83]. 
 
In addition to the a priori selection, consistent definition, measurement and 
reporting of outcomes, to provide unbiased estimates of treatment effect, trials 
must follow a predetermined protocol that describes the patients, an appropriate 
method for random allocation, follow up procedures and the statistical methods 
that will be used [84, 85]. As such, the choice of outcomes in clinical trials is an 
important design consideration. 
 
1.3.1 Primary and secondary outcomes 
 
Generally, there should be only one primary outcome, and a limited number of 
secondary outcomes in a clinical trial [85]. The greater the number of outcomes, 
the greater the number of tests undertaken, raising the probability of finding a 
statistically significant result by chance alone [86]. Additionally, this places a 
greater burden on the patients under investigation and the available resources. 
Clinical trials frequently measure more than one primary outcome, either because it 
is unclear which outcome will best answer the research hypothesis or where they 
are thought to be of equal importance. Outcomes may also be added during the 
course of a trial or may not be reported having been pre-specified in the protocol. 
When Smyth et al. interviewed trial investigators, the reasons for omitting pre-
specified outcomes related to data collection being too expensive or complicated, 
as well as there being insufficient time and resources to collect less important 
secondary outcomes [87]. Reasons given for the addition of outcomes were 
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associated with poor research practice and were attributed to shortfalls in the 
writing of the protocol.  
 
The primary outcome of a study should be that which is capable of providing the 
most clinically relevant and convincing evidence directly related to the primary 
objective of the trial. This will usually be an efficacy variable, because the primary 
objective of most confirmatory trials is to provide strong scientific evidence 
regarding efficacy [85]. Effectiveness trials (pragmatic trials) measure the degree 
of beneficial effect under “real world” clinical settings, and the design of an 
effectiveness trial is therefore formulated based on conditions of routine clinical 
practice and on outcomes essential for clinical decisions [88]. 
 
Secondary outcomes evaluate other beneficial or harmful effects of an intervention. 
These may be specific to only some comparisons in the review. For example, 
laboratory tests and other surrogate measures may not be considered as main 
outcomes as they are less important than clinical endpoints in informing decisions, 
but they may be helpful in explaining effect or determining intervention integrity 
[89]. 
 
1.3.2 Types of outcomes 
 
Outcomes can relate to the effect of an intervention on key clinical indices, such as 
survival or disease control; they can also relate to surrogate markers such as 
laboratory tests or physical signs, used as a substitute to a clinical outcome [90]. 
The theoretical advantage of surrogate outcomes is that they may be able to predict 
the benefit of an intervention in advance of clinical outcomes, allowing for smaller 
recruitment to trials or shorter follow-up time. Where urgency dictates, such as in 
cancers with few therapeutic options, surrogate outcomes may allow for 
interventions to be made available to patients more quickly [90]. They are 
commonly employed in clinical trials but many criticisms have been levelled at 
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their use [91-93]. Systematic reviews of oncology clinical trials suggest that the 
strength of association between surrogate endpoints and life extension is generally 
low [94, 95]. Furthermore, drug approvals based on surrogate outcomes are 
frequently not followed up with prove of benefit on outcomes such as survival and 
quality of life. In a retrospective cohort study, Davis et al. analysed EMA oncology 
drug approvals 2009 – 13 to determine the availability of data on overall survival, 
the gold standard primary outcome for oncology trials, and quality of life benefits 
of cancer drugs approved in Europe [96]. This showed that most drugs enter the 
market without evidence of benefit on survival or quality of life, and with a median 
of 5.4 years’ follow up, only 51% were associated with significant improvement in 
survival or quality of life.  
 
Its reliability, straightforward interpretation and clinical usefulness make overall 
survival the gold standard endpoint to measure the effect of treatment in SCCHN 
[97]. Detecting statistically significant differences in this outcomes requires a large 
number of patients and an extended follow-up period and surrogate endpoints are 
therefore commonly employed. The strength of association between these 
surrogate outcomes and overall survival is variable. Loco-regional control and 
event-free survival have been shown to have a strong association with overall 
survival. In 116 treatment comparisons for 22,744 patients Michiels et al. showed 
that for radiotherapy treatment, effects on both duration of loco-regional control 
and event-free survival were strongly correlated with those on overall survival. For 
chemotherapy, correlation coefficients between treatment effects on event-free 
survival and overall survival were larger than those between duration of loco-
regional and overall survival [97]. Response rate is rigidly defined by criteria for 
tumour shrinkage [98, 99] and frequently used to assess the benefit of systemic 
chemotherapy. An initial response to treatment with chemotherapy is common in 
SCCHN, yet this outcome has been consistently shown to have little association 
with survival benefit in studies of SCCHN [100, 101]. In gaining accelerated 
approvals, the U.S. FDA deem that surrogate endpoints may be acceptable, with a 
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sponsor commitment to provide evidence of clinical benefit in a subsequent trial 
[102]. Furthermore, close attention must be paid to reduce the risk of bias when 
using such outcomes; blinding of both patients and investigators to treatment 
assignment may be necessary. In the last couple of decades, accumulating research 
has sought to establish the best methods for validating surrogate outcomes. Whilst 
no consensus exists regarding the standards needed to identify valid surrogates, 
correlation and meta-analytic approaches are the most widely accepted methods 
[103, 104]. The use of surrogate outcomes must be carefully considered, and only 
those chosen for which there is strong evidence of an association with longer term 
outcomes such as survival and quality of life. Where survival between treatment 
arms is equivalent, or there is an assumption of equivalence, outcomes other than 
overall survival may take precedence. This approach has been used in trials of 
laryngeal preservation [105-107] and HPV-positive OPSCC [108]. 
 
Smaller sample sizes, and/or shorter follow up are also permitted by the use of 
composite outcomes, thereby improving statistical efficiency in time to event trials 
[84]. Composite outcomes, in which multiple endpoints are combined, are 
frequently used in clinical trials that are expected to have an effect on mortality and 
major morbidity.  However, methodological issues are often associated with their 
use, as identified in a systematic review by Cordoba et al. who found that trials 
with composite outcomes were often problematic, ‘characterised by a lack of logic 
behind the construction of the composites, inconsistent and unclear reporting, post 
hoc changes to the composites, and cherry picking’ [109]. A substantive risk 
associated with the reporting of composite outcomes is that the benefits described 
may be presumed to relate to all of the components [84]. A relationship must exist 
between the variables of the composite outcome such that they can sensibly be 
added together as being aspects of the same underlying disease process. Ferreira-
González et al [110] make 3 recommendations for use of composite outcomes: they 
should include components that are similar in importance to patients, that occur 
with similar frequency, and that are affected to a similar degree by the intervention. 
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Composite outcomes are frequently employed in clinical trials in SCCHN. Loco-
regional control refers to disease control at the primary site and in the cervical 
lymph nodes; an event may therefore comprise either local or regional disease 
recurrence. The use of this outcome is further complicated by inconsistent 
definitions across the trials using it. In a large systematic review of SCCHN 
randomized trials published in 2009, Le Tourneau et al showed that loco-regional 
control and overall survival account for 70% of primary endpoints, yet, among 72 
endpoints tracking loco-regional failures 29% did not define the term and 64% 
specified the absence of complete response as a failure [111]. As previously 
mentioned, event-free survival is a surrogate outcome shown to have a strong 
association with overall survival in SCCHN trials. In their paper suggesting that 
event-free survival is a more suitable surrogate outcome for SCCHN trials than 
loco-regional control Michiels et al. also noted heterogeneity between trials in the 
definition of these outcomes. They chose to define event-free survival as the time 
from randomisation to the first event of either loco-regional or distant recurrence or 
death from any cause. This outcome, defined as such, was often called disease-free 
survival in trials that included patients with resectable tumours and progression-
free survival in trial that included patients with non-resectable tumours [97].  
 
Patient reported outcomes (PRO) measure how a patient feels or functions and are 
collected directly from the patient without interpretation by anyone else [112]. 
PROs may measure health-related quality of life (HR-QOL), symptoms, 
satisfaction or adherence to medication and help to evaluate the burden of disease 
and treatment from the patients’ perspective [113]. They are often collected using 
measurement tools (PROMs) that assess the patient’s view of their symptoms, 
functional status or quality of life [114]. The measurement of PROs in clinical 
trials has increased substantially in the last 20 years [115]. The same 
considerations must apply to the measurement of PROs in trials as for other 
outcomes, as their inappropriate use or lack of transparency in their measurement 
or reporting could compromise the quality of trial data. With some of these 
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concerns in mind, the CONSORT (Consolidated Standards of Reporting Trials) 
group, whose guidance facilitates the transparent and robust reporting of RCTs, 
published a PRO extension to their guidance that aims to improve the reporting of 
PROs in trials to facilitate the use of results in informing clinical practice and 
health policy [116]. CONSORT is discussed in more detail later in this chapter. 
Many PROMS are available in oncology, several with SCCHN specific extensions. 
There are also PROMS designed for SCCHN specifically, and to measure patient 
symptoms of specific sequelae of treatment.  
 
1.3.3 Outcome domains 
 
Outcome domains are constructs used to classify broad aspects of the effects of 
interventions e.g. functional status. In the context of clinical trials, outcomes from 
multiple domains or multiple outcomes within a domain may be important to 
measure [117].  
 
1.3.3.1 Outcome-related frameworks 
 
Outcome domain models for frameworks exist to provide essential structure to the 
conceptualisation of domains, however in a review of Health Related Quality of 
Life (HRQOL) models, Bakas et al. found that there were wide variations in 
terminology for analogous HRQOL concepts [118]. Some of the frameworks to 
classify health, disease and outcomes are described below. 
 
World Health Organisation (WHO) 
The WHO is responsible for developing a number of frameworks related to health 
outcomes. In 1948, the WHO defined health as a construct comprising three 
domains: physical, mental and social wellbeing [119]. They do not however 
specify what should be included within each of these domains [120] and this 
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definition is considered out of date by some given the rise in chronic diseases 
[121].  
 
The International Classification of Functioning, Disability and Health (ICF), 
endorsed by WHO (member states) in 2001, provides a framework for classifying 
health and health-related domains for measuring health and disability at both 
individual and population levels. This was developed as a globally accepted 
framework and classification system based on a bio-psycho-social model to assess 
and compare functional outcomes [122]. The ICF-classification contains more than 
1,400 categories. To make these applicable to every-day clinical practice, ICF core 
sets have been established. The ICF core set for head and neck cancer serve as 
minimal standards for the assessment and documentation of functioning and health 
of persons with SCCHN in clinical studies, clinical encounters and multi-
professional comprehensive assessment. Although the ICF is widely 
comprehensive, it is not all inclusive. For example, the ICF does not include 
outcomes such as death, an outcome that is especially important to measure in 
clinical trials investigating treatments for life threatening illnesses such as cancer. 
Furthermore is has not been widely adopted and is not used by cancer registries. 
 
Patient-reported Outcomes Measurement Information System (PROMIS) 
PROMIS (Patient-Reported Outcomes Measurement Information System) is a set 
of person-centred measures that evaluates and monitors physical, mental, and 
social health in adults and children [123]. It can be used with the general 
population and with individuals living with chronic conditions. The PROMIS 
domain framework builds on the WHO definition of health to provide subordinate 
domains beneath the broad headings in the definition of health: physical 
(symptoms and functions), mental (affect, behaviour and cognition) and social 
wellbeing (relationships and function). 
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5Ds 
This framework for representing patient outcomes was developed specifically for 
rheumatic diseases and is presented as a systematic structure for representation of 
patient outcomes including five dimensions: death, discomfort, disability, drug or 
therapeutic toxicity and dollar cost [124]. 
 
Wilson and Cleary 
Wilson and Cleary propose a taxonomy for different measures of health outcomes 
and specific causal relationships between them that link traditional clinical 
outcomes to measures of health-related quality of life [125].  
 
The Outcome measures in rheumatology (OMERACT) Filter 2.0 
The OMERACT Filter 2.0 is a conceptual framework for the measurement of 
health conditions in the setting of interventions comprising three core areas: death, 
life and impact and pathophysiological manifestations [120]. A measurement of 
resource use is also strongly recommended. They recommend that the ICF domains 
are also considered under life impact (ICF domains: activity and participation) and 
pathophysiological manifestations (ICF domains: body function and structure). 
OMERACT recommends the inclusion of at least one outcome reflecting each core 
area in COS, however this may not always be appropriate [126]. 
 
Outcome Measures Framework (OMF) 
This project was funded by the Agency for Healthcare Research and Quality (a 
branch of the U.S. Department of Health and Human Services) to create a 
conceptual framework for development of standard outcome measures used in 
patient registries [127]. This comprises three broad domains: characteristics, 
treatments and outcomes, with six subcategories within the outcome domains: 
survival, disease response, events of interest, patient/caregiver-reported outcomes, 
clinicians-reported outcomes and health system utilisation.  
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Survey of Cochrane reviews 
Cochrane reviews were analysed by Smith et al. to identify whether similar 
outcomes were measured across different disease categories [128]. Fifteen 
categories of outcomes were prominent across Cochrane review groups: adverse 
events of effects, mortality/survival, infection, pain, other physiological or clinical 
psychosocial, quality of life, activities of daily living, medication, economic, 
hospital, operative, compliance (with treatment), withdrawal (from treatment or 
study) and satisfaction (patient, clinician, or other health care provider). 
 
1.3.4 Outcome selection in clinical trials 
 
The outcomes measured will depend on the clinical condition, the research 
question and the intervention being assessed. Trialists must bear in mind the 
clinical relevance of an outcome, whether it is responsive to the interventions being 
compared, how it is assessed, and whether it is appropriate and practicable given 
the time and financial constraints of the trial and the nature of the clinical 
condition.  
 
The heterogeneity of outcome reporting in clinical trials is a significant barrier to 
the synthesis of individual trial data. Meta-analyses are frequently unable to make 
firm conclusions about the effectiveness of interventions because comparable trials 
don’t use comparable outcomes, or define or measure them in the same way. The 
five most accessed Cochrane reviews in 2009, together with the top cited review in 
that year, all described inconsistencies in the outcomes reported in eligible trials 
and a call for the standardization of outcomes is a regular conclusion of systematic 
reviews [129]. Clinical guidelines and recommendations are based on this evidence 
and otherwise well conducted trials may have little to contribute to this evidence 
base if the outcomes reported are inconsistent with those in comparable trials. 
Research findings may also have little application in the real world if the outcomes 
reported are not clinically relevant or are of little value to patients. Consistent 
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outcome selection in trials in a particular clinical area has the potential to improve 
the quality of research by allowing for results between trials to be more easily 
compared and combined [130]. Kirkham et al. demonstrated an increase in the 
consistency of outcome measurement in clinical trials in rheumatoid arthritis (RA) 
in the years following the publication of the RA COS [131]. 
 
1.3.4.1 The effect of bias in outcome selection and reporting 
 
Well-designed randomized controlled trials will specify the outcomes to be 
measured in their study protocol and adhere to reporting these irrespective of the 
results. The failure to report all pre-specified outcomes in a clinical trial can 
introduce a type of bias known as outcome reporting bias (ORB). This is the 
selective reporting or ‘cherry-picking’ of the outcomes to be reported from those 
measured in the course of a trial, because of the results [132]. This kind of bias 
affects not just the interpretation of the individual trial but also any subsequent 
systematic review of the evidence base that includes it [133] and raises serious 
questions about the legitimacy of the research and possibly the integrity of the 
researchers [87].  
 
In a review by Kirkham et al. investigating ORB in an unselected cohort of 283 
Cochrane reviews, more than half of the reviews did not include full data for the 
review primary outcome of interest from all eligible trials [134]. Of the 42 meta-
analyses with a statistically significant result only, eight (19%) became non-
significant after adjustment for outcome reporting bias and 11 (26%) would have 
overestimated the treatment effect by 20% or more. This study is likely to 
underestimate the effect of outcome reporting bias because it looked only at 
primary outcomes. Secondary outcomes are more likely to be changed than 
primary outcomes as they are usually of less clinical importance. 
 
20 
 
 
 
 
In a related study, Smyth et al. conducted a systematic review and series of 
interviews with trialists to establish the frequency of and reasons for ORB [87]. 
The prevalence of incomplete outcome reporting was high, and trialists seemed 
generally unaware of the implications for the evidence base of not reporting all 
outcomes. A general lack of consensus regarding the choice of outcomes in 
particular clinical settings was evident and this had an impact upon trial design, 
conduct, analysis, and reporting. Issues such as missing data, delays in data 
collection and concerns about the validity of trial results render study outcomes 
more likely to remain unreported [87]. Chan et al. have suggested this may arise 
because researchers did not feel that some results were of any clinical relevance or 
statistical significance [135, 136].  
 
Publication bias is a further type of bias to affect clinical trials and meta-analyses 
[137-139]. This arises when studies are published or not depending on their results 
and has been well demonstrated in the medical literature [140, 141]. Empirical 
research consistently suggests that published work is more likely to be positive or 
statistically significant than unpublished research [142]. Study publication bias will 
lead to an overestimation of treatment effects and has been recognised as a threat to 
the validity of meta-analyses [139]. Furthermore, research without statistically 
significant results takes longer to achieve publication than research with significant 
results, giving rise to “time-lag bias” [143]. 
 
To circumvent these problems with outcome selection and reporting, trialists, trials 
methodologists and systematic reviewers have, for some time, supported the 
development of outcome reporting standards for clinical trials, specific to clinical 
conditions or areas of healthcare. Such standardisation would facilitate the 
comparison and synthesis of individual trial data and improve the efficiency of 
research. 
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1.3.4.2 Outcomes standardisation and Core Outcome Sets 
 
World Health Organisation (WHO) 
The concept of outcomes standardisation in clinical trials was first proposed by the 
World Health Organisation (WHO) in 1981 [144] . A series of consensus meetings 
between 1977 and 1979 established that, as a minimum standard, clinical trials in 
oncology should measure the response of the tumour and metastases, duration of 
response to treatment and acute and long-term adverse effects of therapy.  
 
Outcome measures in rheumatology (OMERACT) 
Out with the field of cancer clinical trials, the OMERACT (Outcome Measures in 
Rheumatology) collaboration has made the most notable advances in outcomes 
standardisation. OMERACT is an independent initiative of international health 
professionals interested in outcome measures in rheumatology, and whose aim is to 
improve outcome measurement in rheumatology through the development and 
implementation of Core Outcome Sets  (COS) through ‘data driven’ consensus 
processes involving relevant stakeholder groups [145]. Although initially limited to 
improving outcome measurement in clinical trials in rheumatoid arthritis, 
OMERACT’s remit has expanded across the spectrum of rheumatology 
intervention studies and they have developed a conceptual framework for 
developing COS in rheumatology [146].  
 
IMMPACT (The Initiative on Methods, Measurement, and Pain Assessment 
in Clinical Trials) 
IMMPACT aims to develop consensus reviews and recommendations for 
improving the design, execution and interpretation of clinical trials of treatments 
for pain in adults and children [147].  
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HOME (Harmonising Outcome Measurement for Eczema) Initiative 
The HOME (Harmonising Outcome Measurement for Eczema) Initiative is an 
international group working to develop COS to include in all eczema trials [148]. 
 
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative 
The COMET Initiative (www.comet-initiative.org) was founded in 2010 with the 
aim of facilitating the development and application of Core Outcome Sets (COS) in 
all areas of healthcare. It defines a COS as ‘an agreed standardised set of outcomes 
that should be measured and reported, as a minimum, in all clinical trials in 
specific areas of health or health care’ [117]. The consistent use of COS in clinical 
trials has the potential to increase the evidence base for a particular condition or 
intervention by allowing results to be compared and combined as appropriate; 
contributing more data for meta-analyses. COS have the added benefit of ensuring 
that data from even small studies are not wasted. This is particularly important for 
less common conditions such as OPSCC, where study populations are already 
being refined on the basis of biologic tumour features.  
 
COMET’s specific objectives are to [149]: 
 
1. Raise awareness of current problems with outcomes in clinical trials 
2. Encourage COS development and uptake 
3. Promote Patient and Public Involvement (PPI) in COS development 
4. Provide resources to facilitate these aims 
5. Avoid unnecessary duplication of effort 
6. Encourage-evidence based COS development 
 
The COMET initiative website houses a database which is a repository of studies 
relevant to the development of COS. Website and database usage have increased 
significantly over time reflecting the growing interest in this field [150, 151]. The 
Cochrane collaboration and the National Institute for Health Research, the largest 
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funder of healthcare research in the UK, advocate the use of COS, and, in their 
grant applications, the NIHR Health Technology Assessment funding body asks 
that COS be used if they exist in the area of healthcare to which the trial applies 
[152]. Furthermore regulatory bodies [153, 154] and journal editors [155]  are now 
calling for the use of and/or development of COS. 
 
1.3.4.3 Patient inclusion in choosing the outcomes measured in trials 
 
Until relatively recently, patients were seldom involved in trial design or in making 
recommendations for the outcomes of importance. One of the first groups to 
integrate patients into this process was OMERACT. Patient involvement in 
outcome selection was initially proposed at the OMERACT meeting in 2000, when 
clinicians struggled to answer the question of what would be defined as a 
‘clinically important change’ in response to treatment. Patient involvement in 
subsequent OMERACT meetings helped to enrich the research agenda by 
identifying novel outcomes and instruments of relevance [156]. New outcomes, of 
significant value to patients, were identified and integrated into the core set for 
rheumatoid arthritis (RA) clinical trials. 
 
A number of groups in the UK now value patients as major stakeholders in setting 
the research agenda and in contributing to decisions about which outcomes should 
be measured in clinical trials. The James Lind Alliance (http://www.jla.nihr.ac.uk) 
brings patients, carers and clinicians together in Priority Setting Partnerships 
(PSPs) to identify and prioritise the Top 10 uncertainties or unanswered questions 
about the effects of treatments. Their aim is to make sure that health research 
funders are aware of the issues that matter most to patients and clinicians. 
INVOLVE (http://www.invo.org.uk) is a national advisory group whose role is to 
bring together expertise, insight and experience in the field of patient and public 
involvement (PPI) in research, with the aim of advancing PPI as an essential part 
of the process by which research is identified, prioritised, designed, conducted and 
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disseminated. The Core Outcome Measures in Effectiveness Trials (COMET) 
initiative have launched the People and Patient Participation, Involvement and 
Engagement (PoPPIE) working group to lead and oversee the public participation, 
involvement and engagement work of the COMET initiative in promoting and 
facilitating Core Outcome Set (COS) development and uptake [157]. 
 
1.3.4.4 Improving the transparency of clinical trial reporting 
 
The Consolidated Standards of Reporting Trials (CONSORT) statement is a set of 
recommendations for the reporting of randomized trials in healthcare [158]. 
Published in the 1990s, it sets out the essential items that should be included in 
reports of RCTs, aimed at primary reports of RCTs with two group, parallel 
designs. The content of CONSORT focuses on items related to the internal and 
external validity of a trial. The main aim of CONSORT is to provide guidance to 
authors about how to improve the reporting of their trials, and whilst not originally 
intended as a quality assessment instrument it may allow readers, peer reviewers 
and editors to critically appraise and interpret reports of RCTs [159]. The 
CONSORT guidelines have been updated twice since their inception [159, 160] 
and there are many trial design specific extensions and specifically one for the 
reporting of patient reported outcomes [116]. A 2012 Cochrane review to assess 
the impact of the use of the CONSORT statement on completeness of reporting of 
RCTs published in medical journals suggested that journal endorsement of 
CONSORT may benefit the completeness of reporting of RCTs they publish. 
However, despite relative improvements when CONSORT is endorsed by journals, 
the completeness of reporting of trials remains sub-optimal. Fidelity of 
endorsement by journals has been weak to date [161]. 
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1.4 Rationale for the work in this thesis 
 
There is strong evidence that heterogeneity of outcome reporting in effectiveness 
trials hampers the synthesis of trial data in meta-analyses in oncology [162-165]. 
Variability in how outcomes are defined or measured can make it difficult or 
impossible to synthesise and apply the results of different research studies [166]. 
The outcomes selected are often not those that are regarded as important by 
patients [167] and different reporting methods and study outcomes create high data 
redundancy and costs [168]. These methodological problems lead to delays in 
establishing the relative effectiveness of interventions and, a frequent conclusion of 
systematic reviews and meta-analyses in SCCHN and OPSCC is a call for greater 
consistency in the outcomes measured in comparable trials [100, 169-171].  
 
A series of Cochrane reviews of interventions for the treatment of oral cavity and 
oropharyngeal cancer published between 2010 and 2011 found a number of 
problems with outcome reporting. The review of radiotherapy interventions found 
that adverse events  were  poorly reported and the authors concluded that ‘more 
accurate methods of reporting adverse events are needed in order to truly assess the 
clinical performance of different radiotherapy regimens’ [170]. The review of 
chemotherapy interventions originally sought to evaluate the benefits of 
chemotherapy in addition to loco-regional treatments, against the potential increase 
in the adverse effects of treatment associated with toxicity [169]. However, 
toxicities and adverse events were often reported as numbers of events rather than 
numbers of patients with adverse events, and there was considerable variation in 
the way harms were reported. As such, there was so little quantitative data in the 
reports regarding harms associated with treatment, the protocol had to be modified 
to report only the benefits associated with chemotherapy, in terms of survival and 
response to treatment. This is an important omission, given the known increased 
toxicity associated with the addition of chemotherapy [172]. Furthermore, the 
authors commented that ‘The large quantity of research on chemotherapy focused 
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on finding better treatments that prolong overall survival, disease free survival and 
progression free survival. Quality of life is inconsistently reported in trials which 
address a primary outcome of overall survival’. The review of surgical 
interventions by Bessell et al. [171] found the overall quality of the evidence to be 
poor, with all included studies having either a high or unclear risk of bias. This is 
less surprising in the context of trials in surgery where it is both difficult and 
possibly unethical to blind trial participants. There was little data in the included 
studies regarding the patients’ HRQOL which made it difficult to fully assess the 
benefits and harms of the different surgical procedures. A 2016 Cochrane review 
by Howard et al. of minimally invasive surgery (Trans-oral laser microsurgery or 
Trans-oral robotic surgery) versus radiotherapy/chemoradiotherapy for small-
volume primary OPSCC found that no completed studies met the inclusion criteria 
for the review. There is currently no high-quality evidence from RCTs regarding 
clinical outcomes for patients with OPSCC receiving minimally invasive surgery 
compared with primary chemoradiotherapy [173]. The MACH meta-analysis, 
perhaps the most seminal meta-analysis in SCCHN, which looked at the benefits of 
adding chemotherapy to loco-regional treatment found that clinical heterogeneity 
and trial design were significant barriers to establishing conclusions regarding 
effectiveness [100].  
 
The aim of this research was to develop a COS for clinical trials in OPSCC. At the 
induction of this research, I intended to develop a COS for clinical trials in all 
SCCHN subsites. However, it soon became clear that reaching consensus on 10 or 
fewer outcomes of key importance would be difficult, and probably futile because 
of the heterogeneous nature of the disease. As already discussed, tumours arising 
from different anatomical sub-sites - and even between individuals with tumours at 
the same sub-site, exhibit substantial differences in tumour behaviour, response to 
treatment and choice of treatment strategy. These differences provide challenges 
when choosing which outcome to measure in clinical trials in SCCHN; the 
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outcomes important to someone with laryngeal cancer may not be the same as or 
even relevant to someone with an oral cancer.  
 
The rising incidence of OPSCC, in a younger population and the associated rise in 
de-escalation trials in this area prompted us to focus our efforts on developing a 
core outcome set for OPSCC. Furthermore, the changing patient demographic 
caused us to question whether the short- and long-term outcomes associated with 
contemporary treatment strategies were deemed acceptable to patients, who will 
live for longer with adverse effects of treatment and therefore may have higher 
functional and HR-QOL expectations. We wished to understand which outcomes 
were important to patients when survival became less of an uncertainty.  
 
The importance of this decision was underlined by discussions with our Head and 
Neck cancer multi-disciplinary team, and, in particular, speech and language 
therapists. There was an acute recognition that future treatment strategies would 
need to ensure better functional outcomes for long-lived survivors.  
 
A 2016 systematic review by Blanchard et al. which aimed to establish outcomes 
priorities for patients with SCCHN found that studies relating to OPSCC were 
heterogeneous in both design and endpoints, complicating the ability to draw 
meaningful conclusions about which outcomes of treatment OPSCC patients 
prioritise [174]. This study emphasized the need for future research to harmonize 
outcome measurement. 
 
The focus of the work undertaken in this thesis is to address issues of outcomes 
heterogeneity and poor quality outcome reporting by developing a COS for clinical 
trials in OPSCC. I will do this using methodology advocated by the COMET 
initiative, and in particular, the following questions will be explored: 
 
 Is outcomes heterogeneity a problem in contemporary RCTs in OPSCC 
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 Which outcomes are measured in contemporary RCTs in OPSCC 
 Which outcomes are important to patients and healthcare professionals 
 Is there consensus regarding the outcomes of importance 
 
This research study was entitled The CONSENSUS (Squamous Cell CarcinOma of 
the OropharyNx: Late PhaSE CliNical TrialS; Core OUtcomeS) study, and this 
name was used in all study literature and presentations and publications arising 
from the research. 
 
1.4.1 Aims and objectives  
 
1.4.1.1 Aims 
 
1. To develop a COS for use in OPSCC clinical effectiveness trials including both 
patients’ and healthcare professionals’ perspectives 
2. To investigate patient experiences of OPSCC 
 
1.4.1.2 Objectives 
 
a. Develop a comprehensive list of outcomes of OPSCC informed by the 
literature and qualitative interviews with patients 
b. Use the list to develop a questionnaire to survey patients and healthcare 
professionals on the importance of each outcome 
c. To use qualitative interviews to understand the patients’ experiences of living 
with OPSCC 
d. Identify the outcomes most important to patients and healthcare professionals 
(COS) using Delphi consensus methods 
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1.4.2 Methodological approaches in COS development  
 
At the outset of this research, no formal guidance existed for those wishing to 
develop COS. A number of different methodological approaches had been taken by 
different COS developers. Although, now superseded by the COMET handbook, 
published in 2017 [117], in 2012 Williams et al. made recommendations for the 
important issues to consider when developing a COS which informed the work in 
this thesis [152]. This included: 
 
1. Identifying existing knowledge  
2. Establishing the scope of the COS 
3. Stakeholder involvement 
4. Use of consensus methods  
 
In the COMET handbook [117], this has been expanded upon, and a four-stage 
COS development process is now recommended: 
 
Step 1. Define the scope of the COS 
 
Step 2. Check whether a new COS is needed 
       Register the COS in the COMET database 
 
Step 3. Develop a protocol for the development of the COS – the ‘what’ to measure 
 
Step 4. Determine ‘what to measure’ 
(i) Identify existing knowledge  
(ii) Fill gaps in knowledge if needed 
(iii) Elicit views about important outcomes in a consensus process 
(iv) Hold a face to face meeting to finalise the recommended COS 
(v) Report the work using the COS-STAR guidance 
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A further step, beyond the scope of identifying ‘what to measure’ advises on steps 
to take to determine ‘how to measure’ (Step 5) the COS. Throughout the COS 
development process and once it is published, implementation must be considered 
and uptake assessed. The COS must be reviewed and updated as necessary. 
 
As our COS was developed prior to publication we made the following 
considerations in line with the available recommendations at the time: 
 
Identifying existing knowledge 
One of the objectives of COMET is to avoid duplication of COS research, and by 
holding a regularly updated database of COS studies, they can advise potential 
COS developers on whether a COS already exists or is in development in a 
particular clinical area. This is also directly searchable via the COMET database 
[175]. A review of previous trials or a systematic review in the area can provide 
evidence of the need for a COS and also identify a list of potential outcomes [176]. 
We consulted the COMET database and the COMET study team at the outset of 
this research to establish whether there were any existing COS for clinical trials in 
SCCHN or OPSCC or any registered projects aimed at developing COS for 
SCCHN or OPSCC. We also performed scoping searches of the literature in case 
any important work had been missed by the COMET database developers.  
 
Establishing the scope of the COS 
Most COS apply to a clinical condition, however, they may be more specific than 
this and apply to, for example, glue ear in children with cleft palate [177]. 
Similarly they may apply to all interventions or only specific ones, for example to 
surgery for colorectal cancer, but not other interventions [178]. It is important to 
establish from the outset to which patients, interventions and clinical condition(s) 
the COS will apply as this will almost certainly affect how the research to identify 
the key outcomes for the COS is conducted. 
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Our COS was limited to late phase clinical trials of interventions available at the 
time of designing the COS, namely surgery, radiotherapy, chemotherapy and 
immunotherapy. The COS was designed for trials with curative intent in HPV-
positive and HPV-negative patients. We felt that the outcomes of most importance 
for trials of interventions in patients with recurrent or metastatic disease were 
likely to be different to those in primary disease, with interventions of curative 
intent.  
 
COS are not necessarily comprehensive. The outcomes identified should represent 
the minimum that should be measured and reported. Additional outcomes are 
encouraged and should be chosen at the discretion of the trials team bearing in 
mind the circumstances of the study. A COS containing many outcomes may be a 
barrier to implementation in clinical trials as this will increase outcome 
measurement, and in all likelihood, the resources required and the cost of the trial. 
 
The first stage in COS development is to identify the outcomes that should be 
measured, once this is established, research to identify how these outcomes should 
be measured can be undertaken. The COMET initiative facilitates collaborations 
between COS developers and COSMIN (Consensus-based Standards for the 
selection of health Measurement Instruments.) who make recommendations about 
‘how’ the identified outcomes should be measured [179]. COSMIN aims to 
improve the selection of outcome measurement instruments (OMIs), and has 
developed methodological standards for studies on the measurement properties of 
OMIs [180]. 
 
Stakeholder involvement 
Key stakeholders should be identified and invited to participate in deciding which 
outcomes should be included in the COS. They may be participants in identifying 
possible outcomes and/or in consensus exercises to prioritise the contents of the 
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COS. Key stakeholders will almost always include patients and healthcare 
professionals with knowledge of the clinical condition, but this could also include 
regulators, industry representatives and researchers. 
 
COMET differentiates between patient and public participation in research and 
patient and public involvement (PPI). Research participants take part in research 
which is “to”, “about” or “for” them. In contrast, PPI refers to research where 
patients are involved in designing the study; where research is ‘being carried out 
“with” or “by” members of the public [181] 
 
Patients, carers and healthcare professionals were all involved in this study, both as 
research participants and in facilitating certain methodological decisions, and 
providing guidance on certain aspects of study conduct. In seeking to identify a list 
of possible outcomes to be included in the COS we undertook a series of 
qualitative interviews with OPSCC patients and carers and in ratifying the contents 
of the COS through consensus methods we involved OPSCC patients, carers and a 
number of different types of healthcare professional. COMET’s PPI co-ordinator, 
Heather Bagley, advised on patient and carer information sheets and on some of 
the qualitative aspects of the study. I chose not to interview healthcare 
professionals as I felt the systematic review would adequately identify outcomes of 
importance to healthcare professionals. In most cases, it is unlikely that a diversity 
of healthcare professionals will be involved in outcome selection in clinical trials, 
as discussed in the relevant chapter, the use of consensus methods amongst a 
diversity of healthcare professionals allowed us to identify differences in the 
outcomes prioritised by the different stakeholder groups. 
 
Use of consensus methods 
For any condition, there are likely to be multiple outcomes that could be included 
in a COS, and stakeholders may differ in their opinions about which outcomes to 
include. For these reasons, group consensus methods are frequently employed to 
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both elicit opinion on outcomes of importance and refine a long list of possible 
outcomes to an agreed list of around ten or less for the COS. Expert panel 
meetings, sometimes using nominal group techniques, and Delphi studies are the 
methods used in previous COS studies to elicit opinions and develop consensus 
[152]. The ability of the method to achieve true consensus amongst a diverse range 
of stakeholders with methodological rigour is the most important consideration. 
However, one must also bear in mind factors such as practicality and cost.  
 
The nominal group technique employs a highly-structured face-to-face meeting of 
relevant stakeholders to both elicit opinion and reach consensus on a given topic. 
Meetings usually comprise 5-9 stakeholders and last around 2 hours [182]. 
Stakeholders are coordinated by a facilitator to ensure participation by all. 
Although the specifics will vary for different purposes, that used in healthcare 
seems to follow a similar pattern to that described by Potter et al [182]. In the first 
stage of the process participants are introduced and an explanation is given of the 
purpose of the session. Information sheets may be given and consent taken along 
with the setting of ‘ground rules’ around confidentiality, respect and protection of 
participants’ identity [183]. This is followed by the ‘silent generation of ideas’ in 
response to a number of questions. Participants are then invited to share their ideas 
using a ‘round robin’ technique until all ideas have been presented. Discussion is 
discouraged until all ideas have been recorded so that each participant has the 
opportunity to share their opinion prior to it being modified or rejected by the 
group. Once all responses are listed, group discussion can ensue to clarify ideas. 
Finally, participants are asked to prioritise their ideas about each question 
discussed. The number of meetings required will depend on the nature of the 
question and accessibility of stakeholders, for healthcare issues, a number of 
meetings are normally required and should only conclude, like focus groups, when 
now new ideas are being generated i.e. data saturation is achieved [182, 184, 185].  
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The Delphi technique was originally developed by the RAND corporation in the 
1950s in order to forecast the influence of technology on warfare [186]. Whilst the 
specifics of conduct vary between studies, this method comprises sequential 
questionnaires answered anonymously by a panel of participants with relevant 
expertise. After each questionnaire, the group response is fed back to participants 
who are asked to reflect on and possibly change their voting in light of how other 
participants have voted to move towards group consensus. There must be at least 
two rounds in a Delphi study to allow reflection on the previous rounds scores. 
There may also be a ‘blank paper’ round to elicit opinion prior to scoring items. 
 
Over NGT, one of the advantages of the Delphi method is that it is anonymous. 
Participants do not meet face to face and there is less chance of more vocal or 
authoritative figures dominating the discussion or influencing others’ voting. 
Additionally, participation can be done remotely using postal or online surveys, 
and therefore location is of no barrier to participation, which means a more diverse 
and numerous group of individuals can participate. For these reasons it has become 
the most popular choice of consensus method for developing COS [117]. 
 
Study protocol 
There are potential sources of bias in the COS development process, and in their 
handbook, COMET recommend that a protocol be developed prior to the start of 
the study, and made publicly available. In order to improve transparency and share 
methods with others we published the protocol for this study in an open access 
journal [187]. There was significant interest in the protocol which was ‘highly 
accessed’ in the first few months of publication. 
 
Project registration 
The COMET initiative aims to provide a means of identifying existing, ongoing 
and planned COS studies. The COMET database acts as a repository for such 
studies and is a free-to-access, unrestricted public repository which maximises the 
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potential of potential COS developers finding relevant studies, thereby avoiding 
duplication of effort and facilitating collaboration. The project was registered with 
the COMET database in 2011. 
 
1.4.3 Methods employed in this research 
 
The COMET handbook describes what is currently known about COS 
development, implementation, review and uptake, yet, there is no gold standard 
method for developing COS and research to identify optimal methods is ongoing 
[188]. In the handbook, for some areas of COS development there are 
‘recommendations for practice, in other areas ‘issues to consider’, and areas 
highlighted where there is a need for further research. 
 
Most COS developers employ a mixed methods approach in order to ensure 
adequate identification of outcomes, stakeholder involvement and consensus 
opinion. A mixed methods approach is commonly used by COS developers to 
identify outcomes for inclusion (systematic review, interviews, surveys), and then 
establish which of the possible outcomes should be included in the COS, using 
stakeholder consensus techniques. Mixed methods approaches combine elements 
of qualitative and quantitative research with the broad purpose of increasing the 
breadth and depth of understanding [189]. Such ‘methodological triangulation’ was 
helpful in this work as it allowed me to investigate and understand the perspectives 
of different stakeholder groups and engage them in a consensus exercise to identify 
outcomes of key importance. This comprised the steps shown in figure one and 
discussed below and in the forthcoming chapters two, three and four. 
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Figure 1 Mixed methods approach 
 
1.4.3.1 Identifying existing knowledge 
 
I started out by identifying existing knowledge and COS research in SCCHN and 
OPSCC. No COS studies were registered with the COMET database, however 
scoping searches identified a conference abstract for a study to develop an 
‘outcomes toolbox’ for use in SCCHN clinical trials. The purpose of this study was 
not to establish which outcomes were important, rather, to identify a set of 
instruments suitable for widespread application in the conduct of clinical trials for 
SCCHN, allowing non-specialists to accurately evaluate the acute and late toxicity 
of a regimen and its impact upon a patient’s quality of life (QOL) and function. 
This instruments were chosen by a group of healthcare professionals and patients 
were not involved at any point in the design or conduct of the study. I made three 
attempts at the time to contact the lead author of the abstract, as there could be 
some cross-over in the research, however I received no response. The ‘outcomes 
toolbox’ has subsequently been published [190]. 
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The previously mentioned ICF core sets for SCCHN were also identified in these 
scoping searches [122, 191-193]. Although the ICF is widely comprehensive it 
does not include outcomes such as death, an outcome that is especially important to 
measure in clinical trials investigating treatments for life threatening illnesses such 
as cancer. 
 
1.4.3.2 Systematic review  
 
The previously mentioned series of Cochrane reviews of interventions for the 
treatment of OPSCC had identified heterogeneity in the reporting of outcomes 
between OPSCC clinical trials [169-171]. I therefore felt it was pertinent to 
examine the outcomes measured in OPSCC RCTs through a systematic review of 
the literature. I wished to establish whether there was any standardisation in the 
outcomes measured, which outcomes were measured and thus which outcomes 
were important to trialists and clinicians, as they select the outcomes in trials. The 
outcomes identified would be added to a comprehensive outcomes list to be used in 
the development of a Delphi Consensus Study. 
 
Systematic reviews are an efficient way of identifying outcomes used by 
researchers in a particular clinical area, they do however just aggregate the 
opinions of the previous researchers on what outcomes they deemed important to 
measure. We therefore knew that we would have to involve researchers in the later 
phases of the study to ensure consensus development in the wider community of 
stakeholders.  
 
We decided not to include qualitative studies or other study types in our systematic 
review, only RCTs. This was decided a priori, for the following reasons: 
 
1. We had established from previous research that PROs were poorly reported in 
the literature 
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2. We intended to interview OPSCC patients and carers, to establish the 
experiences of those going through treatment, particularly in relation to PROs 
3. As chemoradiotherapy was the current standard of care for patients with 
OPSCC at the outset of this research, we knew that there were a significant 
number of RCTs from which to draw outcomes 
4. Including all study types would have significantly increased the amount of 
literature to search and resources were not available for this within the 
constraints of this project 
5. We wished to establish the outcomes used in effectiveness trials as this is the 
type of trial to which the COS would apply 
 
There is no recommended time window to conduct systematic reviews, however 
we wished to include contemporary RCTs and so restricted our search to the 
preceding ten years. Another strategy is to start with a smaller time window and 
test for outcomes saturation by extending the search and comparing the results. If 
no new outcomes are identified, the search can be limited in timeframe. Our data 
extraction was consistent with that now recommended in the COMET handbook, 
considered in terms of: 
 
1. Study characteristics 
2. Outcomes 
3. Outcome measurement instruments and/or definitions provided by the authors 
for each outcome 
 
Also, as is now recommended in the handbook, we extracted the outcomes 
verbatim, the synthesis of the same outcomes with different verbatim terms is also 
clearly described. In contrast to recommendations in the handbook, I did not 
perform a specific PROM review or extract PROs from PROMs, I also did not 
search for qualitative studies for outcomes.  
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1.4.3.3 Qualitative interviews 
 
To identify the outcomes of most importance I felt it would be appropriate to ask 
those with experiential knowledge of OPSCC and treatments for OPSCC; patients 
and those who care for them. We know that adverse effects of treatment for head 
and neck cancer are common; they are frequently quantified, but few researchers 
have tried to establish the significance of these adverse effects to patients in trying 
to choose between treatments. By understanding this, and where these outcomes sit 
alongside outcomes relating to disease control and survival, we can better 
understand patients’ and carers’ outcome priorities. The COMET initiative 
advocate seeking patient opinion about the outcomes to be included in a core 
outcome set. We felt this to be of the utmost importance in this instance as we 
suspected that functional outcomes would be of significant concern to patients. The 
changing patient demographic demands that we question whether the outcomes 
identified as priorities for OPSCC patients in previous research, still apply. We 
also wished to ensure that important outcomes were not overlooked from the 
comprehensive outcomes list identified from the systematic review and to 
understand the ways in which patients describe outcomes, to inform the Delphi 
consensus study, and possibly inform how outcomes should be measured.  
 
Other COS developers have used qualitative methods in COS development to 
access perspectives of groups such as patients, carers, members of the public and 
healthcare professionals because these views may not be encompassed in a 
systematic review of outcomes [177, 187, 194, 195]. Furthermore, participation in 
COS development may be more meaningful to certain groups when qualitative 
methods are employed.  
 
Qualitative methods may be used:  
 
1. To identify the outcomes of relevance to the whole stakeholder community 
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2. To preserve the distinct perspective of different stakeholders 
3. To help make consensus processes accessible to patients 
4. To inform deliberations in the final stages of COS development 
5. To address gaps in existing COS 
 
In certain circumstances, the use of qualitative methods may be particularly 
helpful. If all potentially important outcomes have not been identified before a 
consensus process, qualitative interviews could help ensure that no potentially 
important outcomes are missing. Retention of Delphi participants can be 
problematic and qualitative studies may help to minimise the number of rounds (by 
allowing for omission of the open ‘blank’ round). Qualitative methods may help to 
define the scope of the COS, population and interventions to be covered and 
provide insight into why certain outcomes are important to patients. 
 
Discussions with the Mersey Head and Neck Cancer Patient and Carer Research 
Forum informed our decision to use qualitative interviews over other forms of 
qualitative inquiry. We had considered conducting a focus group to elicit opinion 
on outcomes of importance, however the forum felt that the issues were highly 
emotive and that discussing these with others present would be difficult for patients 
and carers. They felt that patients would hold back and that carers may not want to 
speak openly about their perceptions of the patients’ experience; it might seem that 
they were somehow undermining the patients’ experience as they didn’t go through 
treatment themselves. They agreed, however, that carers could provide a unique 
insight into the condition and treatment, and suggested a focus group after the 
interviews if there was concern that important outcomes were missing. 
 
We chose not to interview healthcare professionals because we were considering 
their opinion when eliciting outcomes through the systematic review and later in 
the Delphi survey. Clinical and non-clinical trialists choose the outcomes to be 
measured in clinical trials, and we felt the review would therefore encompass their 
41 
 
 
 
 
opinion on outcomes of importance. Furthermore, the first round of the Delphi 
survey had a ‘blank sheet’ to elicit further opinion on outcomes of importance. 
Healthcare professionals from multiple stakeholder groups were invited to 
participate in the Delphi survey to increase the diversity and experience of those 
participating. 
 
1.4.3.4 Delphi Study 
 
A Delphi Study was used to elicit views of participants on outcomes of importance 
and reach a consensus about which outcomes should be included in the COS. In the 
case of our research, the advantage of this approach was that it is not face-to-face, 
and avoids the problem of more vocal or apparently senior participants dominating 
the group discussion and therefore influencing others’ voting, as was the risk with 
a patient/clinician cohort. Secondly, we wished to achieve international consensus 
and online Delphi methods allowed us to do this without incurring any additional 
costs. 
 
As previously stated, the COMET handbook was not published at the time of 
conducting this research, however it discusses the important methodological 
considerations when designing a Delphi survey in some detail. I contributed to a 
qualitative study of COS developers undertaken by the COMET initiative as an 
interviewee and discussed several of these methodological considerations, as I 
encountered them during the course of this project [196]. These include [117]: 
 
The number of panels 
This depends on the stakeholders required and the way in which it is felt 
appropriate to their opinions. The single homogenous panel approach will result in 
core outcomes deemed essential by a one stakeholder group e.g. patients with the 
clinical condition under study or knowledge of this. In a single heterogeneous 
panel, the views of multiple stakeholder groups are combined. Feedback and 
42 
 
 
 
 
criteria for consensus are based on the group overall and careful consideration and 
justification is needed of the panel mix, because the resulting core outcomes may 
depend on the relative proportions of stakeholders participating i.e. be weighted 
towards the views of a particular stakeholder group. Where differing stakeholder 
opinions are anticipated, multiple homogenous panels in which feedback and 
criteria for consensus are isolated to a single stakeholder group have distinct 
advantages. The final COS or outcomes taken forward to the next stage of COS 
development are likely to consist of the outcomes deemed essential by all 
stakeholder groups 
 
Group size 
There are no statistical methods for calculating power or sample sizes for Delphi 
studies. This is often a pragmatic choice and will depend to some degree on 
resources and the clinical condition and number of experts available. It is most 
important to ensure representation from key stakeholder groups with individuals 
with a deep understanding of the issues. However the greater the number of 
participants, the more likely the COS is to be generalisable to future patients and in 
convincing others of its value. 
 
Participant information 
Well informed participants will contribute more meaningfully to the consensus 
process and it is essential that participant information is tailored to the individual 
groups to enable informed consent and equip participants to be able to score and 
prioritise outcomes. 
 
Number of rounds 
There must be at least two rounds in a Delphi survey, including at least one round 
of feedback. The number of rounds will depend to some degree on the amount of 
work already performed in eliciting stakeholder opinion. Some studies have used 
open-ended rounds with no voting to elicit opinion as an alternative to performing 
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a review of the literature. The number of rounds does not have to be pre-
determined but criteria for selecting an end-point should be defined. Although 
consensus will not be reached on all outcomes it is necessary that a reduced 
number of outcomes has been agreed, in line with a pre-defined stop criterion. 
  
Structure of questionnaires 
It is important that questionnaires are tailored to the individual stakeholder groups, 
avoiding jargon that would be unfamiliar. Anecdotal evidence from the piloting of 
Delphi questionnaires for COS for cancer surgery and otitis media with effusion in 
children with cleft palate suggest that lay terms are preferred to medical terms, 
even by healthcare professionals. Stakeholder involvement in the design and 
piloting of the Delphi questionnaire is recommended.  
 
Order of questionnaire items 
There is evidence from one nested methodological study within a COS study that 
the order in which outcomes are delivered affects their scores and ultimately 
consensus [197]. Chalmers et al. presented clinical and patient reporting outcomes 
(PRO) in varying orders to participants developing a COS for oesophageal cancer. 
They found that patients were more likely to rate PRO items as essential when they 
appeared last in the questionnaire, whereas professionals were more likely to rate 
them as essential when they appear first. 
 
Additional open questions 
There are different methods for identifying an initial long list of outcomes to 
inform the Delphi survey. This list can be added to by eliciting opinion with an 
open question round or section of the first round of the Delphi. Whatever the 
method, criteria for adding additional items should be stated i.e. any new outcomes 
or only those suggested by two or more respondents might be added. 
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Scoring system 
Most COS studies have used a Likert type scale with outcomes scoring 1-3 deemed 
not important, 6-8 important but not essential and 7-9 essential [177, 198, 199]. 
This system is a framework recommended by the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Working Group for assessing 
the level of importance about research evidence [152, 199]. Other studies using a 
Likert type scale have simply stated 1 as ‘not essential’ and 9 as ‘absolutely 
essential’ and asked participants to vote somewhere on this scale [200, 201]. Other 
studies have asked participants to divide a total number of, say 100 points between 
all of the outcomes [202] and others still to rank all outcomes [203]. 
 
Feedback between rounds 
Reaching consensus requires reconciliation of different views. In a Delphi this is 
achieved by providing feedback after each round on how other participants have 
voted in that round. This allows reflection on how others have scored before re-
rating in the following round. At the end of each round the results for each 
outcome are aggregated and descriptive statistics presented. The way in which 
results are aggregated and presented depends on the number of panels and if the 
scoring is weighted by stakeholder group. There are currently no best practice 
guidelines on the best way to summarise and present feedback and there is 
methodological research within ongoing COS studies to evaluate this. 
 
Retaining or dropping items between rounds 
After the initial Delphi round, outcomes not reaching the pre-defined cut off may 
be dropped (not presented in the subsequent round) or kept and re-presented in the 
second round. If items are dropped after the first round, participants will not get the 
opportunity to re-score those outcomes taking into account feedback on scores 
from other participants. If however, the initial list of outcomes is large, including 
all outcomes in each Delphi round may impose sufficient burden on participants to 
increase attrition from one round to another [117]. 
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Attrition and attrition bias 
Attrition rates vary between studies and seem to depend to some degree on the 
method of recruitment; attrition rates are reported to be higher in studies using a 
less targeted recruitment approach, somewhere in the region of 15 - 20% between 
rounds [198, 204]. There is no guidance on what constitutes an adequate response 
rate, however around 80% for each stakeholder group is deemed satisfactory in 
most situations [117]. There is little evidence regarding the impact of attrition bias 
in COS studies, however it is likely to be more methodologically sound to compare 
average scores for each outcome between groups than average scores for all 
outcomes. 
 
Defining consensus 
A number of different criteria have been used to define consensus. One of the most 
commonly employed approaches in recent COS studies is a version of that used by 
Wylde et al. (2015). They implemented a threshold for inclusion in the core set of 
70% of participants scoring outcomes as 7 to 9 and 15% or less scoring 1 to 3 to be 
met by both the clinician and patient panels or 90% or more scoring 7 to 9 from 
any single panel [205]. Harman (2015) [177], Potter (2015) [200] and Blazeby 
(2015) [201] have all used a ‘70/15%’ cut-off.  
 
Assessing the degree of consensus 
An assessment of the degree of consensus between rounds is advisable to ensure 
that the Delphi is working as a consensus technique. 
 
1.5 Structure of the thesis 
 
Following on from this unified introduction, the individual components of this 
study will be presented in three different chapters. Chapter two will present the 
methods and results of a systematic review to identify the outcomes currently 
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reported in OPSCC RCTs; chapter three will present the methods and results of a 
series of qualitative interviews with patients and carers to establish the outcomes 
they believe are important and chapter four the Delphi study methods and results. 
In chapter five, I will discuss the recommendations for the contents of a COS for 
OPSCC clinical trials and consider the limitations of the study; in chapter six I will 
identify areas for future work. 
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Chapter 2 
A systematic review to identify the outcomes reported in 
randomized controlled trials in oropharyngeal cancer 
 
 
2.1 Rationale for this chapter 
 
This systematic review was conducted to identify the outcomes reported in 
contemporary RCTs of interventions for the curative treatment of OPSCC. As 
outcomes in RCTs are chosen by clinical and non-clinical trialists, this is likely to 
identify the outcomes these stakeholders prioritise and deem most worthy to 
measure in OPSCC RCTs. 
 
The comprehensive list of outcomes identified in this review was categorised by 
the study team; comprising two otolaryngologists, a trials methodologist and a 
qualitative researcher; and carried through to a consensus process to ratify the 
outcomes to be included in the final core outcome set.  
 
2.2 Objectives 
 
To identify, summarise, compare and critique the outcomes reported in RCTs of 
interventions for the treatment of OPSCC.  
 
2.3 Methods 
 
This systematic review adhered to a predefined protocol, published in ‘Trials’ 
http://www.trialsjournal.com/content/15/1/168, see Appendix one [74]. 
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2.3.1 Inclusion criteria 
 
Phase III RCTs of interventions for the curative treatment of OPSCC, including 
SCCHN RCTs that comprise patients with OPSCC, and RCTs including only 
patients with OPSCC. Trial participants were adults over the age of 18, with a first 
diagnosis of OPSCC who hadn’t had any other form of treatment. The review was 
limited to human studies in the English language published between 1 January 
2003 and 14 May 2013 to restrict the review to evaluations of current practice. 
Open-label trials were included. 
 
2.3.2 Exclusion criteria 
 
RCTs including patients with recurrent or metastatic disease and those of 
interventions for the sequelae of treatment, such as xerostomia were excluded. 
Abstracts and conference reports without corresponding published articles were 
excluded because the information was likely to be incomplete.  
 
2.3.3 Identification of studies 
 
We identified studies by searching electronic medical literature databases and by 
hand searching relevant systematic reviews. Scoping searches had been conducted 
at the outset of the study first to identify any existing COS work in OPSCC, and 
secondly to identify important RCTs.  
 
2.3.3.1 Search strategy and information sources 
 
To optimise our chances of identifying all relevant studies, we searched a variety 
of medical literature databases. The Cochrane Central Register of Controlled Trials 
(CENTRAL) is the most comprehensive database of RCTs [206], this database 
contains citations to reports of clinical trials from a wide range of sources. The 
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Cochrane Handbook recommends that supplementary searches of both MEDLINE 
and Embase are undertaken too [206]. There is a time lag of approximately one to 
two years with respect to Embase records appearing in CENTRAL. Over Medline, 
PubMed has the advantage that it includes in process records. The lead author 
(AW) therefore performed electronic searches of the Cochrane Central Register of 
Controlled Trials (CENTRAL), PubMed and Embase. 
 
The search strategy was adapted iteratively from one developed for a review by the 
Cochrane Ear, Nose and Throat disorders group to identify all RCTs in OPSCC. 
On initial testing, the search strategy failed to pick up several key papers, identified 
in early scoping searches, we therefore had to truncate this, ending up with a broad 
search strategy and therefore a large number of identified studies. Attempts to 
rationalise the search strategy still led to the exclusion of eligible studies and we 
therefore had to accept a search strategy with a high sensitivity, but low specificity. 
 
The Cochrane Highly Sensitive Search Strategy for identifying randomized trials 
was implemented and combined, using the Boolean operator “AND” with MeSH 
terms for OPSCC and SCCHN. Systematic reviews were excluded by combining 
this with the Boolean operator “NOT” for (“systematic review” OR “meta 
analysis”) OR “Cochrane Database Syst Rev”. Truncations were used to improve 
the sensitivity of the search. The strategy was developed for PubMed (Appendix 
two) then translated for CENTRAL and Embase, to allow for differing subject 
index terms and RCT filters. Endnote reference management software was used to 
import the identified records. Cochrane reviews of interventions for the treatment 
of oropharyngeal cancer [169-171] were hand-searched and cross-referenced with 
the search findings; this process was conducted by 2 reviewers (AW and KL).  
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2.3.3.2 Study selection  
 
Two reviewers (AW and LW) independently assessed the identified records. A 
three phase exclusion process was implemented. 
 
Phase I – exclusion by study title 
 
All identified records were reviewed by title, and studies that were ineligible were 
excluded. A single reviewer (AW) made an initial assessment of all study titles, 
and subsequently re-reviewed a random sample of 100 excluded studies and their 
abstracts to ensure accurate exclusion. A second reviewer (LW) assessed full 
papers for 40 of the excluded studies at title, to check for accuracy of exclusion. 
 
Phase II – exclusion by abstract 
 
Studies that were eligible from the title or for which there was uncertainty, had 
their abstracts reviewed in the second phase. 
 
Phase III – exclusion at full paper review 
 
AW reviewed all studies and LW assessed a proportion of these. In order to ensure 
accurate exclusion, a proportion of all included/excluded titles, abstracts and full 
papers were reviewed by the senior authors (TMJ and CTS). Any disagreement 
between AW and LW was also discussed with the senior authors. 
 
2.3.4 Data extraction 
 
Data was extracted from eligible studies directly into an excel database by one 
reviewer (AW) and, for a selection of studies, cross checked by a second reviewer 
(LW). For each study, the following data were extracted: 
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 Outcomes reported, their definitions, methods of measurement and whether 
they were a primary or secondary outcome 
 Outcome on which sample size was based, whether a sample size calculation 
was performed and whether sample size was recruited 
 General study features: interventions, number of participants, proportion of 
OPSCC participants 
 Participant characteristics comprised age, gender, disease stages and sub-sites 
 
All outcomes reported in the results were extracted whether or not they were 
specified in the methods as outcomes, and all outcomes stated in the methods were 
extracted whether or not they were reported in the results. Outcomes were judged 
to be defined if they were described in the text or referenced with a citation. Acute 
and late toxicity were said to be defined if they were either described in the text or 
measured using a validated tool. The individual outcomes within composite 
toxicity and HR-QOL patient reported outcome measures (PROM) were not 
extracted or analysed separately as they were so incompletely reported. 
Furthermore, we wished to undertake qualitative interviews with patients and 
carers later in the study to establish PROs of importance. 
 
Outcome definitions were compared and outcomes with the same definitions were 
merged under outcome domains using the verbatim term most commonly used for 
the outcome described. Outcomes with the same verbatim term but contrasting 
definitions were not synthesised, and will be described later. The mapping of 
individual outcomes to domains was undertaken by (AW) and then checked by the 
whole study team (TMJ, CTS, BY). 
 
As we wished to establish what was measured rather how it was measured we 
chose to categorise outcomes into domains, excluding time-points such that three- 
and five-year loco-regional control were absorbed into ‘loco-regional control’. 
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Time-points are important, and work to establish the best time-points at which to 
measure outcomes included in the COS will be conducted after the COS is 
established.  
 
2.3.5 Assessing the quality of included studies 
 
We recorded intended sample sizes, how these were calculated and whether they 
were recruited. An assessment was made of the method of randomization, and all 
adequately randomized Phase III trials that met the eligibility criteria were 
included, and studies with inadequate randomization were excluded. Blinding 
method was noted but not part of our eligibility criteria and open-label trials were 
included.  
 
An assessment of disparities between outcomes stated in the methods and results 
was initially made, however this was felt to be of little value without actually 
consulting trial protocols. It would provide inadequate evidence to assess bias, and 
this was not an objective of the review. Trial protocols were not requested and 
Cochrane risk of bias assessment [207] or comparison against the CONSORT 
checklist was not performed [159]. This was decided a priori as the objective of the 
systematic review was to identify a comprehensive outcomes list for the Delphi, 
not to make an assessment of bias or methodological rigour in the included studies. 
The COS-STAR minimum standards for reporting COS studies only specify that 
the sources of the initial long list of outcomes are identified, not that any other 
assessment of the sources from which they were extracted is made [208].  
 
2.3.6 Data analysis and presentation of results 
 
Results are tabulated and descriptive statistics used to summarise the data. 
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2.4 Results 
 
2.4.1 Study selection 
 
The initial database search conducted on 14th May 2013 identified 16,077 records 
in PubMed, Embase and CENTRAL. Following the removal of 4150 duplicates, 
11927 records were screened, and 11845 excluded by title and abstract review. 
Full-text articles were retrieved and reviewed for 82 studies, of which 51 were 
eligible. These 51 reports related to 43 published RCTs which were included in the 
narrative synthesis. (See PRISMA flow diagram, Figure two). No additional 
studies were identified by hand-searching three relevant Cochrane reviews [209-
211].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PRISMA flow diagram, identification of studies 
Records identified through database 
searching  
n = 16077 
Additional records identified hand 
searching of relevant Cochrane reviews 
n = 0 
Records after duplicates removed  
(n = 11927) 
Records screened  
n = 11927 
Records excluded  
n = 11845 
Full-text articles assessed 
for eligibility n = 82 
Full-text articles excluded 
 with reasons n = 31 
 
Other study type   n=11 
Study reported pre-2003  n=7 
Ineligible patients included  n=3 
Unclear whether OPSCC  
patients included  n=2 
Study protocol  n=1 
Unable to source full paper  n=7 
Reports included  
n = 51 
This relates to 43 studies 
54 
 
 
 
 
2.4.1.1 Exclusion of studies 
 
Phase I - exclusion by title  
 
Due to the large number of studies (n=11,245) excluded at title review we did not 
individually categorise by reason for exclusion. The main reasons for exclusion 
were however: 
 Non-SCCHN/OPSCC studies 
 Ineligible study design e.g. case report, editorial or early phase RCT 
 RCTs of interventions for the management of side-effects of treatment  
 
Phase II – exclusion by abstract 
 
In phase II, a further 600 studies were excluded. A large number of foreign 
language studies and conference abstracts were identified and published work was 
searched for using PubMed and the clinical trials registry, www.clinicaltrials.gov. 
 
Phase III – exclusion at full paper review 
 
At this point we were able to identify all eligible phase III RCTs and those studies 
to which a number of published papers related. Excluded studies were mainly 
SCCHN trials that did not feature OPSCC patients, RCTs of interventions for the 
management of side-effects of treatment, treatments for patients with metastatic or 
recurrent disease and subsequent published work relating to trials reported and 
published prior to the eligibility time frame (1st January 2003 – 14th May 2013) e.g. 
long-term follow up reports.  
 
Of the 82 studies fully reviewed, 51 were eligible. These related to 43 individual 
RCTs. Of the 31 excluded studies, 11 were another study type, 7 were long term 
results for studies that had been reported before 1st January 2003, 2 did not clearly 
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state whether they included oropharynx patients, 2 included patients with 
metastatic or recurrent disease, 1 study included a 17-year-old patient and 1 was a 
reference to a study protocol which wasn’t published. We were unable to source 
full papers for 7 studies (see figure 2). 
 
2.4.1.2 Intra- and inter-rater agreement  
 
A random sample of 50 excluded titles were identified. Their abstracts were 
reviewed by AW, and one study was identified that should have been included for 
full paper review. A further 50 abstracts were reviewed and no further studies were 
identified. A second reviewer (LW) assessed full papers for 40 of the excluded 
titles, to check for accuracy of exclusion. There was 100% agreement that the 
identified papers were ineligible. A further clinician reviewer (KL) and the senior 
authors (TMJ and CTS) reviewed a random sample of 20 of the identified studies 
to judge at what stage they would have included or excluded them. Whilst there 
were disparities in the stages at which the different authors would have excluded 
studies, this wouldn’t have had an impact on the final studies included as when full 
papers were reviewed there was 100% agreement. The senior authors (TMJ and 
CTS) reviewed studies about which there was uncertainty. 
 
2.4.2 Outcomes extraction 
 
The study team agreed to extract all outcomes either specified in the methods or 
reported in the results whether or not they were listed as study endpoints. 
 
2.4.3 Description of the included studies 
 
The 51 included reports related to 43 individual RCTs. Additional publications 
arising from the studies are outlined below. These reported quality of life, 
additional analyses and long-term follow up data for trials reported in the review 
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time frame. Appendix three presents the characteristics of all the included studies 
and the outcomes they reported. Table one shows the additional reports for the 
included studies. 
Papers Study 
Smid, 2003 
 
 
Zakotnik, 2007 
Postoperative concomitant irradiation and chemotherapy with mitomycin C 
and bleomycin for advanced head-and-neck carcinoma 
 
Patterns of failure in patients with locally advanced head and neck 
cancer treated postoperatively with irradiation or concomitant 
irradiation with Mitomycin C and Bleomycin 
Cooper, 2004 
 
 
Cooper, 2012 
Postoperative concurrent radiotherapy and chemotherapy for high-risk 
squamous-cell carcinoma of the head and neck 
 
Long-term follow-up of the RTOG 9501/intergroup phase III trial: 
Postoperative concurrent radiation therapy and chemotherapy in 
high-risk squamous cell carcinoma of the head and neck 
Huguenin, 2004 
 
 
Ghadjar, 2012 
Concomitant cisplatin significantly improves loco-regional control in 
advanced head and neck cancers treated with hyperfractionated radiotherapy 
 
Concomitant cisplatin and hyperfractionated radiotherapy in locally 
advanced head and neck cancer: 10-year follow-up of a randomized 
phase III trial (SAKK 10/94) 
Bonner, 2006 
 
 
Curran, 2007 
 
 
Bonner, 2010 
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and 
neck 
 
Quality of life in head and neck cancer patients after treatment with high-
dose radiotherapy alone or in combination with cetuximab 
 
Radiotherapy plus cetuximab for locoregionally advanced head and 
neck cancer: 5-year survival data from a phase 3 randomised trial, 
and relation between cetuximab-induced rash and survival 
Vermorken, 2007 
 
Van Herpen, 
2010 
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer 
 
Short-term health-related quality of life and symptom control with 
docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-
fluorouracil (PF) for induction in unresectable locoregionally 
advanced head and neck cancer patients (EORTC 24971/TAX 323) 
Ackerstaff, 2009 
 
 
Rasch, 2010 
 
 
Ackerstaff, 2012 
First-year quality of life assessment of an intra-arterial (RADPLAT) versus 
intravenous chemoradiation phase III trial 
 
Intra-arterial versus intravenous chemoradiation for advanced head and neck 
cancer: Results of a randomized phase 3 trial 
 
Five-year quality of life results of the randomized clinical phase III 
(RADPLAT) trial, comparing concomitant intra-arterial versus 
intravenous chemoradiotherapy in locally advanced head and neck 
cancer 
 
Table 1. Additional reports for included studies 
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2.4.3.1 Participants 
 
In total, 10,951 patients were randomized, 5286 (48.3%) had OPSCC. Additional 
subsites included oral cavity (30 studies), hypopharynx (38 studies), larynx (34 
studies), unknown primary (2 studies), nasopharynx (3 studies) and paranasal 
sinuses (2 studies). Two studies included ‘other’ subsites, not specified [212, 213]. 
Only 2 studies recruited OPSCC patients exclusively [214, 215]. 
 
2.4.3.2 Interventions 
 
Interventions are shown in table two. There were 5 trials of radiotherapy alone, 27 
trials of chemotherapy and radiotherapy, 9 trials of surgery and chemotherapy 
and/or radiotherapy, 1 trial of radiotherapy and the Epidermal Growth Factor 
Receptor antagonist, Cetuximab (Erbitux®) and 1 trial of radiotherapy plus 
Carbogen breathing.  No surgery only RCTs were identified. 
 
Intervention(s) Number of trials (%) Number of patients (%) 
Radiotherapy and chemotherapy 27 (62.7) 6888 (62.9) 
Surgery +/- radiotherapy +/-
chemotherapy 
9 (20.9) 1791 (16.3) 
Radiotherapy alone 5 (11.6) 1747 (16.0) 
Radiotherapy and Cetuximab 
(Erbitux®) 
1 (2.3) 424 (3.9) 
Radiotherapy and Carbogen 
breathing 
1 (2.3) 101 (0.9) 
Total 43 10951 
 
Table 2. Interventions in the included studies 
 
2.4.3.3 Centres 
 
The cohort included 12 single centre and 26 multi-centre studies (range 2-82). A 
number of studies were conducted by national and international collaboratives, 
namely the Eastern Cooperative Oncology Group (ECOG), Southwest Oncology 
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Group (SWOG), Radiation Therapy Oncology Group (RTOG), Trans-Tasman 
Radiation Oncology Group (TROG), Multicentre Hellenic Cooperative Oncology 
Group, Groupe d'Oncologie Radiothérapie Tête Et Cou (GORTEC) and the 
European Organisation for Research and Treatment of Cancer (EORTC). From the 
published report, it was not possible to identify the number of centres for 5 studies 
arising from Cuba, India, Singapore and the USA [216-220].  
 
2.4.4 Powering of studies 
 
Thirty-four studies reported a sample size calculation, with 50% of these recruiting 
to target. Studies that did not report a sample size calculation were more likely to 
recruit fewer patients. The median number of recruits to non-powered studies was 
72, (IQR 60 to 106) and to powered studies, 247 (IQR 132 to 381).  
 
2.4.5 Number of outcomes measured 
 
Initial screening identified 77 verbatim outcomes. Ten of these were defined by the 
time at measurement. As we wished to establish what was measured rather than 
when it was measured, we categorised these outcomes, excluding time-points such 
that three- and five-year loco-regional control were absorbed into ‘loco-regional 
control’. Synthesis of outcomes, excluding time-points reduced the number of 
outcomes to 67. I reviewed the definitions of the outcomes in each study, and the 
ways in which the outcomes were measured. This process and the outcomes 
synthesis was cross-checked by the rest of the study team (TMJ, CTS and BY). 
 
Nine different verbatim terms had the same definitions or were measured in the 
same way and could feasibly be categorised as the same outcome (see table three), 
therefore a total of 58 distinct outcomes were identified in the 43 included studies 
with a total of 259 outcomes measured across all studies and a mean number of 6 
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outcomes per study (range 2 to 12). The list of 58 outcomes is shown in appendix 
four. 
 
2.4.6 Outcome definitions 
 
Only 6 studies (14%) provided a definition of every outcome in the trial and 2 
studies failed to define any of the outcomes. Of all outcomes, 58.3% (151/259) 
were defined. Overall survival was defined in 46% (18/39) of studies, either as 
survival from randomisation or from the start of treatment. In different settings the 
time from randomisation to starting treatment will vary, and it is difficult to say 
how much heterogeneity this introduces as this information was not published in 
any of the studies. Some studies censored patients at the last known follow-up, 
others didn’t state how patients were censored. Loco-regional control was only 
defined in 7 of the 18 studies (38.9%) that measured it. In 5 of these studies loco-
regional control was the primary outcome. Important differences were observed in 
how loco-regional control was defined. Most studies considered loco-regional 
recurrence of tumour to signify an event for loco-regional control, whereas Grau et 
al. defined loco-regional relapse as any persistent or recurrent disease. In all other 
definitions loco-regional failure was defined by disease recurrence, not persistence. 
Their definition would represent two different outcomes; loco-regional control and 
progression-free survival. By this definition, patients who were never tumour free 
were not censored. Zackrisson et al. [221] were careful to point out that patients 
who were never tumour free were censored at time-point ‘0’ for loco-regional 
control, because they never had loco-regional control. 
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Verbatim term 
 
 
Outcome domain 
 
Adverse event 
 
 
Acute toxicity 
Early normal tissue reactions 
Incidence of major and minor 
complications 
Late normal tissue reactions Late toxicity 
Local relapse-free survival Local recurrence-free survival 
 
Tumour response 
 
Response 
 
Overall response rate 
 
 
Time to local or nodal treatment 
failure 
 
Time to loco-regional failure 
 
Duration of loco-regional control 
 
Loco-regional control 
 
Table 3. Outcome domains 
 
2.4.7 Outcomes in the included studies 
 
The most commonly measured outcomes were acute toxicity, overall survival and 
late toxicity, measured in 100%, 90.7% and 69.8% of the included studies 
respectively. These were the only outcomes reported in more than 50% of the 
studies. Even then, acute toxicity was only specified as a primary or secondary end 
point in 60.5% (26/43) of studies. Thirty-four outcomes were each only measured 
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in a single study, therefore less than half of the outcomes (24/58, 41.4%) were 
measured in more than one study. Only 7 RCTs, all published after 2006, measured 
health-related quality of life (HR-QOL). This was often reported in separate 
publications from the main study report, and, in some studies, conducted 
longitudinally over a number of years [222, 223]. The ten most commonly pre-
specified or reported outcomes are shown in table four. 
 
Outcome Number of studies (%) 
Acute toxicity 43 (100.0) 
Overall Survival 39 (90.7) 
Late toxicity 30 (69.8) 
Loco-regional control 18 (41.9) 
Response 16 (37.2) 
Disease-free survival 14 (32.6) 
Progression-free survival 10 (23.3) 
HR-QOL 7 (16.3) 
Distant metastases 6 (14.0) 
Local control 5 (11.6) 
 
Table 4. The ten most commonly reported outcomes 
 
2.4.7.1 Primary outcomes 
 
The primary outcome was clearly stated in 34 studies, deduced from the sample 
size calculation in 3 studies, deduced from the text in 3 studies and unclear in 3 
studies. The most common primary outcomes were loco-regional control (12 
studies), overall survival (7 studies), progression-free survival (3 studies), disease-
free survival (3 studies) and loco-regional recurrence-free survival (2 studies). Six 
studies stated more than one primary outcome. Some functional outcomes are 
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routinely measured using toxicity criteria; however studies are rarely powered on 
these. This review identified only two studies powered on functional outcomes; 
Nutting et al, 2011 which was powered on Xerostomia at 12 months according to 
the Late Effects of Normal Tissues Subjective-Objective Management Analytic 
(LENT SOMA) and Gupta et al which was powered on acute salivary gland 
toxicity (grade 2 or greater) measured according to the Radiation Therapy 
Oncology Group (RTOG) acute salivary gland toxicity criteria [224, 225]. 
 
2.4.7.2 Types of outcomes 
 
Survival outcomes included overall survival, cancer-specific survival and failure or 
progression-free survival. These were measured and analysed as time-to-event 
outcomes. Outcomes related to disease control, including response, progression or 
recurrence were measured radiologically or by clinical assessment. Disease control 
was either measured as response rate at a particular point in time or, like survival, 
as a time-to-event outcome e.g. time to progression or loco-regional failure. Loco-
regional control was the most commonly used outcome to assess disease response.  
 
Adverse events are routinely measured as a requirement of safety reporting, and 
were measured in all of the included studies, but specified as outcomes in only 
60.5% of trials. Acute toxicity was measured and reported using a validated 
composite outcome tool in 35 of the 43 studies. In 8 studies acute toxicity was 
measured but it was unclear whether a validated tool was used. Acute toxicities 
were predominantly measured using the Radiation Therapy Oncology Group 
(RTOG) Acute Radiation Morbidity Scoring Criteria (20 out of 36 studies) for 
radiation and the US National Cancer Institute Common Toxicity Criteria for 
chemotherapy (14 out of 33 studies). These are observer reported outcome 
instruments. No single study reported all of the toxicities. It is unclear whether this 
is because many of the toxicities were not experienced or whether they were 
measured but just not reported. Late toxicity was measured less consistently, with 
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13 studies not reporting any late morbidity data. The RTOG/EORTC late morbidity 
criteria was the most commonly used measure of late toxicity, used in 24 studies. 
No methods were employed to specifically measure surgical morbidity. 
 
Health-related quality of life was assessed using a number of different patient 
reported outcome measures. The European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire Core Module (EORTC QLQ-
C30) and Head and Neck Module (EORTC QLQ-H&N35) were used in 6 of 7 
studies, although the questionnaires were not always completed in their entirety, 
and not for all patients, even for baseline or early assessment and, as expected, 
attrition increased with time. The Functional Assessment of Cancer Therapy 
(FACT) - Head and Neck Symptom Index was used in one study. All studies 
measured HR-QOL longitudinally, over varying periods of time. At baseline, 
Curran et al [226] collected data for 419 of 424 patients, van Herpen et al [227] for 
353 of 358, Ackerstaff et al [228] for all 207 patients, Zackrisson et al [221] for 
683 of 733 patients, Rischin et al for 836 of 853 and Rodriguez et al [216] for only 
42 of 106 patients. Nutting et al [224] only reported numbers for xerostomia 
assessment, being 39 of 94 at baseline and 12 months and 33 of 94 at baseline and 
24 months, this was contrasted with 73 of 94 patients having reportable data for the 
primary endpoint at 12 months and 55 at 24 months. HR-QOL outcomes were not 
collected as consistently as clinical outcomes. In addition to the problems 
identified in this review with missing assessments, incomplete PROMs are also a 
methodological concern that cause problems with the statistical assessment and 
interpretation of PROM data from a trial [229, 230]. Ackerstaff et al [222, 228] 
explicitly stated that only selected questions from EORTC-QLQ C30 and EORTC 
QLQ-H&N35 were used, in addition they used a trial specific questionnaire. 
Selective use of HR-QOL questionnaires like this makes statistical analysis 
difficult and is a methodological concern, and a potential source of bias [229, 230]. 
Zackrisson et al used average score imputation to replace missing scores in HR-
QOL questionnaires, allowing questionnaires with up to a third of the answers 
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missing [221]. This is a commonly used method for accounting for missing scores 
[231], a particular problem when such questionnaires are completed by patients 
remotely [232]. In most cases, baseline questionnaires were completed at the point 
of randomisation or prior to starting treatment. No studies specified whether 
patients completed baseline questionnaires themselves or with a clinician, in most 
cases however subsequent questionnaires were posted out to patients to be 
completed at home, so it is assumed these were completed by patients without the 
assistance of a clinician. 
 
2.4.8 Comprehensive outcomes list 
 
Fifty of the 58 outcomes could be categorised under broader constructs known as 
‘outcome domains’ relating to toxicity (10 outcomes), survival (16 outcomes), 
disease control (23 outcomes), and health-related quality of life (1 outcome). These 
domains were not determined a priori but rather upon analysis of all of the 
identified outcomes. They were categorised independently by AW and then the 
study team (TMJ, CTS, BY). The remaining eight outcomes were not taken 
forward to the comprehensive outcomes list as they were trial specific, not 
repeatable, or not technically outcomes of treatment. Non-categorised outcomes 
were 1) Identification of parameters that might predict a benefit from carbogen 
breathing 2) Immunogenicity 3) Influence of variations in dose–volume 
distributions in targets and critical organ volumes on the outcome regarding both 
disease and morbidity 4) Pathological response 5) Patterns of failure 6) Prognostic 
factors 7) Time to radical surgery 8) Variations in outcome in different sub-sites 
and stages with respect to treatment type.  
 
 
 
 
 
65 
 
 
 
 
2.5 Discussion 
 
2.5.1 Key findings 
 
The systematic review identified 58 distinct outcomes reported in 43 RCTs. Only 
three outcomes were measured in more than 50% of studies, and fewer than half of 
the outcomes (24/58, 41.4%) were measured in more than one study. Therefore, 
more than half of the outcomes could not be compared with results from 
comparable trials, or combined in a meta-analysis. This is a waste of researchers’ 
time and effort, a waste of research funding and, above all, unethical if patients are 
subjected to repeat testing that will have little added value.  
 
In the studies included in this review, definitions were only provided for 58.3% of 
the outcomes measured, with only 6 studies (14%) defining all reported outcomes. 
This could lead to the erroneous synthesis of differing outcomes in meta-analyses 
if verbatim terms are taken for granted as measuring the same events. Cause-
specific survival was defined by Cooper et al. as ‘death due to the study cancer’ but 
by Haffty et al. as ‘those deaths that occurred with recurrent disease or as a result 
of recurrent disease’ [66, 219]. These outcomes are given the same name but could 
be measuring different events; Cooper et al might consider death following 
progression of the cancer whereas Haffty et al appear to only consider recurrent 
disease – not progression. Two further studies measured cause-specific survival but 
did not define it [221, 233]. Conversely, it is likely that studies measured outcomes 
with different verbatim terms in the same way, however lack of definitions or any 
form of standardised nomenclature makes this assessment difficult.  
This problem has been identified in clinical trials in other areas of healthcare, 
leading to calls for standardised definitions of efficacy endpoints. In a review of a 
selection of the most recently published clinical trials of aromatase inhibitors in 
breast cancer by Hudis et al. [234], disease-free survival (DFS) - a commonly used 
surrogate endpoint in OPSCC clinical trials - was found to be defined differently 
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between trials, with different events included in its definition between trials. 
Additionally, individual events were found to have been inconsistently defined, 
compounding the variability in its definition between trials. This raises the 
possibility that a treatment may be declared as resulting in improved DFS as 
defined one way, but not when defined differently. These findings prompted a 
drive for Standardised Definitions for Efficacy End Points in adjuvant breast 
cancer trials (The STEEP system); endpoint definitions that identify the component 
events that comprise the endpoint and define each component event.  
 
This is not the only such initiative. The National Cancer Institute (NCI) developed 
the Common Data Elements (CDE) to serve as a controlled vocabulary of data 
descriptors for cancer research [235]. This sits within the broader resource portal of 
the US National Institutes of Health (NIH) (http://www.nlm.nih.gov/cde/). This 
may be consulted to identify end points with standardised definitions for use in 
clinical trials, or for data elements to be collected by future studies. Some studies 
have sought to identify CDEs alongside COS development for specific clinical 
conditions, as the two complement one another, increasing the homogeneity and 
consistency of outcome measurement and reporting thus facilitating cross-study 
comparisons or synthesis [236]. COSMIN use consensus methods to agree on the 
taxonomy, terminology and definition of outcomes [237] and this process will need 
to be applied to our COS to improve and refine outcome measurement in clinical 
trials in OPSCC. 
 
The review demonstrated that outcome selection in contemporary OPSCC RCTs is 
focused on disease control and survival, with little attention in many cases given to 
the assessment of functional outcomes and HR-QOL. These findings were 
consistent with previous systematic reviews of OPSCC RCTs which have 
demonstrated inconsistent reporting of HR-QOL and incomplete reporting of 
adverse events [169-171, 238]. In 1981, the World Health Organisation (WHO) 
made recommendations that a measure of patients’ emotional well-being should be 
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made in clinical trials in oncology [239]. Despite this, and despite the well-known 
effects of treatment for head and neck cancer on quality of life, this was only 
reported in 7 trials in this review, all published after 2006. Jensen et al. [240] 
demonstrated strong correlation between treatment-related toxicity and HR-QOL in 
head and neck cancer patients, yet, as described below, adverse effects were also 
incompletely reported.  
 
Acute toxicities of treatment were universally measured, but rarely completely 
reported. Validated, standardised criteria were commonly used for the assessment 
of toxicities however trial reports generally failed to report more than a few of the 
outcomes. Whilst it is assumed that this is due to word count limits, it is not known 
whether studies selectively measured or selectively reported the outcomes or 
whether the events simply didn’t happen. It is now possible for evidence such as 
this to be made available online, as reported by Rischin et al, 2010 [223]. This was 
the only study to report all acute toxicities. 
 
Late toxicities were less frequently measured than acute toxicities, and therefore 
less is known about these late effects of treatment. Thirteen studies failed to report 
any late toxicity data. Acute toxicities were measured at similar time-points during 
and immediately after treatment, time-points for measurement of late effects were 
far more variable, and these were often not measured for more than two years 
beyond the end of treatment. Also, because mortality is relatively high, the number 
of patients or events for late effects may be small. Consideration of late effects is, 
however, of paramount importance in younger, HPV-positive OPSCC patients who 
will live for a long time with the adverse effects of treatment. Where equipoise 
exists for survival, the incidence and severity of such adverse effects, long-term 
dysfunction and health-related quality of life are likely to be important to clinicians 
when making treatment recommendations, and for patients when making treatment 
decisions [46]. Efforts must therefore be made to ensure that patients are followed 
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up for longer time periods to establish the trajectory of adverse events, which are 
likely to inform future treatment strategies, health-care decision making and policy. 
 
2.5.2 Conclusion 
 
The consistency with which clinical and patient-reported outcomes are measured in 
OPSCC RCTs is poor. Redundant outcomes may never contribute to a meta-
analysis or influence clinical practice. The development and adoption of a 
minimum outcome reporting standard, such as a COS would significantly improve 
outcome reporting in trials, providing data to be compared and combined in meta-
analyses. The list of outcomes identified in this systematic review will be used to 
develop a comprehensive outcomes list and questionnaire for the Delphi study 
described in chapter four, and ultimately to a COS for clinical trials in OPSCC. A 
unified discussion for the thesis is presented in chapter five. 
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Chapter 3 
A qualitative study to identify outcomes of importance to patients 
and carers in clinical trials in oropharyngeal cancer 
 
 
3.1 Rationale for this chapter 
 
Oropharyngeal cancers and their treatments often have a profound effect on a 
person’s quality of life, due to their impact on normal functioning [241]. It is often 
difficult for people to carry on their normal lives because of the combined effects 
of multi-modality therapy. For this reason, those close to someone being treated for 
OPSCC are often involved in their day to day care. For example, they may help 
with, or be entirely responsible for, meal preparation, self-care, physical mobility, 
medicines management and transport to and from hospital appointments. 
Furthermore, carers are often required to manage illness-related symptoms, make 
care decisions, respond to emergencies and provide emotional support [242]. Due 
to these demands, a head and neck cancer diagnosis has significant consequences 
for the quality of life of the carer, as well as the patient [243]. Patients have real, 
experiential knowledge of what it is like to have OPSCC and go through treatment, 
and carers are first-hand or ‘involved witnesses’ to this [194]. With different 
perspectives, both are experts in the lived experience of a cancer diagnosis and 
treatment, and therefore have much to contribute to research in this area.  
 
In a qualitative study, Hubbard et al. explored the role of the carer in decision-
making in cancer care [244]. In some circumstances, patients found it difficult to 
process information, and on occasions, carers acted as a conduit for information. In 
this sense, the carer can contribute to moving the patient from a relatively passive 
position in the process to one where they have a greater degree of input and 
knowledge exchange in relation to treatment decision‐making. Carers can also play 
a role in eliciting information from clinicians so that the patient is more informed 
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during the consultation. At times, when it may be difficult for the patient to engage 
in discussion, the carer may be able to pre‐empt what information the patient 
would like to receive, judging the quantity and type of information that the patient 
needs. Thus, the carer can play a role in not only directing information flow but 
also in deciding on the amount and type of information. The carer therefore 
provides a unique perspective on the factors that influence patient decision making 
regarding treatment, and therefore on which outcomes they prioritise. 
 
The emergence of HPV-related OPSCC in a younger patient cohort with greater 
odds of survival, draws more focus to the long-term sequelae of treatment [10]. 
The desire to establish whether contemporary treatment strategies can be de-
escalated to reduce treatment related morbidity whilst preserving survival 
underpins much of the current research in OPSCC [10, 245]. Whilst research in 
laryngeal cancer has shown that some patients will accept reduced odds of survival 
in favour of laryngeal preservation [246-250], acceptable trade-offs have not been 
established for OPSCC [47]. There is therefore an urgent need to establish outcome 
priorities for these patients, particularly in the HPV-positive cohort. 
 
As discussed in the introduction to this thesis, canvassing patient opinion is a key 
step in COS development, as there is good evidence that healthcare professionals 
do not always know which outcomes are most important to patients [251, 252] or 
may prioritise outcomes differently [252, 253]. Research may contribute little to 
the evidence base if it does not measure outcomes that are clinically important and 
patient relevant. There are many ways in which patients can be involved in COS 
development, and in this study we decided to involve patients in the identification 
of outcomes of importance and in the consensus exercise to ratify the contents of 
the COS. 
 
Qualitative interviews were employed to identify outcomes of importance to 
patients at the suggestion of a patient and carer research forum in Liverpool who 
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we consulted on study design. From clinical experience, and our knowledge that 
outcomes related to functioning and quality of life were likely to be highly 
important to patients, we proposed involving patients in some form of qualitative 
inquiry – possibly a focus group. Patients and carers felt that the privacy of one-to-
one interviews would be easier for the research subjects as this would be a highly 
emotive topic for many people to talk about, and open discussion may be stifled in 
a group setting. Furthermore they suggested that interviewing patients and carers 
together may not work for some couples as their experiences could have led to 
changes in the nature of their relationship, the balance of power and at times to 
conflict, all of which may have caused them to hold back in the interview.  
 
I therefore decided to use one-to-one qualitative interviews with patients and carers 
to elicit opinions about outcomes of importance, and to try to understand how 
outcomes relating to functioning and quality of life sat alongside ‘harder’ clinical 
outcomes such as survival. I also wished to investigate whether patients with HPV-
positive disease prioritised different outcomes. Due to available resources, I chose 
to undertake the interviews myself. In choosing to do so it was important to be 
reflexive about my role, and the influence of my position, beliefs and behaviours 
on the research process. My own reflections on this are presented later in this 
chapter. 
  
3.2 Objectives 
 
The objectives of this qualitative study were to: 
 
1. Identify which outcomes are important to patients and their carers 
 
2. Ensure that the comprehensive list of outcomes developed for the Delphi   
study does not overlook outcomes of importance to patients 
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3. Identify the language used to describe outcomes to facilitate the 
development of the Delphi consensus survey 
 
3.3 Methods 
 
I conducted a series of semi-structured interviews with patients treated for OSPCC 
and their carers between March and October 2013, in the UK and the US. I will 
present the methods employed to identify their outcomes of importance in the 
context of clinical trials, and the results of this enquiry. 
 
3.3.1 Setting 
 
Patients were recruited from head and neck cancer survivorship clinics. Three 
centres were used for recruitment; NHS hospitals in Liverpool and Sunderland, UK 
and The University of Texas MD Anderson Cancer Center, Houston, Texas. 
 
The three treatment centres differ by primary treatment modality and patient socio-
economic status; patients with locally advanced OPSCC in Liverpool are largely 
offered transoral laser microsurgery (TLM) and adjuvant radiotherapy and those in 
Sunderland and MDACC primary chemoradiotherapy, which is considered the 
current standard of care. Socio-economic status has a significant impact upon 
outcomes in SCCHN and broadly speaking, MDACC patients are of higher socio-
economic status because of the system of healthcare funding in the US and the 
costs of treatment at that particular centre. It was hypothesised that increasing the 
diversity of our patient sample would add to the richness of the data collected and 
the breadth of both the perspectives and the transferability of the findings.  
 
 
 
 
73 
 
 
 
 
3.3.2 Participant eligibility 
 
Inclusion criteria 
 Patients: Adults, over the age of 18, who were up to 5 years following 
completion of treatment for OPSCC  
 
 Carers: An individual, such as a spouse or family member, who provides 
informal care to the patient 
 
Exclusion criteria 
 Patients with active disease were excluded because the window of 
opportunity to interview them prior to commencing treatment would be 
very short and we did not believe it to be ethical to interview patients going 
through treatment 
 Patients with known or suspected recurrence were excluded because we felt 
the anxieties and concerns associated with this state would skew outcome 
priorities 
 Non-English speakers 
 
3.3.3 Recruitment process 
 
Recruitment methods differed between the three centres and are discussed below. 
 
Liverpool  
(Aintree University Hospital NHS Foundation Trust, Royal Liverpool and 
Broadgreen University Hospitals NHS Trust and St Helens and Knowsley Teaching 
Hospitals NHS Trust) 
Outpatient clinic lists and case notes were scrutinised by local research staff to 
identify eligible patients, attending for routine cancer follow up. The patients’ 
treating clinician approached them to ask if they would participate in the study at 
74 
 
 
 
 
the end of their outpatient appointment. If they were interested, AW or local 
research staff then discussed the study in more detail. If the patient’s spouse was 
present they were asked to participate. Potential participants were given an 
information leaflet and called after five days by AW to ask if they would like to 
participate. Arrangements were made for the interview if the patient provided 
verbal consent. 
 
City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK 
Outpatient clinic lists were scrutinised by JMP, a speech and language therapist, to 
identify eligible patients attending for routine cancer follow up. They were 
contacted by telephone by JMP to discuss the study. If they were interested they 
were posted an information leaflet and contacted by AW after five days to discuss 
the study in further detail and if verbal consent was provided, make arrangements 
for the interview.  
 
The University of Texas MD Anderson Cancer Center, Houston, Texas 
MP, a data analyst at MDACC screened case notes for eligible patients in 
upcoming surveillance clinics. Eligible patients were invited to participate by 
letter, sent at least 14 days before their appointment. This described the study and 
asked patients to call a secure line at MDACC to schedule an interview during their 
next visit, should they wish to participate. AW then called patients and, using a 
telephone script (Appendix five), provided further information about the study and 
confirmed verbal consent to participate.  
 
3.3.4 Participant sample 
 
Patients were sampled with the aim of achieving diversity for certain clinical, 
social and demographic characteristics that we thought may influence their 
experiences, their perceptions of their experiences and their priorities.  These are 
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discussed later in the chapter. Carers of recruited patients were sampled by 
convenience. 
 
There is a certain temptation in qualitative research to sample patients who will 
‘perform’ well at interview; that are known to have strong opinions or offer 
interesting insights into the condition; I met several patients like this involved in 
the patient research collaborative who were keen to be interviewed for the study, 
and whom I know would have provided good ‘soundbites’. It was felt however that 
their perspectives might be atypical compared to other patients because of their 
experiences with clinical trials and relationships with healthcare professionals.  
 
In purposive sampling, participants are selected because they meet the criteria 
anticipated by the researcher as being relevant to the research question. This 
process was facilitated by a sampling matrix. Initially, patients’ characteristics 
were recorded against this matrix, and subsequent attempts were made to identify 
patients with characteristics not yet identified in the patient sample, to ‘fill the 
gaps’ (see table five). That is, patients were initially approached consecutively, by 
convenience sampling, to reduce the risk of inadvertent researcher sampling bias, 
and, latterly purposively sampled, to increase the diversity of our participant 
sample [2].  
 
 
Table 5. Sampling matrix for patient recruitment 
(CRT=chemoradiotherapy; F=female; M=male; PORT= post-operative radiotherapy; 
TLM=transoral laser microsurgery) 
 
Eligible patients were identified by case note review, and once verbal consent was 
provided by patients, AW reviewed case notes in order to collect demographic and 
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clinical data. The patient’s age, gender, co-morbidities, tumour site and stage, 
treatment modality and length of time post-treatment were recorded. HPV status 
was recorded as we anticipated that this may influence outcomes prioritised by 
patients and carers, however this was not a variable in our sampling matrix as we 
knew this information would not be available for patients treated prior to routine 
testing for HPV. Socio-economic status was estimated via the Index of Multiple 
Deprivation (IMD) in the UK and by educational level in the US. 
 
We know that culture and patient values are important factors that may affect 
decision making and how treatment and recovery are negotiated [254]. Significant 
efforts were made to recruit ethnic minority participants, however none were 
available in the study time frame in the UK and none responded to invitations to 
attend for interview in the US. 
 
Based on work by Guest et al [3] we anticipated that we would need to interview 
around 30 patients and carers in total to reach a point of theoretical saturation, that 
is, the point at which no new conceptual insights would be generated through 
further interviews [255]. Thus, we aimed to recruit 10-15 participants per site. Our 
sampling began in Liverpool, and ongoing analysis of the data from this site was 
used to inform recruitment at subsequent sites.  
 
3.3.5 Interview setting and format 
 
In the UK, interviews were conducted in patients’ homes. In the US because most 
patients did not live near MDACC, we interviewed them in the outpatient clinic 
when they were attending for follow-up. We endeavoured to interview MDACC 
patients after follow-up appointments as anxiety about recurrence was likely to be 
elevated beforehand, which may have biased the reporting of outcomes [193].  
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A semi-structured interview format was used, comprising open ended questions 
that defined the area to be explored. This allows the interviewer or interviewee to 
diverge from the questions or prompts in order to pursue an idea in more detail 
[256]. Such an approach facilitates focused yet conversational interactions, and this 
was felt to be particularly appropriate for this group of patients and for the 
objectives of this study, as it allows the interviewee to set the agenda and therefore 
potentially identify previously unanticipated outcomes. Additionally, because of 
the morbidity associated with treatments, interviews were expected to be somewhat 
emotionally charged, and it was hypothesised that a more conversational approach 
would allow me the flexibility to show empathy and explore these issues without 
having to strictly adhere to a list of questions, required by more structured methods 
of inquiry.  
 
We requested to interview the patient and carer separately to avoid the difficulties 
of interpreting individual experiences from data collected at joint interviews, 
whereby it would be necessary to interpret the accounts of each party in the context 
of how it is shaped by the presence of the other party, however, where participants 
expressed a preference to be interviewed together I agreed to this [257]. 
 
3.3.6 Data collection methods 
 
Topic guides were developed by BY and myself, reviewed by the Mersey Head 
and Neck Cancer Patient and Carer Research Forum and piloted by Heather 
Bagley, the COMET PPI co-ordinator. These guided the discussions and ensured 
comparability between interviews (Appendix six). Different topic guides were 
developed for patients and carers. These were developed iteratively over the course 
of the study, with some questions removed and some added in light of the ongoing 
analysis. Certain questions were re-worded if they were found to be unclear to 
patients, and some removed altogether if they did not generate any useful data. 
Some questions were added to probe interesting themes that arose during the 
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course of the interviews. Field notes were made after each interview to record 
observations about the interviewee(s), environment and initial thoughts and 
analysis. These were triangulated with the transcripts and interview notes during 
my analysis. 
 
The remit of the interviews was to identify outcomes of importance to patients. 
Rather than engage in a discourse about research and clinical trials, which would 
be unfamiliar to most and to minimise the risk of obtaining generalised or idealised 
accounts, interviews initially focused on participants' experiences of tangible 
aspects of their current day-to-day lives, activities and pastimes before exploring 
their opinions and reflections on how their lives and priorities have changed since 
their treatment.  
 
At the end of each interview I summarised the main problems or priorities of 
interviewees as a form of respondent validation. I asked them to prioritise the 
outcomes mentioned during the interview, and to consider which outcomes would 
help them to differentiate between treatments if there was equipoise for survival. 
Whilst the interviews were conversational in nature, discussion was progressively 
directed towards identifying priority outcomes. Patient and carer pairs, interviewed 
separately, would occasionally contradict one another however I did not draw 
attention to these discrepancies to preserve confidentiality. 
 
3.3.7 Data processing 
 
Interviews were audio-recorded. In the UK, audio-recordings were downloaded to 
a secure drive at the University of Liverpool. I personally transcribed the first three 
interviews verbatim, including any ‘erms’, ‘errs’, ‘hmmmms’, moments of 
hesitancy, affectations and utterances. A professional transcription agency was 
used to make subsequent transcriptions and I provided the agency with a protocol 
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specifying the document formatting and exact level of transcription required. I 
reviewed all transcripts to ensure their accuracy and make necessary corrections.  
 
It is not possible to anonymise transcripts from semi-structured interviews because 
the combination of circumstances and events could still be recognised by the 
interviewee or someone familiar to them, the transcripts were therefore 
‘pseudonymised’. In this process the names of places and people are removed, 
along with dates or other unique patient identifiable data. Once transcribed and 
pseudonymised, interviews were deleted from the audio-recorder. I transcribed and 
pseudonymised all US interviews, these were then emailed securely to me on my 
return to the UK. 
 
3.3.8 Data analysis 
 
The first four interviews were coded independently by BY and myself. We then 
met to discuss our coding framework and analysis. The codes identified were 
consistent and therefore subsequent interviews were only coded by me. An audit 
trail was kept of my analysis and the subsequent changes to the interview topic 
guides. 
 
 As a theoretical framework, I drew on the principles of grounded theory [4]. This 
inductive approach involves identifying analytical categories from the data rather 
than defining them a priori. I felt this to be the most suitable approach for this 
study in which I was keen to avoid making assumptions about outcomes of 
importance, because of my clinical experience. Initial content analysis allowed me 
to identify the outcomes and language used to describe them in order to develop 
my comprehensive outcomes list. Subsequent analysis was more interpretive and 
informed by the principles of the constant comparative method, with several 
procedural steps to ensure its quality [258]. I used open coding to identify the 
concepts and categories in the data which formed the basic units of analysis. I then 
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used axial coding to confirm that the concepts and categories I had induced from 
the data were accurate and explored these concepts and how they were related. I 
wished to understand whether there were nuances in the patient sub-groups (i.e. 
older vs younger; HPV-positive vs HPV-negative; treatment modality) that 
affected the outcomes of importance and hoped that such an approach would shed 
light on these differences. The language used by patients was helpful for adapting 
my questioning style as the interviews progressed, and I often probed themes using 
terms used by other patients.  
 
Initially, I read each transcript several times before developing open codes to 
describe each relevant unit of meaning. Initial open coding occurred at multiple 
levels, from detailed descriptions of experiences line by line, to the general stance 
participants took towards different aspects of their lives. Through comparison 
within and across the transcripts, the open codes were gradually developed into 
theoretical categories and subcategories to reflect and test the developing analysis.  
 
The categories were organised into a framework to code and index the transcripts 
using Excel software. The framework categories were continually checked and 
modified to ensure an adequate 'fit' with the data, whilst also accounting for variant 
or exceptional cases. The categories and the assignment of data to them was 
reviewed by a second member of the project team (BY). 
 
The analysis of patients’ and carers’ accounts initially proceeded in parallel but 
related, courses. That is, I first analysed data within each group for common 
themes, such as what was important to patients and carers and how their lives had 
been affected by their illness and treatment [259]. As the analysis developed I 
compared across the different groups to identify convergences and divergences. I 
examined how participants presented their accounts as well as the content of the 
interviews; I did not simply take participants' accounts at face value. This was 
important because many of the issues discussed were emotive and I expected a 
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certain amount of stoicism and underplaying of the importance of events in this 
sample. 
 
Finally, I compared data across the different groups (gender, age, HPV status, 
treatment modality and socioeconomic status) and analysed for recurrent patterns 
in how these characteristics shaped participants’ priorities. I kept field notes to 
systematically record the contextual details of the interviews and the evolution of 
the analysis. I lead a process of ‘cycling' between the developing analysis and new 
data, and the study team (BY, CTS, TMJ) ‘tested' the analysis by periodic 
discussion of transcripts and my analysis.  
 
3.3.9 Ensuring quality 
 
Systematic, rigorous, and auditable analytical processes are among the most 
significant factors distinguishing good quality, from poor quality research [6]. 
There has been a move in recent years towards the use of ‘checklists’ to ensure that 
the reporting of qualitative research meets these requirements. Adherence to these 
reporting guidelines does not, however, guarantee quality. The uncritical and 
overly prescriptive adoption of such ‘technical fixes’ whilst appealing, achieves 
little unless they are embedded in a broader understanding of the principles of 
qualitative research [7].  
 
As the interviewer, reflecting on one’s own personal characteristics and how these 
influence the data improves the credibility of the findings by allowing readers to 
assess how these factors might have influenced your observations and 
interpretations. One’s own relationship with the patient and how they may perceive 
your position should also be stated [8]. I have reflected upon these factors in 
section 3.2. 
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I have made judicious use of reporting guidelines in this study, namely the 
Standards for Reporting Qualitative Research (SRQR) [9] and the Consolidated 
Criteria for Reporting Qualitative Studies (COREQ) [10] as recommended by the 
EQUATOR network. 
 
I have endeavoured to demonstrate my analytical process, such that the conclusions 
reached can be traced back to open codes arising from the data (See example in 
appendix seven).  
 
3.3.10 Patient and public involvement 
 
Prior to seeking ethical approval for this study, the patient and carer information 
sheets were reviewed by Heather Bagley, the COMET PPI co-ordinator, for 
suitability of language and clarity of description of the research objectives 
(Appendix eight).  
 
The interview protocol, patient and carer consent forms, information leaflets and 
topic guides were subsequently presented to and reviewed by the Mersey Head and 
Neck Cancer Patient and Carer Research Forum in Liverpool 
(http://www.hanc.org.uk/research.html). This forum is attended by patients who 
have been treated for SCCHN and their carers. As well as helping to ensure 
consideration is given to the views and interests of patients and carers when 
designing research projects, the forum provides advice on research proposals from 
a patient and carer perspective.  
 
I sought general feedback from the forum on the study design and suitability of 
documentation, and more specifically regarding whether patients would prefer 
interviews or focus groups. The opinion was that because of the personal, and often 
emotional challenges faced by patients undergoing treatment, one to one interviews 
were likely to be more acceptable to patients. There was acknowledgment that 
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although those attending the forum were happy to discuss such issues in public, 
this view was not necessarily representative of the wider patient community. They 
suggested that a focus group could be conducted if it was felt that the interviews 
weren’t fruitful. 
 
Reflecting on my discussions with the group, the study team decided that rather 
than only including patients two to five years post-treatment we should extend this 
from immediately post-treatment up to five years post-treatment, as outcome 
priorities are likely to change over time, and will be different for each individual 
based on their own experience. Feedback from the group about wording and 
presentation was integrated into the protocol, patient and carer information sheets, 
topic guides and ethics application. 
 
3.4 Governance, ethics and confidentiality 
 
3.4.1 Research ethics committee and institutional review board approval 
 
Ethical approval for this study was granted in the UK by the Liverpool Central 
Research Ethics Committee (reference 12/NW/0708). The study was registered on 
the NIHR portfolio, ID 13823 (17 January 2013).  
 
Approval at MDACC (Houston, TX, US) was provided by the Institutional Review 
Board (IRB) (protocol number 2013-0285). The IRB was concerned about the 
potentially upsetting nature of the discussions that I would be having with patients, 
and a requirement of IRB approval was that a psychiatrist be available to counsel 
patients following interviews should I have concerns about a patient’s 
psychological welfare. 
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3.4.2 Research and Development 
 
In the UK, research and development (R&D) approval had to be sought for each 
individual trust in which we intended to recruit patients. This comprised three 
separate NHS Trusts in Liverpool, and one in Sunderland. The University of 
Liverpool was the sole sponsor for the study under the Department of Health’s 
Research Governance Framework for Health and Social Care (2005). 
 
Recruiting to ‘theoretical saturation’ meant that the exact number of participants 
required was difficult to specify in advance; this concept was relatively new to 
some R&D departments who were keen for prescribed recruitment targets and 
therefore questioned the methodological ‘soundness’ of this approach. These 
concerns were addressed by justifying the approximate sample size on the level of 
likely heterogeneity within the sample according to our sampling matrix (see table 
5). 
 
3.4.3 Data handling and storage 
 
Identifiable participant information was defined according to the NHS code of 
practice on confidentiality (2003) and handled, processed and stored in compliance 
with the Data Protection Act (1998). This was stored separately to interview 
transcripts, consent forms, audio recordings and field notes. All identifiable 
participant data were encrypted and stored on the central university file store which 
is backed up daily. Hard copies were stored in a secure, locked filing cabinet at the 
University of Liverpool. A key linking identifiable patient information to the 
transcribed interviews was stored at Aintree University Hospital in Liverpool on 
the central research computer which is kept in a locked room. 
 
It was a requirement of the Institutional Review Board (IRB) at MDACC that for 
information security, no identifiable patient information could leave MDACC. 
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Also, a requirement was that audio-recordings be transcribed internally. I therefore 
transcribed and pseudonymised the interviews personally and transcripts were sent 
to me securely on my return to the UK, and stored in compliance with the 
regulations as stated above. The protocol for data handling and storage described 
the procedures to be followed. 
 
3.4.4 Consent 
 
Verbal consent for the interviews was provided by patients when arrangements 
were made for the interview. Written, informed consent was requested on the day 
of the interview. In the UK, this was taken by me, and at MDACC by a member of 
permanent clinical staff, familiar with the study (see appendix nine). Participants 
were informed that they could withdraw consent up to the point of data analysis 
and they were asked whether they would like to see the published reports arising 
from the research.  
 
3.4.5 Sources of funding 
 
I was supported by the Medical Research Council (grant number G0800792) via 
the North West Hub for Trials Methodology Research. Additional travel grants 
were awarded by the British Association of Head & Neck Oncologists and The 
Royal Society of Medicine for grants to fund travel to Houston. 
 
3.4.6 Data presentation 
 
The analyses that follow are based on data from the 23 patients and 11 carers. Data 
extracts are indicated by quotation marks, along with the patient (C) and carer (CC) 
numerical codes. In the extracts, the ellipses (. . .) indicate omitted speech, double 
parentheses (()) enclose speech that was unclear, and brackets [ ] enclose text that 
was entered during transcription or analysis to replace names or aid interpretation. 
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Patients C1 - C9 were recruited in Liverpool, C10 - C15 in Sunderland and C16 – 
C23 at MDACC. Carers CC1 – CC6 were recruited in Liverpool CC7 – CC9 in 
Sunderland and CC10 – CC11 at MDACC. 
 
The themes identified in my analysis that relate to outcomes of treatment are 
discussed below. The other themes identified are outside the scope of this thesis 
and will be discussed elsewhere. 
 
3.5 Results 
 
3.5.1 Participants 
 
The face to face approach strategy used in the UK resulted in higher recruitment 
rates than those in the US done by letter. Compared to the 44 US patients who did 
not respond to the invitation letter, only four patients in the UK declined to 
participate after initial approach. Three gave no particular reason and one said he 
“wasn’t one for talking about his feelings”. In the US we did not have reasons for 
refusal. Table six shows the number of patients screened, approached and 
recruited. All carers that were approached participated in the interviews. 
 
 
Table 6. Screening, approach and recruitment to interview 
 
Thirty-one interviews were conducted with 23 patients (17 male and 6 female) and 
11 carers (1 male and 10 female) between 1st March and 15th October 2013. Three 
of the patient-carer couples opted to be interviewed together, hence fewer 
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interviews than numbers of participants. Interviews with single participants lasted 
between 28 minutes and 2 hours 20 minutes; those with patient-carer couples lasted 
between 1 hour 36 minutes and 2 hours 32 minutes. Patient characteristics are 
shown in table seven, overleaf.  
 
 
Patients 
Age (years) Median Range 
 64 39-82 
Sex Number Percentage (%) 
Male 17 73.9 
Female 6 26.1 
Tumour stage   
Stage III 5 21.7 
Stage IVA 17 69.6 
Stage IVB 1 4.3 
Oropharynx sub-site   
Glossopharyngeal sulcus 1 4.3 
Soft palate 1 4.3 
Tonsil 8 34.8 
Base of tongue 13 56.5 
HPV status   
Positive 10 43.5 
Negative 6 26.1 
Unknown 7 30.4 
Treatment modality   
RT alone 1 8.7 
CRT 7 30.4 
TLM, RT + ND 9 43.5 
CRT + ND 3 13.0 
TLM, CRT + ND 1 4.3 
RT + Cetuximab (Erbitux®) 1 4.3 
Length of time since treatment (months)   
0-12 3  
13-24 7  
25-36 6  
37-48 5  
49-60 2  
Carers   
Age Median Range 
 66 50-70 
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Sex Number Percentage 
Male 1 9.1 
Female 10 90.9 
 
Table 7. Participant characteristics 
Abbreviations in table: BOT=base of tongue; CRT=chemoradiotherapy; GP=glossopharyngeal; HPV=Human 
Papillomavirus; IMRT=intensity modulated radiation therapy; MRND=modified radical neck dissection; 
RT=radiotherapy; TLM= trans-oral laser microsurgery; ND= neck dissection) 
 
When categorised by the English Index of Deprivation (2015), 8 participants (6 
patients and 2 carers) resided in areas between the 1st and 5th deciles (higher 
deprivation) and 16 participants (9 patients and 7 carers) resided in areas between 
the 7th and 10th deciles (less deprived). This index is a relative measure of 
deprivation which combines information from seven domain indices (which 
measure different types or dimensions of deprivation) to produce an overall relative 
measure of deprivation for a small area. There was no directly comparable measure 
for deprivation or affluence in the US, so educational level was taken as a measure 
of socioeconomic status. Seven of eight participants had university or college 
degrees; four were advanced degrees, two bachelor degrees and one an associate 
degree. One participant did not provide this information.  
 
Compared with the tenth annual report of the National Head and Neck Cancer 
Audit [260] for data from 1st November 2013 to 31st October 2014, the proportion 
of base of tongue (BOT) tumours in this cohort was relatively high. In the audit for 
England and Wales, tonsil tumours were nearly twice as common representing 
49.6% of all OPSC compared with 27.7% for BOT. In this cohort 34.8% of 
participants had tonsil tumours compared with 56.5% BOT. HPV status was not 
available for all patients in this cohort or in the audit, because not all patients had 
testing. Of those that did have testing, 62.5% in this cohort were positive, which is 
similar to the audit in which over 70% of those tested were HPV positive. The first 
active treatment for the majority of patients in the audit was non-surgical (55.7%), 
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this was very similar to this patient cohort in which 56.4% of primary active 
treatments were non-surgical. 
 
3.5.2 Outcomes identified 
 
The results are presented under titles relating to the themes in the topic guide e.g. 
‘Diagnosis, priorities and treatment decisions’ relates to questions around their 
diagnosis with cancer, priorities at that point and following and the factors that 
influenced their treatment decision.  The section on burden of presents the 
outcomes relating to treatment associated morbidity. Activities and participation 
relates to discussions around normal participation in every-day life. Process issues 
to themes around the actual delivery of treatment and rehabilitation. Effects on 
relationships presents the themes arising from discussions around relationships 
with those close to them. The subheadings relate to the outcomes actually 
described by patients and carers. In total 136 distinct outcomes were described by 
patients and carers during the course of the interviews. The outcomes contributed 
to the comprehensive outcomes list. 
 
3.5.2.1 Diagnosis, priorities and treatment decisions 
 
Discussion around treatment decisions helped to illustrate what patients’ priorities 
were prior to embarking on treatment. At diagnosis, most patients explained that 
their first thought had been whether they would live or die, as one said “cancer is 
cancer and it’s frightening” (C2). This fear suggested that survival was the most 
important outcome for many, particularly for younger people and those with caring 
commitments. As one young mother admitted “I just couldn’t afford to fail, so I 
didn’t think I was going to.” (C6)   
 
Several patients described “not hearing anything” after they were told they had 
cancer, and two were unaware that they would even need radiotherapy after their 
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diagnostic consultation. Few patients recalled being given treatment options with 
one saying “It’s a relatively binary choice isn’t it- live or die.” (C1). Another 
patient, who enquired of the clinician what would happen if he did not choose the 
recommended treatment recalled having been told “’Well, you die.” This patient 
explained that he did not hesitate further in going with the course of treatment his 
clinician had recommended, saying “That's it, book me in!  And have it done and 
that was it.” (C4). Many patients said they would have agreed to do whatever the 
medical team had suggested, one even questioning the value of doing any research 
at all: 
 
“You get all the pamphlets from the hospital and they give you an... a website that 
you can go on and get, well I, I couldn’t, I couldn’t see the point of wanting to 
understand something when in fact you’re in the hands of the experts and I just 
thought well you know, get on with it.” (C15) 
 
The majority of patients took this stance; that they were in the hands of the experts 
and they would go with whichever treatment was recommended. However this was 
less common in the US where patients tended to have done more of their own 
‘research’ and may have seen other clinicians prior to coming to MDACC. Fears 
about survival were allayed for several patients because of reassurance of a good 
prognosis by their treating clinician. However, looking back at these early 
consultations in the light of their experience of treatment, many felt that the long-
term side effects of treatment were underplayed:  
 
“I thought it's going to be severe, but you get through it and then you may have 
some problems.  But I thought they wouldn't last forever, so whether that was my 
perception, eventually the taste would come back, the saliva would come back, 
everything would come back... And when they didn't that was the hard bit” (C12) 
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Others recognised the quality of life issues but rationalised that the adverse effects 
were of less consequence and worth it for survival: 
 
“The quality of life that I think is important to everybody.  And to know that I've 
got really good quality of life. It hasn’t left me, you know, like with one arm 
missing. It's left me with a few little quirks, but nothing major.” (C6) 
 
Several MDACC patients shared the view of C16 that “the likelihood of a cure is 
just better here than anywhere else”. All patients in the UK were treated by their 
local MDT. None held the impression that treatment would be better elsewhere, 
although two patients who missed out on a Tomotherapy trial (because cancer 
waiting times necessitated an earlier start to their treatment) described now wishing 
that they had waited for this trial, believing they would might have suffered fewer 
adverse effects.  
 
Several of the US participants were professionals and entrepreneurs, and they 
placed greater emphasis than the UK patients on the need to return to work.  
One patient, who was himself a doctor, was particularly keen to avoid open 
surgery, which had been offered in another centre and had chosen MDACC 
because “I basically wanted the highest cure with the minimum torture.” (C16) 
Whilst he attributed his desire for a less invasive treatment strategy to the need for 
a good functional and cosmetic outcome to continue his practice, his wife, who I 
also interviewed, suggested cosmesis wasn’t his primary concern but that the ‘less 
invasive’ nature of a non-surgical treatment approach was appealing. He re-iterated 
several times that he “hated hospitals and doctors” and seemed to find 
relinquishing control and ‘being the patient’ difficult. Thus my interpretation was 
that he had selected MDACC specifically for proton therapy, which he perceived 
to be the least burdensome treatment option. 
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Survival 
Nearly all patients found the side effects associated with radiotherapy the most 
troublesome part of their treatment, with the greatest treatment related morbidity 
and length of recovery. Yet, all patients said they would have the treatment again, 
given the choice, if it led to their survival. Survival was universally prioritised as 
the most important outcome to patients and carers. 
 
Survival meant slightly different things to different people, however. Some 
qualified survival by focussing on certain milestones or living long enough to see 
an important event such as a child’s wedding or seeing grandchildren growing up. 
Others, especially those with young children talked about survival in more absolute 
terms: 
 
“cure in the sense that you are 'gonna' be around.” (C6) 
 
For some older patients, whilst survival was still their priority, they were more 
focussed on short term goals and C5 said “to tell you the truth I, I live day to day”: 
 
“You’re not looking forward to planning things for the next five years or something 
like that or, or things like that.  So err as I say the, the most we, we look forward to 
is probably four months pre booking of a holiday ((laughs)).” (C5) 
 
C23 questioned whether he would go through treatment again were he older, 
stating “If I was eighty, I might say no.” For him, quality of life would be more of 
an issue than survival at this point.  
 
Box one, overleaf, shows some of the other themes around survival that arose. 
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Box 1. Survival 
Trade-offs 
“The treatment was more brutal than the disease itself, but I had to have that 
brutal treatment to stop the disease.  So, you know, it’s a trade-off isn't it?  It’s 
either get really, really ill... And then, or slowly get ill and then die. So you, sort 
of, trade it.” (C6) 
 
Advancing age and changing priorities 
“My whole family was like “Ok, Ok, we gotta know, if it came back would you 
go through with it again?” I said “Yeah. If I was eighty, I might say no, as long 
as I’ve got a chance to watch them get older and see my grandkids grow up, 
yeah, I’ll get through it again.” (C23) 
 
Survival to a point 
“As far as the future, the future goes, um, you know, er, yeah, I, er, I am positive 
about it, um, and like I say, er, I have got to make sure that I walk [my daughter] 
up that aisle.” (C7) 
 
Survival for others 
“I’ve always been in the erm children’s lives and I always want to be because 
erm I am important to both of them because erm, well we see them, we see them 
every day really and so yes, I am important and I want to continue to be.” (C2) 
 
 
Fear of recurrence 
For many patients and their carers, fear of recurrence was highest in the days to 
weeks before their follow-up appointments: 
 
“I know he worries every time we drive up to [the hospital], and that, he is worried 
that it will come back and that he will have to go through the whole thing again.  I 
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think he worried initially for his own mortality I think, but… although he tried, he 
said that he felt very positive about it, because he was told that the outcome was 
quite, would be good, he still worried for his, he’s still worried for his own life.” 
(CC1)  
 
This anxiety would subside after getting the ‘all-clear’ at their appointment. One 
patient who I interviewed the day after his follow up check said: 
 
“I mean the cancer certainly isn’t weighing heavily on me and erm it was weighing 
a little heavily yesterday” (C16) 
 
For this reason many patients were glad when follow-up periods were extended; to 
them it meant the clinicians were less concerned about the cancer coming back and 
it meant fewer appointments with less frequent spells of anxiety in the lead up to 
them. In the UK, patients are followed up for 5 years from the end of treatment and 
then discharged if they are disease-free. One patient described the follow-up as 
being “like a sentence”, “a five year thing and I’m two and a half years through 
it” (C2) 
 
Some viewed the 5-years as a big landmark - once they reached this they would 
feel “off the hook” - others admitted that they felt they would always be concerned 
about their cancer coming back, however the intensity of these concerns seemed to 
lessen as time went by. 
 
Worries about recurrence kept some patients awake at night, and several 
commented that any kind of throat symptoms made them anxious that their cancer 
was back. For many this stemmed from their cancer being so indolent in the first 
place; they did not know what to look out for and were worried that they would 
miss it again. Anxiety about recurrence was more prominent in the accounts of 
carers than patients. There were concerns about recurrence and the need for more 
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intensive treatment, death, and also concerns, for some, about how they would 
cope if their partner died: 
 
“I think I tend to probably worry a little bit more because I know CC4P doesn’t 
worry so I thi- probably I worry a bit more about um ((tuts)) like I suppose like 
everybody um you know, financial security, you know, as you’re getting older.” 
(CC4) 
 
Many carers felt that their partners downplayed concerns about recurrence, so 
whilst fear of recurrence was less apparent in patients’ accounts this was perhaps 
because they were masking their real concerns.  
 
3.5.2.2 The burden of treatment  
 
Treatment side-effects 
Few patients had symptoms from their tumour, with several commenting that they 
“weren’t sick until they started treatment”. The burden of treatment was substantial 
for many patients with multiple adverse effects of treatment limiting their ability to 
live a normal life. Indeed, the nature and severity of the adverse effects of 
treatment overwhelmed many patients: 
 
“[Radiotherapy] was horrible. It was the hardest thing that I’ve ever been through. 
I never had any pain or any kind of physical feeling with the cancer, the treatment 
felt like it was going to kill me.” (C23) 
 
All but two patients in this sample had multi-modality therapy and without 
exception, these patients described the adverse effects of radiotherapy as the most 
difficult to deal with, one patient commented: 
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“The operations, I could cope with them alright, it was just the radiotherapy which 
knocked me for absolute six.” (C7) 
 
At the outset many patients reported having scoffed at the suggestion that they 
would require a prolonged period of time for recovery, and many assumed they 
would be able to return to work and usual activities at the end of radiotherapy: 
 
“I can remember the specialist nurse saying, it was, I think it must have been when 
I was having my PEG fitted, um, you won’t be back [at work] by Christmas, you 
know, it will probably be Easter.  And I was thinking EASTER, but this is, like, only 
September, you know, what's going to be going round till Easter?” (C10) 
 
This seemed to be because few expected the adverse effects to be as severe as they 
were. Most patients felt that the clinical team underplayed the likelihood and 
severity of the adverse effects of treatment, and several postulated that clinicians 
deliberately withheld information from patients, who would not go ahead with 
treatment had they known how difficult it would be: 
 
“It's very clever what they do, but you don't realise how clever until it's all finished 
and you look back because they only tell you just as much as you need to know on 
that particular day.” (CC7) 
 
Others, acknowledged that the discussion of ‘quality of life’ issues did occur at 
least to some degree, however this simply ‘went over their heads’: 
 
“Neither of us expected that he wouldn’t be able to eat certain things, or, um, he 
wouldn’t be able to taste anything anymore, or he wouldn’t be able to-, all his 
saliva had gone, he wouldn’t, none of us expected that. Mr W had talked about 
different, sort of, treatment, or the type of treatment, and that, and what would be 
the best, um, outcome for the, you know, the patient's sort of long term health 
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benefits, or whatever.  Er, quality of life, that’s right, that’s what he said, but we 
just didn’t, that sort of went over our heads, we were just, didn’t, didn’t even 
anticipate that there would be anything different really.” (CC6) 
 
Carers generally seemed to hold more negative views of radiotherapy than patients, 
with CC1 saying “I would take my chances” rather than have radiotherapy 
treatment. This stood in contrast to patients, who although they all described the 
very difficult and traumatic impacts of radiotherapy, not one said that they 
wouldn’t make the same choice to have it again – if it cured them. Coming face to 
face with the possibility of death seemed to have galvanised their determination to 
live, irrespective of the adverse effects of treatment. 
 
Impact on eating and drinking 
Most prominent in patients’ accounts were the adverse effects of treatment on their 
ability to eat and drink. There were several barriers to eating and drinking. Pain 
was a problem for some patients following tonsillectomy and/or trans-oral laser 
resection of their tumour, as this gave rise to a sensation of “swallowing cut glass” 
when trying to eat (C7), although this generally only lasted for a couple of weeks 
after surgery. For most patients, pain related to radiotherapy treatment, was the 
most significant. This was caused by radiation burns to the mouth, throat and neck, 
which made chewing and swallowing very difficult and was a disincentive to 
eating and drinking: 
 
“you start not wanting to, to swallow or to eat, and stuff like that, because you 
know it’s going to hurt.” (C6) 
 
Some needed enteral feeding via nasogastric (NG) or percutaneous endoscopic 
gastrostomy (PEG) tube to maintain nutrition and for some, hospitalisation to 
manage their symptoms. Radiation related ulcers were not only painful, but 
contributed to nausea: 
98 
 
 
 
 
 
“The radiotherapy to the neck em… it’s horrible it’s disgustingly horrible, it 
knackers up your throat, you get ulcers, ulcers become septic, septic goes into your 
stomach you throw up feel ill, that’s basically it.”. (C1) 
   
Nearly all patients had certain foods they avoided either because of taste 
disturbance, pain, mouth dryness, difficulty swallowing or difficulties chewing 
related to ill-fitting dentures. Adverse effects on eating and drinking were also 
associated with chemotherapy, and several patients complained “The worst thing 
with the chemo was I was constantly really sick, constantly nauseated.” (C17) 
although, as noted above, several felt that the radiotherapy had caused their nausea 
“There really wasn’t a whole lot during that period except pain and nausea. I had 
quite a bit of nausea, I thought nausea only came with chemo treatment and found 
out mine started almost immediately with radiation.” (C23). 
 
When considered together, pain, taste disturbance, altered secretions and nausea 
had a profound and cumulative detrimental effect on the ability of many patients to 
eat and drink during and in the weeks following radiotherapy treatment, described 
by one patient as a significant “disincentive to eating” (C23), another commented: 
 
“I couldn’t eat, I just could not eat, and I didn’t feel like eating.  Um, I was 
struggling swallowing, the dryness in the mouth, the tenderness.  And obviously 
just the pain as well, because I had the pain in my shoulder, and I think if you have 
got like a nagging, nagging pain, you just don’t feel like eating all the time.” (C7) 
 
For most, eating and drinking gradually became easier following treatment, 
however there were a number of other difficulties related to eating and drinking in 
the long-term and all patients had adjusted their diet to a greater or lesser degree to 
accommodate these changes. Dental extractions were also required for many 
patients and some struggled with ill-fitting dentures following radiotherapy related 
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changes or because of mouth dryness. Others had difficulty chewing because of 
restricted mouth opening and pain in the jaw, and for some a multitude of factors 
led to ongoing difficulties with eating and drinking: 
 
“Just the whole mouth opening, lack of saliva and not being able to swallow, and 
not being able to talk while I am eating.  And only being able to eat, even when I 
do eat, it’s a teeny plateful of whatever it is.  And it’s exhausting, eating is 
exhausting; it makes my jaws ache, um, er, I can only get tiny pieces into my mouth 
anyway.” (C10) 
 
Taste disturbance 
Taste disturbance appeared acutely during radiotherapy and for most patients never 
returned to normal. During, and in the weeks following radiotherapy, food was 
often described as tasting like ‘cardboard’ or ‘metal’ and water or nutritional drinks 
like ‘oil’ or ‘lard’. Most patients had a heightened sensitivity to spices, saying they 
could “taste spice where there isn't even any spice.” (C10) in some cases 
describing tomato ketchup or bananas as spicy: 
 
“You start off with like this baby mouth on one side, where it’s like I couldn’t even 
go near a Korma ((laughs))… spices, or peppers or anything that’s got a lot burns.  
And you have to get used to flavours, and how things taste.” (C6) 
 
Many patients were unable to eat their normal diet saying that they “suffered things 
they would have enjoyed before” (C1). All patients had long-term reduction in the 
sensation of taste. This seemed partly related to the direct effects of radiotherapy 
and partly to a reduction in saliva. This was quite disorientating for some patients 
initially, especially when combined with a generalised sensory disturbance in the 
mouth.  
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Weight loss 
An inevitable consequence of these difficulties is weight loss, and this was mostly 
described by patients and carers as a negative experience. Clinicians had 
emphasised the importance of weight maintenance and for many, the struggle to 
maintain weight became a significant source of anxiety. They were concerned they 
would no longer fit their radiation mask and would need to have treatment delayed 
to be re-fitted. Others were concerned that they were less likely to be cured if they 
lost more weight; that their ability to ‘fight back’ would be hindered. Furthermore, 
despite high calorie intake, many patients were unable to maintain their weight: 
 
“It was really hard to keep the weight on because it was extremely hard to eat. I 
basically lived on ‘Ensure’ more than they said they regularly ever see anybody do 
it, I was drinking six or eight bottles a day and that was all, but, you know I was 
getting over two thousand calories that way but I was still losing weight hand over 
fist.” (C23) 
 
Anxiety about losing weight was most prominent in the accounts of carers, who 
were often given the responsibility, by healthcare professionals, of ensuring that 
their spouse maintained an adequate oral intake. As a result, meal times often 
became a source of friction for couples: 
 
“It’s hard for someone to understand when you haven’t taste or when after a 
couple of weeks of radiation and chemo everything tastes terrible. And the 
nutritionist is telling my wife ‘you’ve got to make him eat’ and she’s telling me to 
eat and I’m saying quite frankly it’s like eating out of the bottom of a sardine can, I 
mean it was awful, everything tasted awful.” (C22) 
 
Some patients reported that their carers were unable to understand that they could 
not just ‘force food down’. One patient, when explaining this to his partner 
101 
 
 
 
 
provided an evocative analogy to explain the difficulties of eating during 
radiotherapy: 
 
“‘Tell you what, I’ll make myself take a bite of the food and eat it if you will take a 
bite of a jalapeño, before you eat a bite of food, and we’ll both keep eating as long 
as you want to and as long as you’ll take another bite, you know you might get by 
with that one or first two bites of that jalapeño but when you have to eat a third, or 
fourth, or fifth jalapeño you’re gonna say ‘No!’ you’re gonna stop eating, and 
that’s how it is for me.’ When you were nauseated you had no appetite, and it’s 
really hard to eat when you’re nauseated and food tastes wrong, and it hurts, it’s 
just like ‘Who would eat’ in that situation?’” (C23) 
 
Interestingly, a few patients who were overweight before treatment did not mourn 
this loss as much and enjoyed being slimmer. C1 said he was ‘dead chuffed’ after 
trying to lose weight for years unsuccessfully. C16 enjoyed the fact that he could 
eat what he liked and not put weight on, saying: “In the old days when I would 
frequently eat a pound of BBQ potato chips in a day, I’m staying thin now and 
don’t have to work at it at all!” (C16) 
 
For C, her weight loss was positive in the respect that she had always wanted to 
lose weight but negative in the sense that she had no control over this and there 
was a certain sense of loss of identity. 
 
“It's strange, because it, it, you always want to be… I was always big, even from 
when I was a kid I was big, you know, that was me.  And then all of a sudden I am 
not big anymore.” (C6) 
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Socialising around food 
Changes from normal eating and drinking patterns were especially difficult for 
patients who had previously socialised around food and drink, as this was no 
longer something they could enjoy as much, if at all: 
 
“[Life] is totally different because I loved eating and I loved drinking wine.  Um 
((coughs)) and now, even if I do, even if I was to try and eat - which I do try and 
eat something every night - I can’t eat with other people because it’s such a 
difficult thing.  And I certainly can’t talk when I'm eating. So socially, um, it’s just 
a, you know, it doesn’t exist.” (C10) 
 
One patient made the point that this was likely to bother him “more than the person 
who probably eats at home every night.” Saying: 
 
“We were fairly social people. Erm… I had a wine collection worth $100,000 so I 
had a lot of wine and couldn’t drink it. So yeah I would say it might have been 
more… I would say a farmer from Iowa who’s pretty much eating at home would 
find it less difficult. He might find it as difficult to eat things but it wouldn’t bother 
him as much as it bothered me.” (C22) 
 
Some patients who had transoral laser microsurgery (TLM) described a sensation 
of the throat being tighter on the side of the surgical resection meaning that they 
had to take smaller bites. Combined with their lack of saliva, meals took much 
longer to eat, meaning they were unable able to finish at the same time as the 
people they were eating with. Nasal regurgitation was another problem in this 
patient group as a result of surgical removal of the soft palate. This was socially 
embarrassing and, for some, meant that they avoided eating in public: 
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“It’s embarrassing when I’m out, if I don’t get my breath right the whole, 
everything, food, everything just… I’ll have a tray here and the whole lot’ll, 
everything pours down my nose.” (C8) 
 
Eating and drinking for many required significant focus, and was no longer an 
enjoyable activity, especially when in public. 
 
Mouth dryness 
Changes in the consistency of saliva generally started towards the end of 
radiotherapy treatment with several patients initially complaining of foul tasting, 
mucinous phlegm which they were unable to swallow.  
 
“I can’t emphasise enough the muck that was coming up into my neck and mouth. 
((cough)) It was disgusting. It was just all, there wasn’t no let up from it.” (C8) 
 
The consistency and amount of saliva generally improved, although this didn’t 
return to normal for any of the patients and swallowing remained difficult for 
many: 
 
“I've not got enough saliva, or I have [[ate]] something that's quite drying, and I 
have not realised how drying that really is.  And then I have gone to swallow it and 
it’s like, no, that’s not happening!” (C6) 
 
For many, their diet had become less healthy, the mouth dryness imposed several 
dietary restrictions: 
 
“I loved salads, and, I mean, I was a healthy eater.  Um, I mean, I liked rubbish as 
well, but I was generally a healthy eater, and I can’t eat anything like that now.” 
(C10) 
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These effects had a significant impact on patients’ enjoyment of food, with many 
‘eating to live’. One patient had significant anxiety around eating, because this 
continued to be very difficult: 
 
“Eating problems haven’t changed, it’s still no fun… Oh God, I just don’t want to 
go to the table, I dread it. I dread it. It’s just a chore.” (C8) 
 
Patients and carers described mouth dryness as having a cascade-type effect - 
leading to, or contributing to, many other problems: 
 
“It’s his dryness of his mouth which affects everything, you know, it affects his 
sleep and the conversation, as I've said, it's really - They say dryness doesn't do it 
justice, it's really life-changing for him.” (CC7) 
 
Many patients talked at length about the lack of saliva itself and the multiple 
secondary effects of this. For many this was an acute and long term effect. In 
addition to the problems associated with eating and drinking, which are well 
recognised in the medical literature, there were a number of other effects, which 
are less well documented. These are illustrated in box 2. 
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Box 2. Mouth dryness 
Anxiety about oral hygiene 
“[crisps] get in your teeth, and they are all in your mouth, and you get quite, I don’t 
know… but I like to make sure that, you know, like, I have a mouthwash before I go to 
bed and when I get up.  And it’s just because ever since the operation, when I get up, I 
get up and I feel like di-… it feels like somebody's died in my mouth.” (C6) 
 
Tiredness when speaking 
“I was a deputy head teacher in a primary school; I can’t even read a story to my 
grandsons now ((coughs)).  Partly because my mouth gets so dry, and partly just 
because when I start just speaking without a break, as you are doing when you are 
reading a story, I am absolutely exhausted by about the fourth page or something.”( 
C10) 
 
Inability to exercise 
“I just can’t do anything [exercise] because I can’t, my mouth gets so dry and I can’t 
take a drink unless I can hold my breath, and you can’t hold your breath if you are out 
of breath.” (C10) 
 
Interrupted sleep 
“I’m waking up every hour and a half anyway because me mouth just dries up so… I 
have to take a bottle of water now just I don’t know how to put it, it’s like a bit of 
leather all shrivelled up so, I wake up every hour, hour and a half.” (C3) 
 
 
Swallowing 
In the short term, radiation related pain and mouth dryness had the greatest impact 
on ability to swallow. Oropharyngeal resections had very temporary effects, only 
lasting a couple of weeks, in this patient cohort. In the long-term, swallowing was 
affected by a number of factors. Radiation caused hardening and stiffness in the 
muscles in the mouth and tongue leading to difficulties chewing food, forming a 
food bolus, propulsing to the throat for swallowing, and then difficulty initiating a 
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swallow. Several patients had radiotherapy related oesophageal fibrosis which 
meant that the oesophagus was narrowed. It was therefore difficult to get food 
down. Reduced saliva meant that food was poorly lubricated and more difficult to 
swallow. One patient had problems with food going ‘down the wrong way’ into the 
lungs and causing chest infections. This can be sequelae of both the cancer and the 
treatment. 
 
Fatigue 
Fatigue was a significant problem for many patients during and immediately after 
radiotherapy. This had implications for those with other caring duties who were 
unable to care for their children, pets or elderly relatives. For some this meant they 
were unable to travel to radiotherapy and ended up requiring hospitalisation. This 
was something that most patients strongly wished to avoid, in many cases because 
of their own commitments as a carer to others, especially children. Fatigue was 
another factor that contributed to difficulty with eating and drinking. The level of 
fatigue was so great for some patients that they would often want to sleep through 
mealtimes and would have little energy to have a meal, which was already a 
difficult task.  
 
Some patients described how fatigue persisted into the long-term, with some 
complaining of a lack of ‘Get up and go’ or a loss of ‘Mojo’. Patients had to reduce 
their working hours and several continued to have naps during the day or in the 
early evening, often ‘hitting a wall’ after only a few hours of activity. This was 
particularly troublesome for patients who were unable to fill their obligations as a 
parent or in their place of work. For many it meant that they were unable to return 
to exercise or evening activities after a day in work. 
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Tube feeding 
The requirement for enteral feeding was seen as ‘failure’ by many patients. This 
seemed to stem from the way that it was described as a ‘last resort’ or something to 
be done if they ‘weren’t managing’. Similarly, some patients were concerned that 
they would never swallow again if they accepted enteral feeding and took great 
pride in having avoided this. Some described being ‘determined to avoid’ (C1) 
enteral feeding, in some instances against medical advice (C6), as the procedure 
seemed to signal the beginning of a ‘loss of control’ and a slippery slope towards 
increasing medicalisation and eventually hospitalisation. For those patients who 
could not avoid tube feeding, most opted for a PEG, several saying they would feel 
more socially isolated with a NG tube, because this would be visible to others.  
 
Several patients had technical problems with their PEGs which were a significant 
source of anxiety as some described feeling that their ‘life depended on’ their PEG. 
One patient (C8) found the PEG to be unhygienic, saying that he was concerned 
that it had an unpleasant smell and that the device would often get caught under the 
toilet seat. He admitted to being quite a particular person and for him the PEG was 
a considerable challenge. Others were conscious of the appearance of the scar 
following PEG removal. 
 
Dental extractions and jaw problems 
Some patients required dental extractions prior to starting radiotherapy and several 
commented that they were keen to avoid this;  
 
“They put the fear of the Lord into me about losing all my teeth and I can never 
have a crown… but if I ever were to get punched  or break my jaw it will not heal 
without a bone graft so that did make me think that I’m willing to put these things 
in my mouth every night.” (C16) 
 
108 
 
 
 
 
Many patients were concerned about losing teeth post-operatively and of 
developing osteoradionecrosis of the jaw. 
 
Shoulder weakness 
Only patients who had had neck dissection complained of shoulder dysfunction. 
Some attributed this to the surgery and others to radiotherapy. This had significant 
consequences for some patients. One had to change jobs as he was no longer able 
to undertake the manual nature of his work, a second had to sell his motorbike as 
he was no longer able to hold himself in the position required to ride. Several 
patients were no longer able to play sports which they had previously enjoyed, and 
poignantly one was no longer able to take his children out with their horses or skim 
stones with them. Pain was also a problem in this group and one patient found it 
hard to eat because of the ‘nagging pain’ in his shoulder and another felt that it 
disrupted his sleep.  
 
Altered appearance 
Some patients were concerned about their changing appearance and others’ 
perception of them. For some this related purely to their physical appearance; loss 
of muscle bulk and looking ‘like a skeleton’. For others there was more of a 
concern about the connotations of being underweight, with one patient concerned 
that he looked like a ‘drug user’. Another was concerned that his radiation 
dermatitis made him look like a ‘leper’. One patient had a severe skin reaction to 
Erbitux®. He found this particularly challenging because it was outside ‘the norm’, 
and not a usual adverse effect of cancer treatment: 
 
“There are a lot of people here with no hair but there aren’t a lot of people with 
open sores all over and you feel, you don’t want to go out to eat, you don’t want to 
go to the cafeteria hardly, you just want to get your radiation treatment and come 
back- because it’s ugly.” C22 
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For one patient (C1), the wound from his neck dissection was longer than he had 
expected and he thought the surgical clips, drains and lines would be alarming for 
his partner. 
 
Many patients had neck dissections as a part of their treatment and several men 
complained of having a ‘scrawny’ neck afterwards, meaning they had difficulty 
fitting shirts. A female patient grew her hair long and wore it down to hide her 
neck dissection scar, because this often prompted questions from people who did 
not know about her cancer and she preferred not talking about it. 
 
“… if I was to meet a new person I have my hair down, I don’t have my hair up.  I 
don’t talk about the cancer to people that I've just met, or I don’t like talking about 
it to them. And the people around me, we don’t talk about it unless something 
relevant comes up, and then they might say like, this, that and the other.  So I think 
it’s just having that conversation, because it’s just, you know, when you are trying 
to get to know somebody, and somebody goes oh, well thing, and what's the scar 
from?  Oh, I had cancer?  Oh really, well…  Yeah, people really do get awkward 
about the subject.” (C6) 
 
She did, however, speak of being proud of her scar as this reminded her of what 
she had survived.  
 
“I feel like I have been incredibly lucky.  I feel quite, I am proud of my scar, um, 
because it proves that I have been through something and, you know, I am, I am 
stronger for that.” (C6) 
 
Others said they did not want a scar because they felt this would be a constant 
reminder of an awful time. Others felt less likely to have chosen a treatment option 
with a risk of a scar. 
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“I often think if they had said to me do you want surgery or do you want the 
treatment, I would have probably chosen the treatment thinking, well I don’t want 
a big scar on my neck.” (C10) 
 
Some patients described their smile as ‘wonky’ following marginal mandibular 
nerve palsy. In some cases this resulted in drooling and cracked skin at the corners 
of the mouth as a troublesome consequence. One patient, following injury to the 
spinal accessory nerve and the marginal mandibular nerve following neck 
dissection, described himself as ‘disabled’. 
 
“… that’s been hard to deal with because the way it’s left me mouth, it’s left me 
like disabled sort of thing because I can’t raise this arm anymore as high as this 
one, em, the shape of me body is like this, me body’s like lop-sided. I feel like my 
face is lop-sided this side’s stopping em... I started having different sensations, 
even now around me lips” (C3) 
 
Several patients had persisting skin changes as a result of their radiotherapy 
including redness, thread veins, dry lips and thinner hair. Lymphoedema was an 
issue for some patients, particularly one woman who wore a scarf to conceal it. 
Interestingly, despite these concerns, she still did not do the recommended 
exercises. 
 
Speech and voice 
This was another factor that was more important for some patients than others. For 
some a change to their voice was something that they found funny or a mere 
irritant, for others this represented a ‘change of identity’ (C12) and was one of their 
‘greatest concerns’ (C12). One patient was unable to return to work as a teacher 
and engage socially as a Soprano singer because of the effects on her voice: 
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“I can’t sing, obviously, my voice is so deep now, um, I can’t, and I used to sing a 
lot.” (C10) 
 
She was also unable to read stories to her grandchildren because her mouth would 
become too dry.  
 
“Um, so when they are singing things that they have learned at school and I want 
to sing with them, I can’t; things like that really frustrate me.  Um, reading to 
them, I would love to be able to do that.” (C10) 
 
Some patients described their voice as ‘clacky’ (C9) because of their mouth 
dryness, and as noted in box 1 above, several said that extended conversation was 
‘tiring’, requiring regular drinks to be able to maintain conversation (C6). Another 
was unable to project her voice and had a tendency to withdraw from conversation 
in social settings because she struggled to make herself heard (C10). 
 
Social life was very important to C3, and he noted that his partner had commented 
how lucky he was that he could still enjoy karaoke, one of his favourite hobbies: 
 
“We go to town every Sunday and like she’s going…. Sorry… (becomes tearful) … 
eh she knows how much I love the karaoke so she was like god help you you can 
still sing you know what I mean so that was like… and I wasn’t myself with the 
social life.” (C3) 
 
He became tearful discussing this, and described his social life as ‘the main part of 
me life’ (C3). For him any withdrawal from social life would have been ‘a killer’ 
(C3). 
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Psychological well-being 
Low mood and depression were common during and immediately following 
treatment. For many patients their lives had changed completely, and they were no 
longer able to do the things they would have done before. For example, the loss of 
vocation was difficult for C17 who had worked and been a volunteer before 
starting treatment: 
 
“Part of that depression was, I would get up and “What am I going to do today?”, 
I don’t have a job, not healthy enough to go do this, what do I do with myself? I 
can’t just sit every day, you know I don’t like to watch TV and I don’t like to 
become mindless.” (C17) 
 
C13 and his partner, who had a joint interview, felt that he had managed his mood 
well during treatment, but that his depression arose when he had difficulty 
returning to normal activities: 
 
“I did sense that it was a little bit of depression there as well.  And I put that down 
to um not being the person I was before that, before everything that’s happened.” 
(C13) 
 
Another patient attributed his depression to difficulties with eating and drinking 
and a frustration at his circumstances: 
 
“I was depressed because I couldn’t eat, and basically at my age, I own a 
company, I’ve got plenty of money to do things I want to do and here I was, I’d 
been stuck in either a hospital room or a house for eighteen months, so I was 
rather depressed.” (C22) 
 
C10’s treatment had a profound effect on her life: 
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“It just seems like everything, that everything has been taken away; um, everything 
I enjoyed has been taken away, basically.” (C10) 
 
C23’s wife was particularly worried that he would never return to being the person 
he had been before: 
 
“At some point down the line I was watching a television show and I laughed, and 
it stopped her in her tracks because she hadn’t heard me laugh in months, and she 
realized how much she had missed it, it practically made her cry, she realized that  
she really, really missed that, and it was one of those indicators that I wasn’t the 
same person and that scared her to death, that I was never gonna get back to being 
the same person.” (C23) 
 
Two carers described their partners as being depressed during treatment; although 
the patients themselves had not suggested this during their interviews.  
 
Cognitive decline 
Cognitive decline was a problem for several patients after treatment. Memory 
impairment and poor concentration were particular issues, and several patients had 
problems finding the words for what they wanted to say. This was of more concern 
to those still in the work place, two of whom felt their work performance had been 
affected: 
 
“I have organizational skills err problems now, where I used to be a lot more 
organized, not that I was really organized but I’m really disorganized now when I 
start trying to put stuff together and the logic’s not always… I’m having issues 
about trying, how to prioritize and what order it needs to be done, I’m also a bit 
more forgetful.” (C20) 
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One patient found this a particularly difficult and frightening side-effect of 
treatment to deal with: 
 
“I’m driving the familiar route and all of a sudden, stuff won’t look right to me and 
it’s a little unnerving I’m like “You’re in the right place, you’re in the right place 
you don’t… I think it’s been very [voice breaks] frightening [becomes tearful] and 
very depressing.” (C17) 
 
It also affected her desire to socialise because she had difficulty remembering 
names: 
 
“What really drives me crazy is people I have known for years, I grew up in this 
area and we, the girls that I went to High School with - I mean we graduated 52 
years ago – we get to lunch together four times a year and I’ve lost their names. 
And I look at their faces and I know them and now I don’t know their names. It’s 
very frustrating” (C17) 
 
No patients were aware of this possible side effect prior to embarking on treatment 
and this had very different implications for people, depending on the degree of 
disability and what was required of them in their day to day lives. One patient felt 
that her cognitive dysfunction had improved in the time since treatment. 
 
Personality changes 
Several patients noticed personality changes after treatment. Some said that they 
were more emotional, and more likely to cry; some felt their emotions were more 
‘up and down’ and that they were more irritable and quick to anger. One patient 
admitted that he now refused to queue because he did not have the patience for 
this. 
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Dependence on medication 
Some patients described having developed a dependence on opiates during 
treatment, but for a much greater number the fear of dependence meant they used 
them with caution. Others were concerned about their ability to make decisions on 
opiates and the impact this would have on their home life or work. Many patients 
commented that they didn’t like taking medication and so avoided this as much as 
possible – to their detriment at times. 
 
Fluctuating vision 
Several patients complained of fluctuating vision during and following 
radiotherapy requiring several different glasses prescriptions. This was a 
significant financial burden for some patients. One patient felt even more isolated 
during radiotherapy because of her visual problems as she was unable to read or 
watch television. 
 
Hearing loss 
Some patients had cisplatin-related ototoxicity and others Eustachian tube 
dysfunction and glue ear resulting in hearing loss. 
 
Sensitivity to the cold 
Several patients complained that they were always cold during radiotherapy 
requiring multiple layers of clothing. Others noticed that their ear and the area 
around their neck dissection wound was more sensitive to the cold. 
 
3.5.2.3 Activities and participation 
 
Social isolation 
Many patients became socially isolated during treatment because they simply felt 
so unwell. Many explained that they would sleep much of the day, or be sleepy 
from opioid analgesics required to manage the pain from their radiotherapy burns: 
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“When you go through treatment you’re really, really sick you get so limited and 
your world starts closing down and then as you start getting a little better you’re 
real isolated.” (C17) 
 
Many deliberately avoided company, or felt that their friends were far less 
supportive than they would have expected: 
 
“You have what you consider good friends, and you sort of have acquaintances, 
and it’s rather surprising when you’re going through the treatment and the people 
that actually call and enquire and those that don’t, and you have the people that 
you consider your close friends and they may not have called at all in six months. 
So did it affect some of those relationships? Yes. My cancer did, because you can’t 
help but feel a little twinge of bitterness towards that person.” (C22) 
 
Others wished to socialise but found re-integrating to normal society difficult, after 
quite prolonged periods of social isolation: 
 
“I’d forgotten how to dance 'cause I hadn’t been anywhere to dance for years. 
Remember I’ve been locked away now for four odd years and it, it upset me... It 
made me feel my age… I wanted to be with them and I couldn’t.” (C10) 
 
Lighter duties 
Several patients were re-assigned by their employers to lighter duties because they 
were no longer physically able to do the work required of them following 
treatment; one because of shoulder weakness and the other two because of fatigue 
and loss of physical strength. Another patient had to give up her voluntary work at 
a dog shelter because she was too fatigued to undertake the manual work required. 
Patients in office jobs did fewer hours than they had done previously and one 
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patient had been unable to return to work altogether because of difficulties with 
speaking and projecting her voice.  
 
All patients had to withdraw to a greater or lesser degree from the workplace and 
hobbies and social activities. C17, because of her fatigue was no longer able to 
volunteer as she had done previously and felt that she lacked vocation: 
 
“I’m still searching for what I find will make me feel of value... I have to figure out 
some way to serve because I’ve always done that. And I haven’t found the right 
place for that yet, or how I’m going to do it, and I think I have to go further down 
the road and get healthier, where I’m feeling better.” (C17) 
 
For many there were significant financial repercussions of their cancer. One patient 
in the UK lost her carers allowance as she was no longer able to care for her 
mother and was not entitled to other benefits or income support.  
 
Travel 
Travel and outings were difficult for patients who had problems with eating and 
drinking. Several patients preferred to eat at home where they could prepare 
something they knew they would be able to eat. Others were less inclined to travel 
because they would have to explain their problems over and over again to 
restaurant staff. Some patients travelled abroad whilst still PEG-feeding, this was a 
significant logistical challenge. Therefore patients’ social worlds had got smaller: 
 
“I was never a really outgoing person, um, but I was fine around other people; 
whereas now I'm just, you know, I really love to come home kind of thing.  Um, so 
that’s, I mean, that’s made things quite difficult really.” (C10) 
 
For C10, this was partly because she had become more introverted since her cancer 
treatment but was also related to difficulties with eating and drinking. 
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Exercise 
Few patients were able to exercise as they had previously, largely due to fatigue, 
loss of physical strength and mouth dryness. One patient who had enjoyed circuit 
training, was worried about returning and being unable to do as many repetitions of 
exercises as he had done previously. He was worried about what other people 
would think of him and he was worried about letting himself down; not being able 
to do as many repetitions of an exercise would show, in an objective way, that he 
was less able than before. As in the section on mouth dryness- for several patients 
this is what held them back from exercising. 
 
3.5.2.4 Process issues  
 
Masks 
Moulded masks are used to keep patients in position during radiotherapy so that the 
treatment dose goes to the correct place. The process of making the mask was 
traumatic for some patients:  
 
“When you are getting masks fitted and everything that was a horrendous 
experience, um, and being fastened down to the table, I mean, that is just, oh, 
horrendous!” (C10) 
 
Being ‘pinned’ down for treatment everyday was extremely distressing for some 
patients. This became more of a problem as treatment progressed, and patients 
were dealing with nausea and thickened secretions which, normally, they would 
spit out. For many there was significant concern about dealing with these 
secretions or vomiting when flat, and aspirating and asphyxiating.  
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“I was terrified of being, lying flat on my back with a mask while feeling this 
terrible nausea and having just been vomiting that morning I was fearful of 
aspiration and could I get out of that mask quickly enough.” (C19) 
 
For some, the mask was a symbol of what they had endured, and one patient had 
kept hers: 
 
“I think it’s because being strapped to that table with that thing, um, and being left 
while they walk out the room, I think I took all my anger at it out on that, and now I 
just don’t want to ,- ((laughs)) I think, um, that’s just a reminder. I just don’t want, 
um, before I took it for granted, and I took life for granted, now I don’t want to 
ever forget what a gift I have been given.” (C6) 
  
Others never wanted to see their masks again as they had such troubling memories 
of their radiotherapy sessions, and did not want a reminder. Many patients talked 
about not wanting ‘reminders of treatment’ or ‘reminders of their cancer’, and this 
was a reason many gave for preferring non-surgical treatments over surgical 
treatments, because a scar would be a reminder. 
 
Keeping up with the schedule 
To maintain swallowing function at a good level after treatment, MDACC patients 
are encourage to undertake intensive swallowing therapy, MDACC patients may 
also be given fluoride trays and exercises for trismus and lymphoedema. The 
schedule of activities was really quite overwhelming for some patients, particularly 
in the midst of their treatment, with one admitting that she contemplated suicide as 
she became so overwhelmed and depressed by ‘having to do so much’ and the 
burden of expectations upon her: 
 
“I had some low spells of occasional suicidal thoughts because you have to do so 
much, you have to do the swallowing exercises, I had to do fluoride my teeth, do 
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this, do that and all that stuff I was good, and I thought [whispers] is it ever going 
to stop, and little by little it drops off and as it drops off it helps, but I’ve had 
sometimes where I’ve had several days I couldn’t do anything, just so fatigued, and 
I felt like I’m letting my husband down.” (C17) 
 
C16 “hated” doing his exercises and accepted that he was more likely to need 
enteral feeding further down the line if he failed to do them. Even though he was 
self-conscious of his lymphoedema he also refused to do these exercises.  
 
“I’m supposed to be doing two kinds of exercises, for cosmetic for my lymphedema 
of the neck and for swallowing exercises and I try to do those at a little bit but it’s 
eh I just it seems like a half hour of misery but if I wind up in fifteen years with a 
gastrostomy I won’t like it but I won’t complain. But I’m just not doing the 
exercises I just don’t like ‘em and I don’t want to do ‘em!” (C16) 
 
It seemed liked these were a reminder of his cancer, or treatment, or in fact time as 
a patient. As a doctor himself, I think he found it very hard adjusting to this role. 
Another patient had been advised by a family member treated for head and neck 
cancer, of the importance of doing swallowing exercises, he was therefore 
fastidious about doing these but still found it challenging: 
 
“I found it remarkably difficult to do all of the things that you needed to do and 
wondered how anyone was able to keep a job and do all what they were supposed 
to do in terms of timing of when you take medications, timing of when you ate and 
made sure you had plenty to drink, trying to get in some type of exercise, I found it 
remarkably more complicated.” (C23) 
 
In contrast, patients in the UK had a less intensive schedule of rehabilitation, and in 
fact some felt that they did not receive enough support, particularly with regard to 
physiotherapy for shoulder weakness following surgery to the neck: 
121 
 
 
 
 
 
“I think if I was made to have it [physiotherapy] done, my shoulder would be a lot 
better now.” (C6) 
 
Travelling for treatment 
For many patients in the UK, the daily travel to and from radiotherapy sessions was 
a significant burden, and became more of a challenge later in treatment when they 
were more symptomatic. Patients travelling greater distances were more likely to 
be hospitalised for management of their symptoms, as the travel was too 
burdensome.  
 
In all cases, however, patients were willing to travel for what they perceived to be 
the best treatment. In the US some patients had literally travelled from the other 
side of the country, one choosing MDACC because “the likelihood of a cure is just 
better here than anywhere else.” (C16). A surgical approach had been suggested 
for this patient at a different, but still prominent, cancer centre closer to his home, 
however this patient was keen to avoid cosmetic or functional impairment which 
he saw as being “career-ending”. He chose MDACC specifically for proton 
therapy, which at this point was not common practice for head and neck cancer 
treatment. 
 
End of radiotherapy 
On completion of radiotherapy at MDACC, there is a tradition of ‘ringing out’, 
where a large gong is banged to symbolize the end of treatment and “the 
restoration of balance, harmony and life energy.” For most patients, the real 
challenges of radiotherapy continued long ‘after the gong’, both in the US and the 
UK. Indeed, they described the weeks after radiotherapy as the most challenging; 
their pain and secretions often worsened but they no longer had the daily 
interaction with clinical staff for support.  
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“He had that security blanket, that safety net of visiting [the hospital] every day 
and then that suddenly stopped and I think he had no-one to turn to, no one to talk 
to and to actually say ‘Is this normal, that I’m still losing my hair, that ulcers are 
still erupting?’ erm and we did not know who to go to to ask.” (CC1) 
 
For many the continuation of symptoms beyond the end of radiotherapy was 
unexpected and raised questions in some patients’ minds about the effectiveness of 
treatment; ongoing throat symptoms for some made them concerned about 
recurrence. Some patients felt their expectations had been very poorly managed by 
the clinical team which led to much unnecessary anxiety, and anger in some cases. 
 
3.5.2.5 Effect on relationships 
 
The strains of the cancer diagnosis and treatment seemed to either ‘make or break’ 
the patients’ relationship with their partner. Most patients in this sample felt that 
the experience had strengthened their relationship, however they acknowledged the 
challenges: 
 
“My wife and I might slightly be closer now, because of the way that, you know, 
she stuck in there and said “Thick and thin I’m here” and you know we had some 
arguments but I think at the end of it we’re a little closer probably. I think it could 
have gone the other way very easily.” (C22) 
 
One patient’s husband left her when she told him her diagnosis and another patient 
left his wife just after starting radiotherapy. C1 admitted that the cancer diagnosis 
“really does screw up your relationships” and his partner said:  
 
“I hate his cancer and I hate him for having cancer, but that is my issue… I have 
just embarked on counselling because I feel unable to move on from that, and I 
don’t want to hate [him].” (CC1) 
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She struggled to cope with the changing roles within their relationship:  
 
“I am not a very good nurse, I am not a patient nurse, erm and I found that quite 
difficult, I did find it very difficult to care for him because he is supposed to be my 
strong rock and he wasn’t. He was reduced on occasions to quite a, a little boy and 
I found that quite difficult to deal with… I was, for a long, long time I wasn’t his 
wife any more, I was his carer, his nurse his whatever and that is horrible… I 
found it impossible to be both.” (CC1) 
 
Many patients stayed at home in the months following treatment, and this time ‘in 
each other’s pockets’ was difficult for some couples: 
 
“There was a lot of adjustment. Not just with doing the cancer or taking care of the 
cancer issue but all of a sudden I’m back in the house, you know so we’re about to 
get through those adjustments which have been just about as painful as the 
treatment itself.” (C20) 
 
Several patients and carers commented however that treatment would be very 
difficult, if not impossible, without a carer: 
 
“You don’t tend to look after yourself as much; I don’t think men do anyway, and 
living, living alone, and having all of that, I just don’t know how they, I don’t know 
how they would, um, how you would physically cope.” (CC6) 
 
Many couples said they were less sexually intimate, either because of fatigue, dry 
mouth or difficulty mouth opening. A HPV-negative patient worried his partner 
wouldn’t want to kiss him he case she ‘caught’ cancer from him: 
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“I went through a stage where I thought she didn’t kiss me in case she caught it… 
that used to play on me head, that was just me I think cos you do start getting all 
weird feelings that people are looking at you.” (C3) 
 
Others had specific concerns about HPV, which are discussed in the next section. 
 
3.5.2.6 Concerns about HPV 
 
There were 10 patients in this sample with known HPV-positive disease, however 
HPV status was not available for all patients as some had been diagnosed before 
routine testing for HPV. Two patients referred to the stigma surrounding HPV as a 
sexually transmitted disease which raised concerns around other people’s 
perceptions of them. One patient (C19), (who was one of two patients who 
coincidentally had been involved with a head and neck cancer support group), 
reported having encountered several women with HPV-positive OPSCC who had 
tremendous concerns about being perceived as promiscuous because they had a 
cancer related to a ‘sexually-transmitted disease’. Many of these concerns arose 
from the heightened publicity around HPV, oral sex and OPSCC in the media at 
the time as a result of comments of the actor, Michael Douglas, on the issue.  
 
“And so on the headlines did, what’s her name, the Welsh lady… Catherine Zeta- 
‘Did Catherine Zeta-Jones cause Michael Douglas’ cancer?” Well you know for a 
relatively unsophisticated population, particularly of young women with tumors, 
they’re suddenly thinking, ‘Oh, did my boyfriend in High School cause me to have 
Oral Cancer?’ and it’s, it’s a shame it’s unfair, but it is there, it’s out there, it’s 
very real.”( C19) 
 
This patient also described quite astutely the considerable social problems that 
would likely arise for an increasingly younger patient population with head and 
neck cancer given the prolonged effects on home and work life: 
125 
 
 
 
 
 
“As the age scale has decreased for head and neck cancer, I think you’re going to 
address social issues in young families that really haven’t had to be dealt with 
previously, you know this used to be a disease of old smokers, and you know we’ve 
got forty year old healthy nurses who have nasopharyngeal cancer and two little 
kids at home who expect mom to do what mom has always done and mom can’t do 
it for about a year.” (C19) 
 
As clinicians we have a tendency to ‘reassure’ patients that their cancer is HPV-
positive because of the prognostic benefits this confers. Whilst some patients were 
reassured of the positive prognosis, C1 was quite frustrated that this position was 
taken by clinicians, saying: 
 
“It’s a serious thing so there needs to be more done with the doctors instead of 
“it’s dead common, everybody’s got it so don’t worry about it” which is sort of the 
message that comes out and almost what you’ve just said.” (C1) 
 
He described a ‘stigma’ around having a cancer related to a sexually transmitted 
disease, and was particularly struck whilst watching the television show ‘Girls’ in 
which a character had suggested that she could no longer have sex because she had 
HPV, saying: 
 
“It gets you thinking about whether you should be having oral sex or not  again 
and that kind of thing whereas whilst the answer might be ‘No’ eh sorry ‘Yes’ it’s 
not an issue, it’s still something in there” (C1)  
 
He had concerns about passing on HPV “Yeah and you know Hello actually I 
could give you HPV just by shaking hands” and about his son’s risk of developing 
HPV-related cancers and whether he should be vaccinated. His perception of the 
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‘infectious’ nature of his cancer meant that his concerns spread beyond his own 
health, to that of his family and he felt that it was a great burden. 
 
He was also anxious about recurrence of his cancer in the remaining tonsil, and 
was worried that this hadn’t been removed: 
 
“My logic is if it’s coming back, that second tonsil is the target… That’s how I’ve 
rationalised it in my head err if it’s coming so it’s HPV-16 so HPV’s going to hit a 
man it’s going to hit him in the throat. It’s going to hit me in the throat, it’s going 
to hit me tonsil.” (C1) 
 
He was concerned that there had been no treatment for the HPV infection and that 
he would still be carrying this and therefore at greater risk of developing a second 
cancer, in the remaining tonsil.  
 
Another patient intended to have his grandchildren vaccinated against HPV and 
although he wasn’t particularly concerned about the possible link between sexual 
activity and HPV, he said this was a particular concern for his wife. 
 
Two patients, despite knowing that their cancers were HPV-positive rationalised 
that their cancer was more likely due to mobile phones (C13) or industrial exposure 
to carcinogens (C15) despite the latter also drinking alcohol to excess.  
 
Another patient was initially told that he was very likely to be HPV positive. It 
later transpired that his cancer was not HPV positive and his 5-year survival 
probability dropped from around 90% to around 40%. This, understandably, caused 
significant anxiety with regard to the care of his children and the court hearing 
regarding their custody. Whilst he secured custody of his children, his initial 
concerns were that the poorer prognosis would be detrimental to his case. 
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3.5.2.7 How cancer changed peoples’ outlook on life 
 
Many patients described a desire to make their lives better following cancer. To do 
things they had been putting off doing or to value what they had and those around 
them more. One patient talked about the ‘Gift of Cancer’. He had read about this 
and felt very strongly that this applied to him: 
 
“As I reached the point where I recognized that I was going to recover and that 
things were going to be okay again and I was going to do the things I liked to do 
again, it became a celebration of life, I mean it… really was a gift [becomes 
tearful], where you get up each morning and you say ‘I have another day.’ And I 
wish I could have gone through my whole life that way…” (C22) 
 
Several patients commented that they were less ambitious at work following their 
cancer. For example, C6, she had come to the realisation that her children did not 
need more money, just her time, and spoke of how this had changed her focus in 
life: 
 
“Beforehand I was very, um, in work itself I was on the fast track.  I was going to 
be, like, um, a managers' manager, and then this that and the other.  There was a, 
a definite five year plan in 'thingy'.  As soon as I got back there it was a case of, no 
this is a job that I go in, in the morning, do it to the best of my ability, enjoy the 
people around me, have a laugh  and I come home.   This is where my focus needs 
to be... I’ve realised, well the kids don’t really care whether I can afford this, that 
and the other, they just want me here.” (C6) 
 
C13 felt his cancer had made him more relaxed, and that work was less of a 
priority: 
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“I think how life was before was quite pressurised, err with regards to the work 
side of things, that was the first thing which it seemed... well it’s... the work side 
has certainly changed.  There’s no doubt about that… you take... you bring your 
work home as well, and you take your work on holiday as well, don’t you. And err 
that just doesn’t happen now.” (C13) 
 
Several patients talked about spending their money more freely afterwards; the 
cancer had been a ‘Wake-up call’ that they would not be here forever. Others felt 
they had ‘gained more than they had lost’ and that their cancer had made them 
prioritise themselves more: 
 
“It's quite bizarre, but I think I have learnt more from it than I have lost.  If that 
makes any sense… I think it brought it all into focus that you haven’t got as much 
time as you think.  So I started, after I was getting better, started putting myself as 
a priority, where before I, I don’t think I did. I don’t think anything scares me now, 
where before I could be quite timid about things, now I am not… I get out and I 
meet people, and I do things a lot of the time that I wouldn’t have done before.” 
(C6) 
 
Some patients however, whilst hoping that life would change, slipped back into 
their usual routines, as described by this carer: 
 
“I think he wanted to come out of this as a stronger person, with erm… a second 
bite at the… cherry and I think he, he was going to pro-actively improve his life, 
health-wise, exercise-wise, take life by the balls and give it a shake, but that’s not 
happened because routine and everyday life just takes over.” CC1 
 
Several patients and carers referred to life “just going back to normal”. For some 
this is exactly what they wanted, however others felt that the cancer should have 
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changed their lives, to make them appreciate everything more and take more 
advantage of opportunities. 
 
3.5.2.8 Which outcomes are the most important?  
 
Towards the end of each interview I summarised the outcomes discussed by each 
participant and asked them to rank the outcomes in order of importance. This was 
to ensure that important outcomes weren’t missing, and to assess the way in which 
they presented their accounts related to their actual outcome priorities.  
 
Survival was the most important outcome to all patients, irrespective of age, gender 
or HPV status. Interestingly, whilst many patients discussed survival only 
fleetingly, this was the most important outcome of all, suggesting that the length of 
time spent talking about something does not necessarily reflect its importance. The 
challenges encountered with eating and drinking were most concerning to patients, 
with mouth dryness universally described as the most troublesome persistent 
adverse effect of treatment. Difficulty swallowing, taste disturbance and fatigue 
were also particularly prominent complaints, and these could all be linked to mouth 
dryness, which has many broad ranging effects. 
 
In some cases, I discussed the clinical trials context and the concept of equipoise, 
asking “If we were testing a new treatment for your cancer, which outcomes would 
help you choose between treatments?” I would then give examples of some of the 
outcomes they had mentioned and ask them about survival at this point if they 
hadn’t mentioned it. Some patients had difficulty understanding the concept of 
clinical trials and I had to abandon this line of questioning. Patients and carers 
often said that the acute adverse effects of treatment were important and should be 
measured, however ultimately the long-term effects, were most likely to influence 
treatment preferences. Several patients said that they would tolerate ‘short-term 
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pain for long-term gain’. For some however, the ‘long-term gain’ was difficult to 
see when they were living a very different life due to functional impairment(s). .  
 
3.5.2.9 Personality and coping 
 
The response to treatment varied between patients, however their subjective 
assessment of their circumstances played a substantial role in how patients 
negotiated their treatment and recovery. When talking about their treatment some 
patients complained bitterly of swallowing difficulties, yet managed without tube 
feeding. Others gave the impression they had a very easy time of treatment but on 
further questioning, or interview with their carer, it transpired they needed enteral 
feeding after starting treatment because they were struggling to eat and drink. For 
some patients it seemed important to maintain a front of stoicism, although it also 
seemed that some were less inclined to discuss the difficult memories of treatment. 
These nuances can make the interpretation of qualitative interviews difficult, which 
is why interview transcripts must be triangulated with field notes. 
 
3.5.2.10    Multiple, additive adverse effects 
 
Multiple adverse effects may have an additive detrimental impact upon functioning 
and quality of life. The most important outcomes, from which many other 
problems seemed to arise were mouth dryness, dysphagia and fatigue.  
 
3.5.2.11   Beliefs about how age influenced outcomes of importance 
 
Some older patients thought certain adverse effects of treatment possibly bothered 
them less than someone younger. C5 felt less anxious about many of his side 
effects because he knew, due to his advanced age, that these would be relatively 
short lived and affect his life less than someone younger: 
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“I would have been more concerned about, about the effects that it err has or 
would, would have had [if he were younger]” (C5) 
 
Another older patient, felt that his loss of libido was less of an issue than it would 
have been for someone younger: 
 
“The Cisplatin pretty well wipes out your, your gonadal functions so your libido 
drops to zero, err testosterone never really returns to a normal level, but then I’m 
in my seventh decade of life so I, it’s not something that’s especially important to 
me but I erm for younger people it’s very important and I know that, I know several 
who found adapting to that was difficult.” C19 
 
3.5.3 Patient feedback on the process 
 
Several patients said that they enjoyed the interviews, and for many I think that 
they were quite cathartic. A carer, reflecting with her partner after his interview 
said: 
 
“It’s almost like you coming along and talking to us has now, well actually yeah it 
has improved and we’ve not noticed because for a long time there, seemed to be no 
improvement in his lifestyle in his well-being erm and it’s been so gradual that we 
have not noticed that.” (CC1) 
 
3.6 Discussion 
 
This is the first qualitative study to explore patient and carer outcome priorities for 
a COS in OPSCC. This study has identified outcomes of importance and allowed 
me to explore why outcomes are important to different people and how the adverse 
effects of treatment affect people in their day to day lives. As well as providing 
patient centred outcomes to be added to the comprehensive outcomes list for the 
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Delphi, this qualitative study has highlighted the complexity of dysfunction that 
occurs in those treated for OPSCC pointing towards areas for future research. A 
reflection on my role in the data collection and interpretation, the key findings, and 
my analysis of the strengths and limitations of this part of the study are presented 
below. 
 
3.6.1 Researcher characteristics and reflexivity 
 
Qualitative research will inevitably be influenced by the researcher and one must 
carefully consider how their own knowledge, biases and the way in which they are 
perceived will influence the participants’ accounts [261]. Upon deciding to use 
qualitative methods, it was initially thought that a non-clinical researcher would be 
the most appropriate person to conduct the interviews with patients as they would 
be less familiar with the clinical condition, treatment practices and free from 
professional relationships with treating clinicians which may portray them as an 
‘insider’ in the patients’ eyes [262]. On further discussion, however, it became 
clear that a knowledge of the condition may be of benefit in order to understand 
and interpret patients’ accounts of their experiences. In interviews, outcomes of 
importance could be implied rather than stated and clinical knowledge might help 
to probe and further elaborate these. This proved to be the case in this study. When 
independently coding the first interviews, I was able to identify more outcomes and 
understand their context compared with BY, a non-clinician. I was also able to 
understand the relationships between different outcomes i.e. that mouth dryness 
would have implications for oral hygiene and health or that this could impair 
swallowing in the short and long-term. 
 
Having been introduced to the patients in a clinical environment, by a member of 
their clinical team, and as a clinician myself, a possible challenge would be to 
ensure that consent was provided autonomously, and that the patient felt truly free 
to refuse consent. We therefore invited patients to participate in the clinical setting 
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but arranged to discuss further on the phone, outside the clinical environment, once 
they had had opportunity to consider their involvement in the study in their own 
time and space. 
 
I am a surgical trainee in Otorhinolaryngology-Head and Neck surgery and as 
noted above have a knowledge of the clinical condition, treatments, multi-
disciplinary team (MDT) decision making processes and of clinical trials in 
OPSCC. My PhD supervisor was also a clinician, and familiar to some of the 
patients I was interviewing. I introduced myself as a researcher and doctor, whilst 
being careful to make clear that I was in no way affiliated with the patients’ clinical 
team, and that my primary role was that of a researcher at the University of 
Liverpool. In order to avoid patients perceiving me as a figure of authority, I 
described them as the expert and acknowledged that they had been through an 
experience that I wished to know more about. This was emphasised prior to the 
interviews, in my discussions with patients when making arrangements, and on the 
day of the interview. 
 
When patients made statements about clinical matters that were factually 
inaccurate I did not correct these. When clinical questions arose, I usually made 
sure to answer these at the end, rather than during the interviews in order to avoid 
imposing my own concepts on the patient. I was especially keen to avoid 
answering clinical questions prior to and during the interview to avoid swaying the 
‘balance of power’ in which having shared knowledge, I may have been seen as the 
‘expert’. 
 
There was some concern that patients may have seen me as an ‘insider’ or part of 
the clinical team and that they might have modified their accounts to avoid causing 
offence. Patients are often very loyal to their treating clinician and therefore may 
have been keen to present an account of events that could not be perceived to be 
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critical of them. I was therefore very clear that data would be pseudonymised prior 
to being shared with anyone in the clinical team.  
 
Some patients seemed to see the interview as an opportunity to complain about the 
care they had received and some expressed a desire that the interview would 
improve the care that patients receive in the future, through the feeding back of 
these complaints to particular clinicians. I was in no way defensive of particular 
clinicians or practices. I felt it was completely appropriate to let patients have this 
opportunity to ‘vent’ and show that I was on their ‘side’. Many described the 
interview as cathartic; they had often felt their concerns to have fallen on deaf ears 
and one patient said it was nice for a clinician to ‘have the time’ to listen as they 
often felt clinical encounters were rushed. As a clinician, I am acutely aware of the 
time pressures we are under and it was actually very cathartic for me to have the 
time to explore many of these issues. I feel this openness on behalf of the patients 
confirmed that they did not see me as an ‘insider’. 
 
My clinical experience of course influenced the development of the topic guide. 
From my own practice and knowledge of the literature, I know that functional and 
patient-reported outcomes (PRO) are important to patients but less consistently 
measured in clinical trials in OPSCC. I was therefore keen to establish how these 
ranked alongside more objective outcomes such as survival or disease control; 
which are more commonly measured. I also know that radiotherapy regimens are 
very difficult for patients to tolerate, and that perhaps caused me to dwell on PROs 
rather than probing more into the more objective outcomes. 
 
As a clinician I am also familiar with the concepts of outcomes in clinical trials, 
however, it soon became apparent from working with COMET’s patient and public 
involvement co-ordinator that these concepts are actually not easy to grasp. Again 
to position the patient as the ‘expert’ and myself as the ‘student’ and in order to 
avoid imposing assumptions on the interviews, or confuse or intimidate the 
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patients, the topic guide was designed initially to avoid direct questioning about 
outcomes in trials but rather to explore the broader effects of a cancer diagnosis 
and treatment, and to try and identify outcomes from these concepts. The interview 
process also helped me to develop a familiarity with patients’ terms of reference 
and the language they use to describe events, symptoms and outcomes.  
 
I undertook training in qualitative interviewing and analysis prior to developing the 
topic guide and undertaking the interviews. BY, an experienced qualitative 
research supervisor helped me to develop the topic guide and reviewed my initial 
interviews to ensure that I was using an appropriate interviewing style and 
language. In my analysis of the data, I found myself, at times, adopting a more 
deductive approach. Through discussions with BY I managed to identify these 
areas and look at the data in a more interpretive way. 
 
I am Irish, and my accent, expressions and pace of speech had to be adjusted for 
people to understand me at times. I had to be very self-aware throughout the 
interviews to ensure that the interviewees understood my meaning and were 
answering the question I thought I had asked. Commonality of cultural background 
was particularly useful in building rapport with some of the patients with Irish 
connections, both in Liverpool and the US. 
 
3.6.2 Key findings 
 
This qualitative study identified 136 distinct outcomes of treatment to be included 
in the comprehensive outcomes list. These related to survival, cure, the acute and 
late treatment related morbidities associated with surgery and radiotherapy and the 
wider effects that these have on a person’s ability to return to life as before 
treatment. The outcomes prioritised by patients and carers across all interviews 
were fairly consistent. This suggests that we have identified outcomes of key 
importance to patients and carers in this cohort but also those likely to be important 
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to a wider cohort of OPSCC patients and carers. No specific differences were 
observed in the outcomes prioritised by patients and carers in the UK and US, 
rather, individual values, interests and employment seemed to have the greatest 
impact upon how outcomes were prioritised and the adverse effects of treatment 
negotiated. 
 
Outcomes relating to function and quality of life predominated the discussions, 
however survival was universally prioritised as the most important outcome when 
asked to ‘rank’ outcomes in order of importance. Interestingly, many patients said 
little about survival or mentioned it only in passing until directly questioned. This 
may be because death is difficult to talk about, or that my line of questioning did 
not lead patients to mention it. It may seem so obvious to patients that this is a 
prime concern that they did not feel the need to mention it explicitly. In this 
instance, the length of time spent talking about a subject did not necessarily 
correlate with its value to patients. Survival was the most important outcome to 
patients, and carers, irrespective of age, gender or HPV status. This was a priority 
at diagnosis and on completion of treatment. The adverse effects of radical multi-
modality therapy did not change this stance. Although there are no studies looking 
at OPSCC specifically, this supports other research into SCCHN patient priorities 
[46, 263-266]. Only in studies of laryngeal preservation, are a minority subgroup 
of patients willing to compromise survival for function [267]. Patient 
characteristics influenced the strength of feeling about the importance of certain 
outcomes. Survival was more emphatically prioritised by younger patients, 
especially those with children and older participants with caring responsibilities for 
grandchildren. They tended to have a ‘survival at all costs’ approach to treatment 
decisions. Evidence from SCCHN studies shows that the majority of patients are 
willing to tolerate a high level of treatment toxicity to maximise life expectancy 
[46, 268, 269]. On the other hand, older patients without such responsibilities, were 
more inclined to question the degree to which they would accept a reduction in 
HR-QOL in the interests of survival. No patients stated that they had regrets about 
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their treatment but some questioned whether they would have the same treatment if 
they were older. In a study of SCCHN, List et al. found that patient priorities were 
generally unrelated to patient or disease characteristics, with the exception that 
cure and living were of slightly lower priority and pain of higher priority to older 
patients compared with younger patients [46]. Older people were less inclined to 
focus on the future, and more inclined to make short term goals, describing 
survival as living to a set point in time or significant event. 
 
Problems with eating and drinking after treatment were almost universal. For some 
this wasn’t a particular problem and had very little impact, for others this had 
tremendous repercussions on their quality of life, with patients who socialised a lot 
around food now avoiding these types of situations altogether and socialising less. 
HR-QOL and psychological well-being seemed most affected for patients who had 
lost the most function or who were less able to return to normal activities – 
especially social activities. 
 
It became clear that certain key adverse effects of treatment had quite broad 
ranging effects on lots of different aspects of a person’s life. Mouth dryness 
seemed to have the most profound effects, causing problems with chewing, 
swallowing and taste. It also had less obvious implications, causing problems with 
voice, speech and the ability to exercise and sleep. An appreciation of such wider 
implications only became apparent because of the qualitative approach used. 
Furthermore the combination of multiple adverse effects of treatment seemed to 
have an additive detrimental effect on functioning and HR-QOL. For example 
many patients described a reduction in appetite during and after treatment, which 
was related to a number of different adverse effects of treatment; loss of sense of 
taste, pain, fatigue, low mood, mouth dryness, trismus, problems with teeth and 
difficulty swallowing. A number of patients described difficulties with sleeping; 
they would usually be able to get to sleep but would wake frequently with a dry 
mouth requiring water, they would then wake frequently to pass urine and would 
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then often be kept awake by worries and concerns about their cancer. These 
relationships – only demonstrated because I used a qualitative approach - allowed 
me to understand why outcomes are important to patients. HR-QOL questionnaires 
such as the UW-QOL ask whether patients have dry mouth, they allow us to 
quantify the problem but not to understand why it is important and what the wider 
effects are. Understanding the broad ranging effects of such outcomes ensures that 
important outcomes aren’t missing from the comprehensive outcomes list, and 
further helps to prioritise research in this area. 
 
Changes in cognitive function had the greatest implications for, and were most 
often described, by those in employment, and could be quite distressing at times. 
Changes in cognitive function are a recognised sequelae of radiotherapy to the 
head and neck secondary to significant radiation doses to large volumes of brain 
tissue [270]. IMRT has been associated with a net increase in irradiated brain 
volumes. This has implications for younger patients who may find such sequelae 
less acceptable due to the implications this may have for employment, and is an 
important adverse effect that should be discussed with patients prior to embarking 
on treatment with radiotherapy. IMRT is also associated with greater  
 
The interviews highlighted a number of new concerns specific to patients with 
HPV-positive OPSCC which haven’t previously been reported in the literature. 
Patients expressed concerns regarding adequacy of treatment because they had 
uncertainties about how and if HPV needed to be treated. Some questioned 
whether systemic treatments were required and whether leaving a tonsil increased 
the risk of getting a second HPV-related tonsil cancer. Many patients and carers 
expressed concerns about transmission of HPV in the future and some expressed 
concerns that their partner was responsible for their cancer or that their partner felt 
this way. There were anxieties about engaging in sexual activity for all patients 
with HPV-related OPSCC, especially oral sex, however the extent to which this 
limited such activities was variable. Other factors such as mouth dryness or 
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perceived physical deformity also played a role in stifling sexual activity. Some 
had misconceptions about the ease with which HPV could be transferred – possibly 
by a handshake alone. HPV-positivity led to concerns regarding the wider impact 
on the family. It became clear in these interviews that HPV is a shared concern for 
the patient and their spouse, and has effects for the whole family. Parents raised 
concerns that their children would have inherited a predisposition to HPV-related 
cancers, and talked about HPV vaccination. Another patient in this cohort, who had 
attended a patient support group in his home town, found that HPV-positivity was 
very embarrassing for women in particular as it was considered to be a sexually-
transmitted disease. Much of this seemed to stem from media publicity surrounding 
the link between HPV-positive OPSCC and oral sex.  
 
HPV-positivity, although conferring survival advantages, brought with it, for some, 
far wider ranging social concerns and consequences than the cancer alone did. This 
is an interesting area for future research, as, in current practice, we as clinicians 
seem to underestimate these concerns. Whilst patients were glad of a more positive 
prognosis, for some patients there was frustration at being made to feel they were 
‘lucky’ that their cancer was HPV-positive. Anecdotally, such normalisation of 
HPV status is common, and qualitative research amongst clinicians has shown that 
this is regarded a key message to communicate to patients, alongside emphasizing 
the positive prognosis [271]. Although clinicians approach HPV-positive tumours 
with a more positive outlook, because of the favourable prognosis, for patients, 
they have cancer and, as one patient said, ‘cancer is scary’. Clinicians need to be 
careful to acknowledge the seriousness of a cancer diagnosis; patients do not feel 
‘lucky’ that their cancer is HPV-positive, they wish they didn’t have cancer at all. 
These findings have important implications for clinical practice and the ways in 
which healthcare professionals communicate with patients with HPV-positive 
disease, including what information and advice are given regarding sexual 
encounters and HPV vaccination.  
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Carer accounts complemented those of patients, although they did not reveal any 
additional outcomes. They were often more revealing about the emotional and 
physical challenges of treatment. In some cases, this seemed to be due to stoicism 
on behalf of patients; in the combined interviews, carers would sometimes interject 
to paint a darker picture of the events than the patient themselves. In other cases, 
patients simply didn’t recall certain events. It was more difficult to explore these 
differences in separate interviews. Carers were more focused on acute effects of 
treatment than late effects. This might be because they were more involved in 
providing care to the patient at this point in time, because the acute effects are so 
much more dramatic, or because pain is a significant acute issue and is distressing 
for others to witness. This could also appear to be the case because patients may 
have some recall bias about the acute events of their treatment, they are sometimes 
so unwell during treatment that they don’t remember as much as their carers about 
the actual events. Another possibility is that the events are so psychologically 
distressing to recall and talk about that patients are motivated to minimise the 
effects. 
 
Even in the presence of considerable functional deficits however, no patients 
expressed regret at their choice of treatment. Yet, some carers questioned whether 
they would have radiotherapy if ever required, or whether their partner would 
choose it if they had known how severe the adverse effects of treatment would be. 
As suggested in other research, patients might be more willing than non-patients to 
undergo aggressive treatments and endure acute distress in the interest of survival 
[266]. Although survival was prioritised by patients, the cost of this – the adverse 
effects of radiotherapy in particular – were less of a ‘good deal’ from the carers’ 
perspective.  
 
Carer burden was substantial, and largely related to the dependency of their 
partners on them during and after treatment. Role reversal was discussed by several 
carers. For some couples the patient had been the breadwinner and more dominant 
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force in the relationship. Their illness and treatment changed this; because they 
were unable to make household decisions or to manage finances, the dynamic of 
their relationship changed, which some carers found very difficult. In contrast this 
didn’t seem to concern patients.  
 
Concerns about recurrence were of variable prominence in peoples’ accounts, and 
didn’t seem to be related to HPV status, or the length of time since treatment, the 
factors which are likely to be of greatest concerns to clinicians when considering 
recurrence risk. Carers were more inclined to express concerns about recurrence. 
This seemed in some cases related to the fact that they had no control over this- 
they wouldn’t be able to experience symptoms – and they were concerned that 
because their partner didn’t have symptoms until later on the first time around, they 
may be late to pick up on a recurrence. This, however, was also a concern of 
several patients.  
 
Carers had more anxiety about weight loss than patients, which seemed to stem 
from being told by healthcare professionals that it was their responsibility to ensure 
that their partner ate and maintained weight. Unfortunately, this became a source of 
significant friction between patients and their carers; whilst patients were often 
disinclined to eat, their partners were constantly encouraging this. Some patients 
even described a dread or fear of eating. 
 
3.7 Conclusion 
 
Survival is the most important outcome to patients and carers, and this was most 
emphasised by parents of young children and those with caring responsibilities. 
Anxieties around recurrence and weight loss are highest amongst carers. This 
qualitative study has reinforced the existing literature by showing that the adverse 
effects of treatment for OPSCC are severe and in many cases persistent. The 
implications of these effects are different for patients depending on their age, 
142 
 
 
 
 
interests, social circumstances and commitments. Long-term mouth dryness, taste 
disturbance and dysphagia were most troublesome to patients who had enjoyed 
socialising with food prior to their diagnosis. Mouth dryness has multiple broad 
reaching effects beyond dysphagia, and this qualitative study has illustrated the 
ways in which multiple adverse effects interplay to have a profoundly detrimental 
effect on patients’ lives. This study is the first of its kind to have identified 
concerns specific to patients with HPV-positive OPSCC which have implications 
for clinical practice. A unified discussion for the thesis is presented in chapter five. 
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Chapter 4 
A Delphi study to identify outcomes to include in a Core Outcome 
Set for clinical trials in Oropharyngeal Cancer  
 
 
4.1 Rationale for this chapter 
 
In this chapter I will present the results of the Delphi study, used to reach 
consensus on outcomes for inclusion in a Core Outcome Set for clinical trials in 
Oropharyngeal Cancer. This is the third and final methodological strand to the 
research in this thesis, which brings together the outcomes identified in the 
systematic review described in chapter two and the qualitative interviews described 
in chapter three.  
 
4.2 Objectives 
 
The objective of this Delphi study was to establish which outcomes a multi-
stakeholder group of participants believe should be included in a core outcome set 
for clinical trials in OPSCC. 
 
4.3 Methods 
 
In conducting this study, I adhered to a predefined protocol, published in ‘Trials’ 
http://www.trialsjournal.com/content/15/1/168, see Appendix 1 [74]. Ethical approval 
for this study was granted in the UK by the Liverpool Central Research Ethics 
Committee (reference 12/NW/0708). The study was registered on the NIHR 
portfolio, ID 13823 (17 January 2013). Approval at MDACC (Houston, TX, US) 
was provided by the Institutional Review Board (IRB) (protocol number 2013-
0285) for patient interviews, however permission for the Delphi study was not 
required because interview participants volunteered. 
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4.3.1 Participants 
 
The COMET initiative advise the use of a diverse range of stakeholders in Delphi 
studies to reach consensus on outcomes to include in a COS. This includes patients 
with the condition under study and healthcare professionals with knowledge of the 
condition. Patients have a variety of perspectives about living with a condition, and 
much evidence now suggests that clinicians and researchers may not realise that 
certain outcomes are important to patients [272, 273]. This is especially pertinent 
in OPSCC where the side-effects of multi-modality treatment are profound. Patient 
involvement in outcome selection in other clinical areas has led to the 
incorporation of previously unanticipated outcomes into COS [274]. The patients’ 
perspective helps to contextualise the condition, and this helps us to evaluate the 
relative importance of the different outcomes of treatment.  
 
For the reasons discussed in the previous chapter, carers are key stakeholders and 
‘involved witnesses’ to the patient’s journey through diagnosis and treatment. They 
have unique perspectives and have experiential knowledge as well as expertise. 
The purpose of involving carers in this research was not so much to discuss the 
burden of treatment on them but to illuminate the patients’ experience.   
 
The primary remit of a COS is for application in clinical trials to improve the 
consistency of outcome measurement and thus facilitate meta-analyses. We 
therefore felt it was important that the clinicians involved were familiar with 
clinical trials and outcome assessment in this context. OPSCC is managed by a 
multi-disciplinary team of healthcare professionals and we therefore invited 
medical and surgical oncologists, speech and language therapists and cancer nurse 
specialists to participate. To increase the diversity of stakeholders we invited 
patients and healthcare professionals from the MD Anderson Cancer Center in 
Houston to participate in the Delphi. Patients in the UK were treated at two 
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different centres, and healthcare professionals were from a range of specialties 
from a number of different centres in England and Wales.   
 
4.3.1.1 Eligibility criteria 
 
Inclusion criteria 
Patients 
Adults, over the age of 18, who were up to 5 years following completion of 
treatment for OPSCC. 
 
Carers 
An individual, such as a spouse or family member, who provides informal care to 
the patient. 
 
Clinicians 
Clinicians working in the field of Head and Neck Cancer who were at an OPSCC 
clinical trial investigator meeting, comprising: 
 
 Doctors of registrar level or above in the fields of Otolaryngology, Oral and 
Maxillofacial surgery, Plastic surgery or Oncology 
 Speech and language therapists with a special interest in Head and Neck 
Cancer 
 Head and Neck Cancer Nurse Specialists 
 
Exclusion criteria 
 Patients with active disease or known or suspected recurrence 
 
 Non-English speakers 
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4.3.1.2 Sampling 
 
The patients recruited from the interviews had been sampled consecutively, and 
latterly by purposive sampling, guided by a sampling matrix of clinical and 
sociodemographic characteristics. Carers were recruited by convenience sampling. 
Patients and carers recruited exclusively to the Delphi study were approached 
consecutively in survivorship clinics, and no sampling matrix was applied. This 
approach was taken because OPSCC still occurs in relatively small numbers and 
we wished to reach our recruitment target within the time limits of the study. 
Clinicians were sampled opportunistically, whilst adhering to the eligibility 
criteria. Some of the clinicians were familiar to members of the study team but the 
majority were not.  
 
Interviewee participants - UK 
Those who had given verbal consent at the time of interview were contacted by 
telephone to ask whether they would like to receive more information about the 
Delphi Study. If I was unable to contact participants by telephone, I would make 
two further attempts, and cease contact at this point if I was unable to make 
contact. For reasons of confidentiality I did not leave voicemail messages.  
 
Packs containing a letter of invitation, information sheet, consent form and the 
first-round survey were sent by post (see appendices 10-13). Participants were 
asked to return these in the stamped, addressed envelope provided within two 
weeks. This information contained my contact details, should the participant wish 
to discuss the study further. If surveys were not returned within two weeks, a 
reminder phone call was made, and after this contact ceased if there was no 
response. 
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Interviewee participants – US 
Those who had provided email addresses were invited to participate in the Delphi 
study. A small amount of information was sent by email with a link to more 
information and the online version of the survey (Appendix 14). Links were also 
provided to the COMET initiative website (www.comet-initiative.org) and the 
published protocol for the CONSENSUS study 
(http://www.trialsjournal.com/content/15/1/168). Participants were asked to 
complete the survey within two weeks of the email. Reminder emails were sent to 
those who failed to complete the survey in time.  
 
New patients and carers recruited to Delphi 
Eligible patients were identified and approached in survivorship clinics in 
Liverpool by research staff.  In Sunderland, patients were identified and 
approached, as for the qualitative interviews by a study collaborator (JMP). Verbal 
information was provided about the Delphi study along with an information sheet. 
Participants agreeing to receive further information were asked to provide a 
telephone number and email or postal address. Paper packs were posted a week 
following the approach. If surveys were not returned within two weeks, a reminder 
phone call was made, and after this contact ceased if there was no response. 
 
Clinicians – UK 
The PATHOS study investigator meeting on 5th July 2014 was used to approach a 
large group of clinicians with a special interest in clinical trials in SCCHN. I 
presented the CONSENSUS study to the audience of this meeting comprising 
Oncologists, Head and Neck Surgeons, Speech and language therapists, Cancer 
Nurse Specialists and Research Nurses. I asked all eligible participants to complete 
surveys, which I personally distributed in hard copy during a break in the meeting. 
Surveys were collected upon completion at the end of this break. Some clinicians 
took surveys away with them and returned by post. 
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Clinicians – US 
MD Anderson Head and Neck Oncologists, Surgeons and Speech Pathologists 
were invited by email to participate in the study. This email mirrored those sent to 
patients in that they contained a small amount of information about the study, with 
links to more information and the survey. One reminder email was sent to those 
failing to respond. 
 
4.3.2 Study Design 
 
4.3.3 Development of the Delphi Survey 
 
A comprehensive list of outcomes was compiled from the outcomes identified in 
the systematic review described in chapter two and those extracted from the 
qualitative interviews described in chapter three and synthesised into a survey 
comprising 50 questions (Appendix 15). We wished to avoid the survey being too 
long, as we were concerned this would be a barrier to recruitment and retention in 
the second round. An overview of this process is given in figure three. 
 
 
 
Figure 3. Overview of steps in survey development 
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4.3.3.1 Open questions 
 
To avoid researchers imposing their views about items of importance on 
participants, a recommendation for good methodological practice in Delphi studies 
is that researchers begin by asking open questions, rather than presenting 
participants with a list of items generated by the researcher [251]. In the case of 
COS development, the outcomes deemed important to clinicians may not be the 
same as those deemed important to patients. I therefore set out to explore this 
uncertainty in the qualitative interviews with patients and identified key outcomes 
which were incorporated into the survey. Additionally, in round one, I asked 
participants to add any comments about the outcomes included and to add any 
additional outcomes and rate these. 
 
4.3.3.2 Qualitative interviews 
 
The qualitative interviews, described in chapter three were undertaken to identify 
the outcomes of importance to patients, and carers of OPSCC patients, who are 
major stakeholders. We anticipated that this methodology would allow us to 
identify previously unanticipated outcomes, help us to understand the importance 
of these outcomes, ensure that outcomes important to patients and carers weren’t 
missing from the comprehensive outcomes list and identify the language used to 
describe outcomes to inform the Delphi survey. One-hundred-and-thirty-six 
possible outcomes of treatment were identified.  
 
The language used by patients and carers to describe outcomes or events informed 
my use of language in the qualitative interviews, and changed at the different 
recruitment sites. Mirroring the language used by interviewees, showed that I was 
discussing things on their terms, with them as the expert, rather than using 
unfamiliar or bewildering medical terminology. It helped to build rapport. Whilst 
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some patients chose to use medical terminology, I only used this when they did so 
first. 
 
Listening to the language people used helped in developing questions for the 
Delphi survey. Firstly, to establish which medical terms people were generally 
familiar with, and secondly to understand how they defined certain events. 
However, because I was inviting patients from different parts of the UK and the 
US to participate in the Delphi, I had to be careful about using ‘local’ terminology 
that might make no sense to others. Table 8 gives examples of use of patient 
language. 
 
Medical terminology Language used by patients and carers 
Dysphagia Difficulty swallowing 
Enteral feeding Tube feeding 
Mucositis Radiation burns 
Oesophageal dilatation Throat stretch 
Osteoradionecrosis Infection in the jaw  
Xerostomia Mouth dryness or lack of saliva 
 
Table 8. How interviews informed language used 
 
4.3.3.3 Systematic review 
 
We consulted the current literature to identify the outcomes reported in clinical 
trials in OPSCC. We assumed that these were the most important outcomes to 
clinicians, as they design the studies and select the outcomes to be measured and 
reported. To ensure that the outcomes identified were representative of 
contemporary practice, I restricted the review to RCTs reported May 2003 – May 
2013. Published trial reports were scrutinised, and the primary and secondary 
outcomes extracted, further outcomes that were reported, but not listed as 
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outcomes, were also extracted. Thirty distinct outcomes were carried through to the 
Delphi. This systematic review is reported in full in chapter two. 
 
4.3.3.4 Comprehensive outcomes list 
 
Outcomes from the systematic review and interviews were combined to form a 
comprehensive list of 154 possible outcomes of treatment. These related to 
response to treatment, survival, acute and late adverse effects of treatment, 
functioning, health-related quality of life, treatment processes and psychological 
well-being. There was some duplication and overlap of the outcomes identified 
between trials in the systematic review and between trials and the interviews. 
When different verbatim terms were used to describe the same outcome, such as 
cancer-specific survival or disease-specific survival then these were combined 
under the most commonly used outcome term or with a new outcome term that 
retained fidelity to the outcome and the events to be measured. This methodology 
has been used by those developing core information sets in cancer [275]. 
Furthermore, time-points of outcome measurement were seen more as issues of 
how to measure than what and so 3-year and 5-year loco-regional control were 
synthesised into a loco-regional control domain. 
 
4.3.3.5 Developing questions 
 
This survey did not simply present a list of outcomes; out of context this could be 
difficult for patients and carers to understand [194, 276]. We therefore developed a 
questionnaire type survey, with a list of 50 questions about the effects of treatments 
on outcomes. Previous work by Sinha et al. to develop a COS for Asthma in 
children informed this process [277] and the interview transcripts informed the 
language used to describe outcomes to patients and carers. 
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Some composite outcomes were avoided i.e. as local control, regional control and 
loco-regional control were identified in the review, questions were asked about the 
importance of a treatment preventing cancer coming back in the same place, in the 
neck or distantly. In contrast the burden of late toxicities weighed heavily on some 
patients, and through interpretive analysis it became apparent that the patients’ 
concerns were not the specific intervention but the need for further interventions – 
to still be a ‘patient’. From these concerns, we developed a domain entitled ‘the 
need for further interventions as a result of treatment’. 
 
The order in which outcomes are presented in a questionnaire has been shown to be 
of significance. The ‘consistency effect’, where items are answered in relation to 
responses to earlier items, has been researched for more than 50 years. To 
overcome this effect Bradman et al. recommend that general questions should 
precede specific ones [278] and Sudman et al. that questions should be grouped 
into topics [279]. If there is evidence that respondents have stronger opinions on 
some items than others McColl et al. suggest that these should be placed first 
[118]. As there is evidence that survival is the most important outcome to patients 
[46, 47, 266] we placed this at the beginning of the questionnaire alongside the 
outcomes identified in the systematic review related to disease control, survival 
and HR-QOL. The following 43 outcomes related to functioning, acute and late 
toxicities, complications, activities, participation, relationships and further 
interventions. A Delphi study to develop a COS for oesophageal cancer suggested 
that COS studies could be influenced by the ‘consistency effect’. Participants were 
randomised to receive questionnaires with clinical or patient reported outcomes 
first. The study found that the ordering of outcomes may impact on both response 
rates and actual responses, subsequently impacting the final COS [197]. 
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4.3.4 Delivery of the survey 
 
The Delphi study comprised two rounds of voting. In the survey information, the 
concepts of clinical trials and COS were explained. The qualitative interviews 
revealed that these concepts aren’t particularly intuitive and can be hard for 
patients and carers to understand. I reviewed the interview transcripts and 
discussions with patients around these issues and used this to inform the text. I 
endeavoured to ensure that the information provided explained the concepts in 
terms that could be understood by non-healthcare professionals. I took advice on 
this from Heather Bagley, the COMET PPI co-ordinator, who also reviewed the 
literature.  
 
The survey was offered either in hard copy or via an online system, on the 
University of Liverpool central server. Delphi software designed for the 
‘Management of Otitis Media with Effusion in Cleft Palate’ (MOMENT) study by 
information systems staff at the University of Liverpool was adapted for the 
CONSENSUS study [280]. I played a key role in developing this and conducted 
the system testing prior to launch.  
 
All data was handled via the online system and I uploaded all hard copy surveys. 
Each questionnaire was double checked to ensure accurate transfer of scores. Once 
uploaded to this system, participants who had provided email addresses were sent 
the round two survey via this system.  
 
Upon completion of the survey, the online system emailed confirmation and a note 
of thanks. Participants were asked to look out for the second survey which would 
be distributed approximately one month after the closure date for round one. 
Participants were provided with their unique identifier and login details for the 
second-round survey. On completion of round two, participants were thanked for 
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their involvement in the study and those who had sent hard copies were sent a 
handwritten letter of thanks. 
 
4.3.4.1 Round one survey 
 
In the first round, participants were asked to consider the importance of the 
different outcomes of treatment in clinical trials for OPSCC, identified from the 
comprehensive outcomes list, and to suggest any additional outcomes they thought 
were important. Participants were asked to score each of the outcomes listed, and 
outcomes added, using the Grading of Recommendations, Assessment, 
Development and Evaluations scale of 1 to 9, which is a Likert type scale [281]. 
The survey asked participants to rate the importance of individual outcomes, with 1 
to 3 labelled ‘not important’, 4 to 6 labelled ‘important but not critical’ and 7 to 9 
labelled ‘critical’, see figure four.  
 
 
 
Figure 4. Scoring system for outcomes 
 
It was acknowledged that participants may have no experience of many of the 
outcomes however we asked that they score how important these would be in 
helping them to decide between treatments. There was an ’unable to score’ option. 
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Each outcome was presented with the medical and plain English terms and context 
provided with a separate explanation for some outcomes. I developed the text to 
contextualise outcomes, partly by reflecting on the way in which outcomes were 
described in the interviews. There were two surveys layouts – for patients and 
carers the plain English term was presented first, with the medical term below and 
for clinicians the medical term was presented first with the plain English term 
below. Anecdotal evidence suggests that clinicians participating in Delphi studies 
dislike being presented with lay terms. Medical terminology would however be 
confusing for patients and carers. This approach was therefore taken to ensure that 
the same information was presented to all participants, as clearly as possible. 
 
4.3.4.2 Round two survey 
 
In the second round, participants were asked to consider which outcomes were 
core. The need for a COS comprising five to ten outcomes was explained, whilst 
acknowledging the importance of all outcomes. They were asked to reflect on how 
other participants had voted in the first round when re-casting their vote and the 
importance of completing the second round was emphasised. A proportion of 
participants completed the hard copy questionnaires and I uploaded these to the 
online system. 
 
4.3.5 Statistical considerations 
 
4.3.5.1 Sample size 
 
There are currently no recommendations for the number of participants to include 
in a Delphi study, and there is no requirement for a statistically representative 
sample [282]. In a systematic review by Sinha et al. of studies using the Delphi 
method in COS development, the number of participants ranged from 13 to 222 
[6]. We had a relatively heterogeneous group of participants and therefore felt our 
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sample size should be slightly larger to account for the likely diversity of opinions 
[24]. We also wished to have multiple panels, with participants randomised to the 
type of feedback they received. 
 
4.3.5.2 Randomisation to panels 
 
There are no methods for considering different stakeholders’ views in a Delphi 
study, yet it is known that differences in the numbers of participant types in a 
Delphi study could mean the final consensus is numerically dominated by a certain 
cohort’s responses [283]. Additionally, participants may tailor their answers to 
agree with a group they perceive to be more authoritative, such as clinicians [251]. 
Furthermore, some evidence suggests that the way Delphi participants vote is 
affected by their panel composition and from whom they receive feedback [284-
286]. 
 
At the time of designing our study, early results from a Delphi survey reported by 
Macefield et al. were presented at the 2nd Clinical Trials Methodology Conference 
in Edinburgh [287]. This study, to develop a COS for oesophageal cancer surgery, 
comprising patients and clinicians, showed that patients receiving patient and 
clinician feedback (versus patient only feedback) rated fewer items as important 
whereas clinicians receiving patient and clinician feedback (versus clinician only 
feedback) rated more items as important. We wished to investigate this novel 
methodology and felt that, in a clinical area where function and quality of life – i.e. 
the lived experiences of a disease and its treatment - are so profound, it was 
important to investigate the differences between the stakeholder groups.  
 
We therefore randomised patients and carers to a patient and carer only panel or a 
patient, carer and clinician panel and clinicians to a clinician only panel or the 
patient, carer and clinician panel. All stakeholders were given equal importance in 
the analysis. We planned to recruit 30 patients and carers, and 30 clinicians with a 
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view to having a minimum of 20 clinicians and 20 patients and carers completing 
the second-round survey. We approached relatively more clinicians than patients 
and carers because we expected attrition to be higher in this group. 
 
Upon invitation to the Delphi, participants were assigned a unique study ID and 
randomised to one of the three panels, as shown in figure five. For round one, the 
same survey was distributed to all participants, irrespective of their panel. At 
invitation to round two, they were informed of their panel, and that there were 
other panels with different stakeholder groups.  
 
 
 
Figure 5. Allocation to panels 
 
4.3.5.3 Randomisation method 
 
Using sealedenvelope.com (https://www.sealedenvelope.com/) and block 
randomisation, participants within the patient and carer group were randomised in 
a 2:1 ratio to the single or combined panel and participants within the clinician 
group likewise to the single or combined panel. Randomisation lists were 
generated by a research team member not involved with recruiting participants 
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(CTS). The lists were concealed from the recruiting researcher (AW) throughout 
the process.   
 
4.3.5.4 Minimising attrition 
 
Minimising attrition is important in Delphi studies because people with minority 
opinions are more likely to drop out of the process which can lead to an 
overestimation of the degree of consensus in the final results [288]. In order to 
minimise this effect, in advance of distributing surveys, I sought verbal 
confirmation from participants that they would like to receive information about 
the study. The information provided with the survey emphasised the importance of 
completing both rounds, and when the second round questionnaire was distributed, 
this was again emphasised. Secondly, so that people didn’t feel their voices weren’t 
being heard, in the invitation for round two we acknowledged the differences in 
how people voted.  
 
To identify whether there was evidence of bias introduced through participant 
attrition in round 2, the mean score across outcomes from round 1 was calculated 
for each participant and these were compared for participants completing both 
rounds against those completing round 1 only. A Mann-Whitney U test was used to 
test the hypothesis that there was no difference between the groups. 
 
4.3.6 Anonymity 
 
By Sinha et al.’s classification, this study was not anonymised [251]. Patient and 
carer pairs were invited to participate and it is possible that they would have 
discussed the survey and their voting. Also, for the first round, clinician 
participants completed the survey at a meeting with other clinicians; it is possible 
that they too would have discussed the survey and their voting. In the second 
round, all clinician participants completed the survey online. Some of the invited 
159 
 
 
 
 
participants worked together and I cannot presume that they did not discuss the 
survey. The patients and carers were unaware of the identities of the clinicians 
completing the survey and vice-versa. The identities of all participants were only 
known to AW and MHJ, the survey administrator. 
 
4.3.7 Data protection 
 
Data was handled in compliance with the Data Protection Act (1998). In 
accordance with the university policy for the disposal of confidential waste, hard 
copies of the completed surveys were destroyed once uploaded to the online Delphi 
system.   
 
4.3.8 Survey launch 
 
Round one opened on the 5th June 2014, with the clinician surveys being 
distributed first. Responses were requested by 19th June 2014 although completed 
surveys were accepted up to the point of analysis. Round two was launched on the 
17th July with a closing date of 15th August, although again late completed surveys 
were accepted. 
 
4.3.9 Analysis 
 
4.3.9.1 Round one  
 
Additional outcomes identified by participants during round one were reviewed 
and coded by the whole study team. Consideration was given to whether these 
were already included, but perhaps worded differently and whether they were 
clinically relevant. Those felt to be appropriate by the whole study team were 
added to the second-round survey. For each outcome, the number of participants 
who scored it and the distribution of scores (as number and percentage who scored 
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each outcome) was summarised by panel and stakeholder group, and this data was 
added to the round two survey for the respective panels, see figure six. 
 
 
Figure 6. Layout for round two 
 
 All outcomes, irrespective of their score, were carried forward to round two. The 
number of respondents in each panel and stakeholder group was assessed following 
round one closure, and only invitees who completed round one were invited to 
round two. 
 
4.3.9.2 Round two 
 
The total number of participants completing the second-round was evaluated by 
panel and stakeholder group and attrition summarised by panel, stakeholder group 
and method of recruitment to inform future practice. 
 
4.3.9.2.1 Definition of consensus 
 
There are no agreed methods for selecting cut-off criteria, however, on this issue 
we took advice from the COMET initiative and used criteria previously 
implemented in the MOMENT study [280]. These criteria were defined a priori in 
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the published protocol for this study. Consensus to carry an outcome through to the 
core outcome set was reached when 
 
 More than 70% of participants scored its importance as 7 to 9 
AND 
 Fewer than 15% of participants scoring its importance as 1 to 3 
AND  
 The outcome met these criteria in each panel 
 
For each outcome, the number of participants who scored it and the distribution of 
scores was summarised by panel and stakeholder group, and each outcome was 
classified as ‘consensus in’, ‘consensus out’ or ‘no consensus’ according to the 
classification in table nine. 
                       
Consensus classification Description Definition 
Consensus in Consensus that outcome 
should be included in the 
core outcome set 
70% or more participants 
scoring as 7 to 9 AND <15% 
participants scoring as 1 to 3 
Consensus out Consensus that outcome 
should not be included in 
the core outcomes set 
70% or more participants 
scoring as 1 to 3 AND <15% 
of participants scoring as 7 to 
9 
No consensus Uncertainty about 
importance of outcome 
Anything else 
 
Table 9 Definition of consensus (Taken, with permission from the MOMENT study 
[280]) 
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A pre-defined stop criterion for this study was chosen as whichever occurred first 
of 
 Reduction of the long list of outcomes to ten or less, or 
 Completion of the second round of voting 
 
A condition of this was that no new outcomes were suggested in round one, 
otherwise, a second round would have to be conducted to allow for voting on these 
outcomes. If consensus was not reached after round two, or there was major 
disagreement, we planned to conduct a face-to-face meeting of stakeholders to 
resolve these differences and identify consensus outcomes. At this point, if there 
had been disagreement about some outcomes, we would have included a smaller 
number of outcomes, upon which there was consensus, in the COS, as per the 
recommendations by Williamson et al. [152]. 
 
A one-way ANCOVA was conducted to determine whether there were differences 
between panels in the ranking of outcomes in round two, controlling for ranking in 
round one. 
 
4.4 Results 
 
4.4.1 Participants 
 
In total, 37 clinicians and 43 patient and carers (31 patients and 12 carers) in the 
UK and US participated in the study.  Clinician participants comprised Clinical 
Oncologists (n=13), Head and Neck surgeons (n=11), Speech and Language 
Therapists (n=12) and one Cancer Nurse Specialist. The patient cohort comprised 
24 men and seven women, and the carer cohort comprised one man and 11 women. 
 
 
163 
 
 
 
 
4.4.2 Recruitment and attrition 
 
To encourage participation and to try to reduce attrition, I made a telephone call to 
UK patient and carer interviewees in advance of distributing the letter of invitation 
and survey. Of the 24 interviewees, I was unable to contact five, and one declined, 
these were therefore not sent an invitation letter and survey. The flowchart in 
figure seven shows the number of stakeholders invited and randomised to each 
panel, and the number completing each round by panel and stakeholder group. 
Attrition was highest in the clinician only panel and amongst clinician 
stakeholders, however contrary to what I had expected, clinician attrition was 
proportionately higher in the combined panel compared to the clinician only panel.  
 
 
 
Figure 7. Recruitment and attrition by panel and stakeholder group 
*One clinician participant was excluded because their survey was insufficiently completed 
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The breakdown of invitees and responders by country and stakeholder group, 
including clinician specialties is shown in table 10. 
 
 
 
Table 10. Invitation and participation by country and stakeholder group 
NB. Round two responders were a subset of round one responders. No new participants invited to 
round two. 
 
4.4.2.1 Factors affecting attrition 
 
The method of approach had a significant impact upon response rates in the first 
round amongst clinicians, with 93.9% of those responding to a face to face 
approach (31/33), and only 17.6% responding to an emailed invitation (6/34). 
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Response rates were high amongst patients and carers, with 100.0% response to 
postal invitation (37/37) and 75.0% response rate to email (6/8) in the first round.  
The patients and carers who participated in the interviews were more likely to 
complete both rounds, with 90.5% (19/21) completing versus 45.5% (10/22) of 
those patients and carers recruited exclusively to the Delphi. When making 
reminder phone calls, one of these patients commented that she didn’t think it 
would be an ‘ongoing thing’. 
 
Those clinicians who failed to participate in round two were not approached to ask 
their reasons for this, however, from our online software we know that few logged 
in to complete round two. It would therefore seem that the way in which outcomes 
were presented, or the perception of having minority views did not contribute to 
their attrition as they wouldn’t have known how others ranked outcomes without 
logging in to the online system.  
 
Attrition was higher amongst clinicians, and highest in the US cohort of clinicians, 
with only one completing both rounds. US clinicians did not have minority views; 
average scores were similar to those of UK clinicians (US 6.5, UK 6.3) and all of 
the outcomes that reached consensus for UK clinicians in round one, reached 
consensus in the US clinician cohort. 
 
4.4.2.2 Impact of attrition 
 
Nearly a third of participants (32.5%) dropped out between rounds one and two. 
The number of participants remaining in each panel, remained roughly equal, with 
16 participants in panel one, 19 in panel two and 19 in panel three. The proportion 
of clinicians to patients and carers across all panels remained stable at 1:1.2 in 
round one and 1:1.25 in round two. 
 
4.4.2.3 Attrition bias 
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The mean score across outcomes from round one was calculated for each 
participant and then compared between the groups of participants that completed 
one round only and those that completed both rounds. There was no significant 
difference in the mean round one scores for those completing both rounds (n=54, 
median 6.42, IQR 5.6 to 7.3) versus those completing round one alone (n=26, 
median 7, IQR 5.9 to 7.7), p=0.153. It is possible however that the lack of 
significant difference is due to small numbers. 
 
4.4.3 Incomplete surveys and excluded participants  
 
Two participants in panel one and one participant in panel three failed to fully 
complete the second round of the survey. The two participants in panel one ranked 
49 and 54 outcomes. These cases were discussed with the study team and it was 
decided to keep their answers for analysis. The participant in panel three had only 
ranked five outcomes however and was therefore excluded from the analysis. A 
patient in panel two had selected “unable to comment” for 40 of the outcomes, 
when I spoke to her about this she had been told by research staff to only rank 
outcomes that had affected her (despite ranking all outcomes in round one) her 
rankings were included but the ‘unable to comment’ rankings were excluded from 
the second-round analysis. 
 
4.4.4 New outcomes 
 
Participants were asked to add and rank any outcomes that they thought were 
missing from the Delphi in round one. Outcomes were only added if there was 
consensus amongst the whole study team. Twenty additional suggestions were 
made by three clinicians and six patients. Eighteen of these were unique 
suggestions. Of these, eight suggestions were felt to have been already included in 
the existing questions, four were not felt to be appropriate and were excluded and 
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six new outcomes were added for round two. The first four listed below were from 
clinicians, the last two from patients, these were: 
 
 The need for dentures 
 Producing too much saliva 
 The impact of a treatment on earnings/ finances 
 The inconvenience of a treatment i.e. time spent travelling to and from 
medical institutions for treatment 
 The requirement for ongoing or long-term dental care 
 The impact of a treatment on concerns about the cancer returning 
 
Participants were informed of the new outcomes and asked to rank these alongside 
the other outcomes in round two. These are shown in table 11, overleaf. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients Clinicians 
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Longterm impact on future morbidity (Is that a 
lump) 
Hypernasality 
Long term problems with teeth - how can they 
be fixed when my mouth hardly opens. As for 
Q27 but more of a worry for the future 
Wearing obturator 
Being informed of after effects of cancer 
treatment before treatment 
Wearing dentures 
Help to fill in benefit forms Pain on swallow 
Dental care afterwards Excess salivation 
Prior info on the likelyhood of side effects 
post treatment* 
Speech 
Prior info on the likelehood of side effects 
after treatment* 
Voice 
Fatigue Talking on telephone 
Nerve damage to shoulder Solid vs soft diet 
  Effect on earnings/ finances 
  
Time spent on treatment/ transport/ managing 
toxicity 
 
Table 11. Additional outcomes suggested by Delphi participants in round one (verbatim) 
*This comment was made by a patient and carer pair which suggests they completed their surveys 
together 
 
4.4.5 Voting 
Appendix 16 shows the distribution of scores for each outcome by panel and 
round.  
 
 
 
4.4.5.1 Variability in voting between panels 
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There was substantial coherence between panels, with six outcomes achieving 
consensus in round one and maintaining consensus in round two across all panels. 
There was more heterogeneity amongst patients and carers; the patient and carer 
only panel had the highest number of outcomes reaching cut-off (n=15), and, when 
panel three was analysed for patients and carers there was a higher number of 
outcomes that met the cut-off selected by patients and carers than by clinicians (17 
outcomes for patients and carers versus 12 for clinicians). 
 
4.4.5.2 Variability in rankings between rounds 
 
The average percentage change in scores between rounds was 12.1% in panel one, 
8.7% in panel two, and 17.9% in panel three (8.9% clinicians, 24.5% patients and 
carers). Across all panels there was greater change amongst patients and carers in 
their voting, however this was most pronounced in the combined panel. This 
suggests that patients and carers were influenced by clinicians but that clinicians 
weren’t influenced by patients and carers.  
 
4.4.5.3 Analysis by clinical characteristics 
 
There was strong consensus on a core of 5 outcomes for patients with positive, 
negative and unknown HPV status that also reached final consensus and were 
included in the COS. There was no correlation between mean score and age (r = -
0.172, p=0.433). This was not particularly surprising as the qualitative interviews 
had suggested that whilst the emphasis placed on some outcomes was greater in 
younger patients, the same outcomes were still important.  
 
 
 
4.4.5.4 Variability in outcomes achieving consensus between rounds 
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The number of outcomes meeting the pre-defined cut-off increased from round one 
to round two, as shown in table 12. This was only accounted for by one of the new 
outcomes, which met cut-off in the patient only group. 
 
  Round 1 Round 2 
Panel 1 8 11 (3 added) 
Panel 2 12 15 (1 dropped, 4 added) 
Panel 3 10 12 (2 added) 
 
Table 12. Number of outcomes reaching consensus by panel and by round 
 
There were eight common outcomes that met the cut-off across all panels in round 
two, with four outcomes reaching cut-off in two panels and six meeting the cut-off 
in one panel (table 13). By our method of consensus (including outcomes that 
reached consensus in each panel) we could have stopped the study following the 
first round, as 6 outcomes met this criterion. Additional outcomes were suggested 
and added however so we had to proceed to the second round to see how 
participants ranked these.  
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Table 13. Consensus outcomes in round two 
 
4.4.5.5 Outcomes reaching consensus by stakeholder group 
 
When analysed by stakeholder group there was significant heterogeneity in the 
numbers of outcomes reaching consensus (see table 14). This ranged from 9 
outcomes amongst head and neck surgeons to 29 outcomes amongst carers. Again, 
this was not entirely surprising as during the interviews carers tended to place 
greater emphasis on the morbidity associated with treatment, with some saying 
they wouldn’t have radiotherapy if they were in the patient’s shoes. Unfortunately 
this suggests that carers didn’t appreciate the need to identify a core set of a 
smaller number of outcomes. One patient, when providing feedback on the Delphi 
shed light on why they may have struggled to rate a smaller number of outcomes as 
important, saying that they were all critical at one point in time during or after 
treatment.  
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 Long-term dysphagia, enteral feeding, and the ability to breath normally reached 
consensus amongst all stakeholder groups, but patients. 
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Table 14. Outcomes reaching consensus by stakeholder group 
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4.4.5.6 UK versus US patients 
 
There was strong consensus between UK and US patients. Again, the first five 
outcomes reached consensus. Fourteen outcomes reached consensus in the US 
cohort, seventeen reached consensus in the UK cohort. Twelve outcomes were the 
same amongst both groups (see table 15). 
 
  
Table 15. Outcomes reaching consensus; UK versus US patients 
175 
 
 
 
 
4.4.6 Outcomes to be included in the COS 
 
Consensus across all panels was used to define the COS, with eight outcomes 
reaching consensus in each panel, see table 16 for how the Delphi descriptions 
relate to commonly used nomenclature. The outcomes reaching consensus related 
to disease control (local control, regional control and distant control), survival 
(preventing death from cancer and treatment), health-related quality of life and 
dysphagia. 
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4.4.7 Content validation and additional comments 
 
Feedback was sought on the process in the comments section of the survey in both 
rounds and informally by email correspondence with the participants. In an email 
to me about the study, one patient participant, who had also been a US interviewee 
commented: 
 
“This is the first time I have seen all of my annoying side effects from 
chemo/radiation in one list!” 
 
Indeed, several participants, both patients and clinicians commented that all of the 
outcomes were important at one time or another, which made prioritizing these 
difficult: 
 
“[I] don’t think my survey helped very much.  I could not just have a top 5 
items since all side effects are equally aggravating!” 
 
From the interviews, we established that different outcomes take priority at 
different times; at diagnosis, most patients admitted to only being focused on 
survival. As the time since treatment lengthens and the likelihood of survival 
increases, participants became more concerned about the long-term adverse effects 
of treatment, and less focused on recurrence, although this was quite variable 
between participants. The adverse effects of treatment also change as time goes by, 
and for OPSCC patients it is likely that different outcomes are ‘core’ at different 
times. 
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4.5 Discussion 
 
4.5.1 Key findings 
 
Following two rounds of voting, eight outcomes reached our pre-defined consensus 
cut-off for inclusion in the COS. Local control, regional control, distant metastatic 
control, disease-specific survival, death related to treatment, HR-QOL, 
interventions for the management of treatment-related morbidity and dysphagia 
were the eight outcomes that reached consensus in each panel. Further outcomes 
reached consensus in the individual panels, however these were not taken forward 
as per our previously defined and published cut-off criteria [74].  
 
Overall survival did not make the COS as it did not reach consensus in the 
healthcare professional panel. It was not presented as ‘overall survival’ verbatim, 
rather as ‘The effect of a treatment on the risk of death from any cause’. The 
reasons for this are not known. It is possible that it was misinterpreted by 
healthcare professionals, however if this was the case I would have expected its 
absence to have been commented upon when asked for additional outcomes of 
importance in the first round. The results suggest that clinicians valued disease-
specific survival over overall survival. Analysis by stakeholder group showed that 
the only group in which it didn’t reach consensus was surgical oncologists. A COS 
does not prescribe that only the outcomes it includes are measured, but rather these 
are the minimum. We would recommend that overall survival is measured in 
clinical trials in OPSCC. The relative priority this takes amongst different 
healthcare professionals may be worthy of further investigation. 
 
Patients and carers showed the least certainty about which outcomes were core by 
rating more outcomes of critical importance than healthcare professionals. When 
analysed by stakeholder group however, carers (29 outcomes) and speech and 
language therapists (17 outcomes) showed the least certainty about which 
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outcomes were core with patients retaining 12 outcomes and surgical oncologists 
rating the fewest outcomes as critical and for inclusion in the COS (9 outcomes). 
Panel allocation did seem to affect the way in which patients and carers voted as 
the greatest change in voting between the rounds was amongst patients and carers 
in the combined panel. As discussed in the previous chapter, it is an assumption 
that higher scoring of more outcomes reflects uncertainty about the purposes of the 
Delphi study, it is possible that this reflects the significant challenges of selecting 
core outcomes in conditions with high levels of morbidity. As several patients and 
carers told us when providing feedback on the Delphi – different outcomes are 
important at different times. Recent evidence in the development of COS suggests 
that patients are more likely than health professionals to rate an outcome as 
essential; three studies found that the average score awarded to outcomes in the 
round one questionnaire was greater for patients than health professionals [289]. 
This is an important consideration in the analysis; patients may be more likely to 
influence a core set if outcome scores are simply combined across stakeholder 
groups. 
 
Several important outcomes from the interviews did not make it into the COS. 
Mouth dryness, taste disturbance and fatigue were repeatedly discussed by patients 
and carers, yet these did not make the COS. Only 63.2% (panel 2) and 63.6% 
(panel 3) of patients and carers ranked mouth dryness as critical, 42.1% (panel 2) 
and 27.3% (panel 3) ranked taste as critical and 52.6% (panel 2) and 27.3% (panel 
3) ranked fatigue as critical. Research into patient concerns and the problems they 
would like to discuss in clinic consultations by Rogers et al. [290] supports the 
findings from the qualitative study that these outcomes are important. Over a third 
of patients attending outpatient clinics wished to discuss mouth dryness and a fifth 
fatigue. Long-term dysphagia, enteral feeding and the ability to breath normally 
reached consensus amongst all stakeholder groups, except patients. I think these 
outcomes are important to patients, however I think it is likely that these findings 
reflect the greater emphasis that patients place on survival and outcomes relating to 
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disease control than other stakeholders i.e. although these outcomes are important 
they are not core. 
 
Concerns about recurrence were frequently discussed in the interviews. This 
wasn’t included in the first round of the Delphi as a possible outcome, because we 
didn’t consider this to be a treatment outcome. However, a patient listed ‘concerns 
about the cancer returning’ as an additional outcome in round one of the Delphi. 
This caused the study team to re-consider this as a possible outcome and we 
decided to add it to the round two questionnaire. Although it didn’t reach 
consensus overall, it did amongst patient stakeholders. It is possible that different 
treatments will have different effects upon patient concerns regarding recurrence. 
Several patients discussed reminders of treatment in the interviews; it is possible 
that less invasive or less radical treatments or those associated with fewer long-
term adverse effects may be associated with fewer concerns about recurrence 
because there are fewer psychological and physical sequelae of treatment. There is 
a relatively high risk of recurrence with SCCHN, especially in the first two years, 
and follow-up appointments are therefore frequent in this time. In the UK, patients 
are only discharged from routine follow-up at five years. Patients and carers in the 
qualitative interviews admitted that concerns about recurrence were most 
prominent in the days leading up to a follow-up appointment. The frequency of 
outpatient follow-up may therefore exacerbate these concerns. HR-QOL studies 
frequently point to ‘fear of recurrence’ as a pressing concern for patients. Rogers et 
al. identified this as a concern for patients in an audit of the patient concerns 
inventory (PCI). One-thousand-one-hundred-and-ninety-eight inventories were 
completed by 386 head and neck cancer survivors between 1 August 2007 and 10 
December 2014 at University Hospital Aintree, one of the sites for our patient and 
carer recruitment. Fear of recurrence was the second most common (33%) patient 
concern for discussion at follow-up clinic consultations. The PCI is completed 
whilst patients wait to be seen in the outpatient clinic and allows the consultation to 
be directed towards a patient’s individual concerns. Given that concerns regarding 
181 
 
 
 
 
recurrence are highest at this point, it is possible that the PCI results aren’t 
reflective of the prominence of this amongst patient’s concerns the rest of the time. 
One patient was concerned about recurrence in his remaining tonsil, having had 
one removed for HPV-related cancer. Whilst there is less morbidity associated with 
removing one tonsil, his anxiety related to this being a site of recurrence was high. 
The trade-off hypothesis has been described in breast cancer. This hypothesis 
proposes that breast preservation may enhance a patient’s body image, but increase 
their fears of recurrence. Some studies have suggested that mastectomy patients 
felt more confident that their cancer had been cured and less concerned about 
recurrence compared with women receiving conservative treatment, however other 
studies have shown difference in recurrence fears between lumpectomy and 
mastectomy patients. Hilton et al. found that appraisal of the threat of recurrence 
was positively related to the extent of the cancer and negatively related to age. For 
many patients and carers in our interview cohort, concerns about recurrence 
seemed to be related to the insidious nature of their disease. Most patients 
presented with locally advanced disease and had concerns that they wouldn’t be 
aware of their cancer recurring until it was advanced.  Wong et al. found that 
uncertainty surrounding the effectiveness of treatment was positively related with 
anxiety. In this cohort, concerns about recurrence were more often expressed by 
patients who had a negative relationship with their treating team – which most 
often related to dissatisfaction with their treatment and unmet expectations. 
Concerns about recurrence were more prominent in the accounts of carers, which 
seemed related to uncertainty that they would be able to identify recurrence in their 
partner. 
 
Although there was consensus on a core of eight outcomes, the different panels 
identified additional outcomes of importance. Had we chosen to carry forward 
outcomes reaching consensus in every panel, we would have had 19 outcomes at 
the end of the second round of the Delphi survey. Some COS Delphi studies have 
prioritised the patients’ perspective such that their voting carries more weight in 
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the final consensus than that of clinicians [200]. The approach taken in this study is 
similar to that described by Wylde et al. [205] in which outcomes had to reach a 
pre-defined consensus definition in each panel to make the COS, we felt that this 
was more demonstrative of multi-panel consensus. 
 
4.5.2 Nomenclature 
 
In the Delphi study, I largely took the approach of presenting specific outcomes as 
questions rather than outcome ‘domains’ which have been used in other studies. I 
felt this approach would lessen ambiguity in the interpretation of the outcomes by 
participants, but also in interpretation of the final published COS by those using it. 
I felt it likely that a long questionnaire or repeated rounds of voting would be 
significantly burdensome enough to participants to deter them. There was therefore 
a requirement to be pragmatic, and thus have enough questions to include all of the 
outcomes identified in the earlier part of the study but not be so burdensome to 
discourage participation in subsequent rounds. Furthermore, some of the 
descriptions of areas of concern for patients related to broader domains. We 
therefore combined some outcomes into broader domains, such as ‘the need for 
further interventions as a result of treatment’. The resultant problem with this 
however was that in wording the question about this outcome, I gave examples to 
illustrate possible further interventions. It is not possible to know, without directly 
questioning the participants, whether they believed that further interventions were 
an important outcome or whether the specific examples given were (see table 17). 
In any case the need for further interventions was deemed a critically important 
outcome and further research will be required to establish which further 
intervention(s) are important. 
 
Plain English term Medical term Possible outcomes 
Needing additional The requirement for Painkillers/ analgesics 
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treatments to get a 
person through the 
cancer treatment e.g. 
painkillers, tube 
feeding, 
tracheostomy 
supportive treatment 
measures (e.g. 
analgesics, 
antibiotics, feeding 
enterostomy, 
tracheostomy) 
Antibiotics 
Tube feeding 
Tracheostomy 
The need for 
additional surgery or 
invasive procedures 
as a consequence of 
treatment (e.g. 
pharyngeal 
dilatations, further 
reconstructive 
surgery) 
Needing more 
surgery or invasive 
procedures because 
of the treatment e.g. 
throat stretches, 
further surgery to 
treat complications 
Dilatations/throat 
stretches 
Further reconstructive 
surgery 
Further surgery to 
treat complications 
 
Table 17. Outcome domains 
 
The language used to describe outcomes not only differs between patients, carers 
and healthcare professionals but even between patients and between healthcare 
professionals. For transparency and to try and ensure fidelity with the proposed 
outcome, plain English and medical terminology was used to describe all 
outcomes, it is difficult to know how exactly these were interpreted by patients and 
clinicians. Several broader outcomes arose from the qualitative interviews which I 
felt the need to expand upon when describing in the Delphi. For example, the need 
for further interventions with examples as throat stretches, tracheostomy. It is 
harder to know whether giving examples helped illustrate what the outcome meant 
or whether, because of the examples, the outcomes were open to greater 
interpretation, which may differ between participants. 
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4.5.3 Consensus meeting 
 
A decision had been made a priori that a face-to-face consensus meeting would not 
be required if the Delphi reached consensus on 10 outcomes or less. The Delphi 
reached consensus on eight outcomes in the second round of the survey, and so the 
meeting was not conducted. Furthermore, resource limitations meant that this was 
not possible. There are benefits of face-to-face meetings however; this would have 
allowed us to explore the reasons why patients and carers ranked more outcomes 
highly and why important outcomes from the interviews did not reach consensus in 
the Delphi. We could also have sought feedback on the outcomes reaching 
consensus and whether these were felt to be the most appropriate, explored 
differences between the panels and the factors that influenced people to change the 
way they voted. I think this is an important consideration for future COS 
developers.  
 
4.6 Conclusion 
 
This Delphi study used robust consensus methodology to ratify eight outcomes to 
be included in a core outcome set for clinical trials in oropharyngeal cancer. 
Survival was prioritised by patients, carers and clinicians, corroborating other 
research into patient priorities in head and neck cancer [46, 174, 291]. The 
relatively small final sample size did not allow for any firm conclusions to be 
drawn regarding the effect of individual patient, carer or clinician characteristics or 
demographics upon outcomes of importance, however this is the first study to 
assess COS priorities in a cohort of HPV-positive OPSCC patients. Survival and 
outcomes relating to disease control were universally prioritised by OPSCC 
patients, carers and healthcare professionals. Swallowing was the only functional 
outcome to reach consensus, however there is a strong correlation between HR-
QOL and function [292]. A unified discussion for the thesis is presented in chapter 
five. 
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      Chapter 5 
Main Discussion 
 
 
5.1 Rationale for this chapter 
 
In this chapter I will discuss the context and rationale for this research, summarise 
my key findings and critically evaluate the study in the context of the current 
literature.  
 
5.2 Context and rationale for this research 
 
It is widely recognised that overall survival is the gold standard end point for 
assessing the effectiveness of interventions in clinical trials in oncology [96], that 
attention should be paid to the measurement of outcomes relating to disease 
response, the acute and long-term adverse effects of therapy [144] and a patient’s 
HR-QOL [239]. However important outcomes are measured inconsistently and/or 
defined and measured with heterogeneity that compromises data synthesis between 
otherwise comparable trials. Furthermore, although some outcomes may be of 
interest to the researcher, they may have little relevance to patients and clinical 
practice. High quality evidence to inform clinical guidelines and healthcare policy 
is therefore lacking for many interventions and areas of healthcare [77].  
 
Methodological standards for conduct and reporting have the potential to improve 
the quality of data arising from clinical trials, yet this relies on adherence to such 
standards, and there is evidence that uptake is slow and that these may be only 
partially adhered to [159, 293]. Much work is therefore required to ensure uptake 
of such standards if they are to influence the quality of data arising from trials and 
thus the evidence base. 
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There are challenges in assessing the effectiveness of interventions for the 
treatment of OPSCC, because this includes surgical interventions. To date, there 
has been no head to head comparison of surgical and non-surgical interventions 
[60]. For OPSCC, chemoradiotherapy (non-surgical intervention) is considered the 
current standard of care [2, 58], however there is growing interest in the use of 
minimally invasive surgical techniques (trans-oral laser and trans-oral robotic 
surgery) which some believe result in better functional outcomes, whilst preserving 
oncological outcomes [67-69]. Furthermore, de-escalation strategies for patients 
with HPV-positive OPSCC have led to a significant increase in the number of 
clinical trials in OPSCC. The application of stringent methodological standards to 
trials of these interventions would allow for more accurate and timely conclusions 
to be drawn regarding the comparative effectiveness of interventions, it would also 
go some way to reducing bias in these studies. 
 
With these concerns in mind, I set out to develop a COS for clinical trials in 
OPSCC what should be clinically relevant and measure outcomes that are 
important to patients. My ultimate goal was to improve the consistency of outcome 
selection and reporting, thus improving the quality of evidence regarding the 
effectiveness of interventions in for the treatment of OPSCC. At the beginning of 
this research in 2011 there were no published guidelines on COS development, and 
so I worked closely with colleagues within and affiliated with the COMET 
initiative and the MRC hubs for trials methodology research to ensure best 
practice. Key to our methodology was the involvement of major stakeholders in the 
COS development process. There were no other COS studies for SCCHN or 
OPSCC at this point, and no studies had asked patients about which outcomes they 
thought were important in the clinical trials context. One study making suggestions 
about OMI’s for use in SCCHN clinical trials failed to consult patients when 
deciding which outcomes should be measured [190]. My intention was that the 
COS would apply to clinical trials of all contemporary interventions for the 
curative treatment of OPSCC, and be published in an open access journal to 
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increase exposure and awareness of the COS. I understood that ongoing work 
would be needed to validate and refine the outcomes included, with the expectation 
that this would change over time, as new treatments became available. I would also 
need to identify suitable ways of measuring the included outcomes, and make 
recommendations regarding this through work with COSMIN, after publication of 
the COS. The methodology employed and the rationale for this is discussed within 
the body of the thesis. This is methodological research in a relatively new area and 
the work within this thesis has contributed to COS development guidance [117, 
194].  
 
5.3 Summary of key findings 
 
In the systematic review described in chapter two, I identified 58 distinct outcomes 
reported in 43 RCTs with a total of 259 outcomes measured across all studies and a 
mean number of 6 outcomes per study (range 2-12). In order, acute toxicity, overall 
survival, late toxicity, loco-regional control, response, disease-free survival, 
progression-free survival, HR-QOL, distant metastases and local control were the 
ten most commonly measured outcomes. Outcomes brought forward to the 
comprehensive outcomes list could be categorised under broader domains relating 
to toxicity, disease control, survival and HR-QOL. Only 6 studies (14%) provided 
a definition of every outcome in the trial. Of all outcomes, 58.3% (151/259) were 
defined. Overall survival, despite being the most common primary outcome, was 
only defined in 46% (18/39) of studies. HR-QOL was only measured in 7 studies, 
and often separately to the trial report. 
 
In chapter three I present the findings of the qualitative interviews. The objective 
of the interviews was to identify outcomes of importance to patient and carers, thus 
ensuring that the comprehensive outcomes list did not miss any outcomes which 
were important to these stakeholders. Thirty-one interviews were conducted with 
23 patients (17 male and 6 female) and 11 carers (1 male and 10 female) 
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identifying 136 distinct outcomes. These predominantly related to HR-QOL, 
function, toxicity and the wider impact of adverse effects on a person’s ability to 
participate in life as before. However, as in previous research into patient priorities 
in SCCHN, survival was the most important outcome. 
 
The outcomes list from these two strands of the study were combined to form a 
comprehensive list of 154 outcomes. A questionnaire comprising 50 questions 
relating to these outcomes was developed by our study team comprising two 
clinicians, a qualitative researcher and trials methodologist. We presented the 
outcomes in the context of whether these would help someone decide between 
treatments. Separate questionnaires were developed for healthcare professionals, 
patients and carers and after the first round, participants were randomised to the 
type of feedback they received in a nested methodological study to investigate the 
impact of who feedback is received from. 
 
Following two rounds of voting, consensus was reached on eight outcomes for 
inclusion in the COS, namely local control, regional control, distant metastatic 
control, disease-specific survival, death related to treatment, HR-QOL, 
interventions for the management of treatment-related morbidity and dysphagia. 
 
5.4 Appraisal of the COS 
 
The WHO stated in 1981 that clinical trials in oncology should, as a minimum, 
measure the response of the tumour and metastases, duration of response to 
treatment and acute and long-term adverse effects of therapy [144]. The COS 
includes outcomes relating to response of the tumour and metastases (local control, 
regional control, distant metastatic control) which are in current use rigidly defined 
by criteria for tumour shrinkage [98, 99] and frequently used to assess the benefit 
of systemic chemotherapy. The duration of response was not included as a separate 
outcome in the Delphi. This will be an important consideration for future research 
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arising from the work in this thesis when making recommendations for how the 
COS outcomes are measured.  
 
It is widely recognised that overall survival is the gold standard end point for 
assessing the effectiveness of interventions in clinical trials in oncology [96] and 
criticism has been levelled at the use of surrogates for overall survival in clinical 
trials in oncology, when these have been shown to have little correlation in the 
long-term [94]. Loco-regional control, is one such surrogate frequently used in 
clinical trials of OPSCC. It is a composite of local and regional control, two of the 
outcomes in the COS. In contrast to other areas of oncology, loco-regional control 
has been shown to have a strong association with overall survival in SCCHN. In 
116 treatment comparisons for 22,744 patients, Michiels et al. showed that for 
radiotherapy treatment, effects on both duration of loco-regional control and event-
free survival were strongly correlated with those on overall survival [97]. So, 
although overall survival did not reach consensus, the COS includes surrogates 
with which this has a strong correlation. Furthermore, the real-world application of 
overall survival has been questioned by Prasad et al. Three findings in recent years 
– survival gains in trials of cancer drugs are marginal, trials of cancer drugs are 
conducted in unrepresentative populations, and real-world outcomes data find no 
benefits or diminished benefits of cancer drugs – have coalesced to yield the 
conclusion that even overall survival in clinical trials in oncology may be a 
surrogate endpoint [294].  
 
Unlike, overall survival, disease-specific survival benefit does not decrease with 
age and co-morbidities due to competing risks [294]. Disease-specific survival did 
reach consensus and some argue that this is a truer reflection of the effects of a 
treatment than overall survival which reflects all-cause mortality [295]. There is 
little research regarding the relative benefits of measuring disease-specific survival 
versus overall survival in OPSCC, and this will need to be investigated in a 
systematic way in the validation of the COS.  
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Death related to treatment, which is a grade 5 acute toxicity also reached consensus 
for inclusion in the COS, yet other acute toxicities did not. The interviews 
suggested that the long-term adverse effects of treatment are more important to 
patients and carers than acute effects. This was supported by the Delphi; only 
57.9% of patients and carers in panel two and 54.5% of those in panel three ranked 
acute adverse effects as critically important. Measures of the adverse effects of 
treatment are a requirement of clinical trials however and acute toxicities were 
consistently measured in the RCTs identified in the systematic review.  
 
A common criticism of clinical trials in OPSCC is that follow-up periods to assess 
late adverse effects of treatment are too short, often no more than two years [296]. 
The qualitative work undertaken here shows that late effects are important to 
patients and carers and of greater priority than acute effects. Furthermore a 
growing body of evidence on the late effects of radiotherapy, particularly related to 
swallowing outcomes necessitates close scrutiny of late sequelae, especially in the 
HPV-positive cohort of patients who will likely live for longer with late effects. 
Late radiation related swallowing dysfunction is increasingly observed in patients 
who are more than five years from completion of radiation treatment, and 
particularly concerning is the fact that these problems are more common in patients 
receiving IMRT, a type of radiotherapy thought to reduce xerostomia, another 
troublesome late effect of radiotherapy [63, 64, 297, 298]. Xerostomia was a 
common complaint of patients and carers in the qualitative interviews, and the 
wider literature shows that this is a common patient concern [290]. Yet, the 
published literature suggests that adverse swallowing outcomes have a more 
pronounced effect on HR-QOL than mouth dryness [240, 299-301] and, in the 
Delphi, swallowing was prioritised over mouth dryness. The two outcomes aren’t 
independent however, and mouth dryness contributes substantially to swallowing 
difficulties in patients treated with radiotherapy for OPSCC. Mouth dryness may 
be a surrogate for dysphagia. 
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HR-QOL should be measured in clinical trials in oncology, and this outcome 
reached consensus in the Delphi. Despite recommendations by the WHO that HR-
QOL this should be measured in clinical trials in oncology in 1981, this was only 
reported in 7 trials in the systematic review, all published after 2006 [239]. There is 
a strong correlation between HR-QOL and functioning which is why changes in 
HR-QOL are more pronounced in SCCHN than many other cancers [240]. HR-
QOL is an important outcome, and the interviews strongly suggested that this 
would be an important differentiator for patients and carers when choosing 
between treatments. HR-QOL is largely measured using questionnaires. There are 
HR-QOL questionnaires for cancer generally and specifically for SCCHN with 
construct validity, however no one instrument is ideal for all purposes. When 
selecting a disease-specific HR-QOL instrument for SCCHN patients, careful 
consideration must be given to disease subsite, treatment, timing of assessment, 
clinical setting, study purpose and the  research question [302]. 
 
The requirement for interventions for the management of treatment-related 
morbidity reached consensus for inclusion in the COS. This is an outcome domain 
that arose from the patient and carer interviews. Many described a desire to be 
cured and free from long-term sequelae of treatment without a requirement for 
procedures like oesophageal dilatations for dysphagia or further surgery. Several 
patients described a desire for treatments that were as minimally invasive as 
possible. When this outcome was presented in the questionnaire it was given with 
examples of further interventions that were directly taken from the interviews 
namely the need for further surgery for complications and oesophageal dilatation. 
Outcomes that are important to patients should not be excluded on the basis that 
they don’t have established ways of measurement. Careful consideration will need 
to be given as to how this is measured in a systematic and repeatable way in the 
validation process for the COS. 
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5.5 Critical evaluation of the research 
 
The systematic review met its stated objective of identifying a comprehensive list 
of outcomes reported in OPSCC RCTs. This includes clinical and patient-reported 
outcomes. It has identified inconsistencies in the selection, definition and reporting 
of outcomes in SCCHN and OPSCC clinical trials which are a barrier to the 
synthesis of trial data. The search strategy to identify outcomes was rather 
unfocused and retrieved a large number of citations. Whilst initially, this 
inclusiveness was seen as a strength of the study, reviewing and sorting such a 
large number of citations was labour intensive, technically challenging and time 
consuming. Whilst checks were made, it is possible that this led to the inadvertent 
exclusion of eligible studies, although it is unlikely that important outcomes were 
missed.  
 
This review is limited to phase III RCTs. In identifying outcomes of importance 
other COS developers have also included non-randomised prospective trials, 
reports of PROMs and qualitative studies [303]. In the design phase of this study 
we made the decision that the review would be limited to phase III RCTs for the 
reasons discussed in the introduction. This did limit our review findings to trials of 
non-surgical interventions - no surgery only trials were identified. The challenges 
of randomized trials in surgery are well recognized [304], and by only including 
RCTs we have essentially excluded studies of surgery only interventions and 
therefore we may be missing outcomes that are important to surgical trials and 
patients having surgical treatments. This was somewhat compensated for by having 
a significant proportion of surgically treated patients in our qualitative interviews. 
None of these had open surgery, however this is rarely a first-line treatment for 
patients with locally advanced disease in current practice. Although qualitative 
methods were a key part of the work in this thesis, there is an abundance of HR-
QOL literature in SCCHN and including this literature, along with non-randomised 
and qualitative studies would have increased the number and variety of possible 
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outcomes to be carried forward to the Delphi study. I don’t think any major 
outcomes were missing however; healthcare professionals and patients and carers 
suggested few additional outcomes in round one of the Delphi. 
 
The semi-structured interview worked well to identify outcomes of importance, but 
also to understand why these are important. It allowed me to direct participants 
back towards discussion about outcomes, when, in discussing very emotive issues 
some strayed away from discussion around outcomes. The semi-structured 
approach allowed me to probe some topics further and to ask patients what the 
most important outcomes were. As a method of data collection, it was rather 
cathartic for some patients and carers, and several commented that reflecting on 
their experiences and discussing them had been a really positive experience for 
them. Some patients also said it was nice that someone was showing an interest in 
outcomes, because they felt very little concern was given to toxicities, function and 
their impact on HRQOL. Patients and carers said that by contrast to questionnaires, 
which they felt were only serving the purpose of the person collecting the data, a 
face to face interview acknowledged their struggles and was beneficial to them too. 
 
Some patients didn’t acknowledge my position as a healthcare professional, 
however some did and used the interview as an opportunity to address clinical 
concerns or unanswered questions. They seemed to see me as a go-between 
though, there was less formality than in their encounters with clinicians who they 
felt had little time to answer questions, and I was in their home, so the playing field 
was more level.  Although I was seen as someone with knowledge, I don’t believe 
I was seen as a figure of authority.  
 
Initial content analysis allowed me to identify the outcomes and language used to 
describe them in an expedient manner, to develop my comprehensive outcomes 
list. Subsequent analysis was more interpretive. As a clinician, in analysing the 
transcripts to identify outcomes, I will have identified outcomes known to me, 
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those I recognise through my own experience and knowledge. It is possible that I 
may have missed outcomes that I didn’t recognise, or that don’t currently have a 
means of measurement.  
 
All patients and carers were Caucasian. We attempted to recruit non-Caucasian 
patients however none were available in the interview timeframe in the UK, which 
reflects the patient demographic. In the US, only Caucasian patients responded to 
invitation to participate. Therefore, whilst the COS is broadly generalizable to 
Caucasian patients in the UK and US, it may not have cross-cultural 
generalizability. The greatest concern to most patients, aside from survival was of 
the impact of treatment on eating and drinking. This was more of a concern to 
patients in whom socialising around food was a priority; in other cultures this may 
well be even more valued. Additionally, the effects of treatment on aesthetics are 
likely to have varying levels of cultural significance, which we haven’t been able 
to assess for in this study. 
 
Clinical and demographic data was available for all interviewees, however this was 
collected less reliably in the Delphi recruitment. This hindered comparisons of 
voting based on these characteristics, and in randomisation to panels, because these 
characteristics weren’t considered, it is possible that voting was influenced by 
factors other than panel allocation. 
 
Many participants had difficulty identifying a ‘core set’ of important outcomes 
because, as one patient in the Delphi survey commented:  
 
"I wanted to mark nearly everything as critical but realised this defeats the object. 
At some point over the last 5 years though everything has been critical to me 
personally.” 
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Whilst many patients and carers understood the need to prioritise some outcomes 
over others, several found this impossible to do, ranking all the outcomes of critical 
importance. In this case, not for expedience, but because of a genuine feeling that 
the outcomes described had all been core, at one point or another. I did not see this 
as a limitation of the study, rather it points to the significant challenges of selecting 
core outcomes in conditions with high levels of morbidity. Like in other studies of 
cancer – survival is the most important outcome - however there was a large ‘grey 
area’; only two out of 56 outcomes in the second round were deemed  unimportant 
by a consensus majority, the rest were either important, or of critical importance.  
 
Attrition was relatively high, with a third of participants dropping out between 
rounds one and two. The loss of US clinician opinion may have compromised the 
applicability of the COS to US trials, however given that they did not have 
minority opinions in the first round of the survey, and that the remaining US 
participant did not have diverse opinions in the second round, it seems unlikely. 
Attrition was lowest amongst patient and carer participants who had been involved 
in the qualitative interviews; this is likely to be because they were more invested in 
the study. I am certain they felt that their views were genuinely valued because of 
their involvement throughout the different stages of the COS development process. 
Published Delphi studies to develop COS report variable levels of attrition between 
the rounds [117], however, like in this study it seems that attrition is lower with a 
more targeted recruitment strategy. Bennett et al. observed 0% attrition in their 
small Delphi study (fewer than 10 participants) and their recruitment strategy was a 
targeted approach to known experts [198], whereas Smith et al. [204] observed 
higher attrition rates (17%) from 12 participants from inviting trial authors from 
the relevant academic literature. A larger study for oesophageal cancer surgery 
which recruited 126 surgeons and nurses identified through a meeting of the 
Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, and 
by personal knowledge of surgeons, and 185 patients recruited from three clinical 
centres had attrition rates between rounds 1 and 2 of 15% for professionals and 
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17% for patients. In a similarly sized study by McNair et al. attrition rates for 
clinicians were 20% and only 10% for patients [178]. Minimising attrition between 
the rounds of a Delphi study is important to ensure that minority views are not 
discounted and that the final consensus represents all stakeholder groups [251]. 
Although our attrition rate was higher than the other studies quoted, we were able 
to maintain proportionate representation from the stakeholder groups because we 
anticipated higher attrition amongst clinicians and therefore invited more to 
participate in the first round.   
 
To compare and contrast all research in a topic area, a COS must be applicable and 
adopted internationally. With this in mind, we set out to recruit patient and carer 
interviewees, and patient, carer and clinician stakeholders in the Delphi from the 
UK and the US. As discussed, attrition was high amongst US clinicians. Whilst 
they did not have minority views, it is difficult to predict how they were likely to 
have voted in round two having seen the feedback from other participants. There 
was however good participation from US patients in both rounds. We did not 
extend our recruitment to the rest of Europe, Asia or Australasia however and it is 
possible that we missed outcomes of importance or of cultural significance.  
 
A further challenge was ensuring that participants engaged in the Delphi process. 
There were several patient, carer and clinician participants who stated that their 
beliefs and answers simply hadn’t changed between rounds. When feeding back in 
the second round we showed participants how they had voted on a given outcome 
in the previous round. Had we not provided this I think participants would have 
given more time to consider how they ranked outcomes and I think there would 
have been greater variability in voting. Out of expedience, I think some 
participants selected the same rankings as they had done previously.  
 
Consistent high ranking could mean participants perceived all of the outcomes to 
be of critical importance, however there is a risk that participants don’t understand 
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the premise of the consensus exercise – identifying ‘core’ outcomes. I would argue 
that the involvement of a smaller number of invested stakeholders is more valuable 
than the involvement of a greater number of uninvested stakeholders. Invested 
stakeholders are more likely to remain in the study, understand its purpose and 
therefore contribute meaningfully to the consensus process. A face to face 
consensus meeting might make meaningful contribution more likely and would 
allow for discussion; disengagement could be a product of the online format of the 
survey.  
 
5.6 Conceptual issues 
 
5.6.1 Integrating healthcare professional and patient and carer views 
 
In this Delphi study, participants were randomised to panels. Only outcomes 
reaching consensus in every panel were carried forward to the COS. On the one 
hand, we felt that this would represent the outcomes with the very strongest 
consensus, however a risk of this type of analysis is that we could have ended up 
with a very small number of outcomes in the COS should participants have had 
very disparate views. It would also have been possible to combine all the scores for 
outcomes and carry forward those reaching cut off, irrespective of whether they 
reached consensus within individual panels (thus changing the denominator) or to 
have included all outcomes reaching consensus across the three panels. These 
methods don’t account for stakeholder groups however and the final COS could 
end up being influenced by a particular stakeholder group if they are more 
numerous or scores are weighted. Further this could hide those with disparate 
views. In this study all stakeholder views were given equal weighting in the Delphi 
analysis, other COS studies have weighted their analysis when a particular 
stakeholder group’s opinion is felt to be more valuable [117]. This is problematic 
as it is difficult to ascertain what weightings should be given and there is no 
current guidance on this.  
198 
 
 
 
 
 
The work by Macefield et al. [287] described in chapter four, that influenced our 
decision to randomise patients to panels has subsequently been published alongside 
a review of this methodology by Brookes et al. [289]. This research expanded on 
the work done by Macefield et al. showing that in three different studies, the 
randomisation of panel feedback influenced the way participants voted and 
ultimately the items retained at the end of the Delphi process. The level of 
agreement between stakeholder groups depends on the feedback presented, even 
when initial agreement between stakeholders is high. Brookes et al. concluded that 
all participants in a Delphi should see how individual stakeholder groups have 
voted, as this may improve agreement between the stakeholder groups by enabling 
reflection on others’ views [289].  
 
In this Delphi study, the variability in voting between rounds suggests that patients 
and carers were influenced by clinicians but that clinicians weren’t influenced by 
patients and carers. This contrasts with the work undertaken by Macefield et al. 
which showed that clinicians were more influenced by patients and carers [287]. 
These findings are potentially at odds with the purpose of the Delphi, which is 
meant to take away the influence of individuals or groups perceived to have greater 
authority [251]. It does however also show the value of the consensus exercise; 
people changed the way they voted in response to others. It could be argued that 
patients and carers were influenced by factors other than the way clinicians voted. 
More research is required to establish the factors that influences participants’ 
voting in Delphi studies. 
 
5.6.2 Problems with consensus process 
 
In the development of COS, there is little evidence on the relative advantages and 
disadvantages of the various consensus methods. As discussed in the introduction 
to this thesis, expert panel meetings, sometimes using nominal group techniques, 
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and Delphi studies are the methods used in previous COS studies. These have been 
used to both elicit opinions and develop consensus [152]. The ability of the method 
to achieve true consensus amongst a diverse range of stakeholders with 
methodological rigour is the most important consideration. However, one must also 
bear in mind factors such as practicality and cost. When designing this study, we 
therefore considered both consensus methods.  
 
The nominal group technique is a highly-structured face-to-face meeting of 5-9 
stakeholders which lasts around 2 hours [182]. Initially there is silent generation of 
ideas in response to a number of questions. Participants are then invited to share 
their ideas using a ‘round robin’ technique until all ideas have been presented. 
Discussion is discouraged until all ideas have been recorded so that each 
participant has the opportunity to share their opinion prior to it being modified or 
rejected by the group. Once all responses are listed, group discussion can ensue to 
clarify ideas. Finally, participants are asked to prioritise their ideas about each 
question discussed.  
 
The Delphi technique comprises sequential questionnaires answered anonymously 
by a panel of participants with relevant expertise. After each questionnaire, the 
group response is fed back to participants who are asked to reflect on their voting 
in light of how other participants have voted to move towards group consensus. 
There must be at least two rounds in a Delphi study to allow reflection on the 
previous rounds scores. There may also be a ‘blank paper’ round to elicit opinion 
prior to scoring items. 
 
Over NGT, one of the advantages of the Delphi method is that it is anonymous. 
Participants do not meet face to face and there is less chance of more vocal or 
authoritative figures dominating the discussion or influencing others’ voting. This 
was particularly important in this COS study because we wished to invite patients, 
carers and healthcare professionals. Perceived imbalances of power amongst such 
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stakeholders are possible, if not likely, and anonymity went some way to reducing 
the influence of figures with more perceived authority i.e. healthcare professionals. 
In one of the panels in our study, feedback from all stakeholder groups was 
provided, allowing the participants in this panel to reflect on how patients, carers 
and healthcare professionals had voted. This approach is now recommended by 
Brookes et al. as it allows for greater consensus between stakeholder groups, 
however our analysis suggested that patients and carers may have been influenced 
by healthcare professional’s voting because they were more likely to change their 
voting in response to feedback. This isn’t necessarily a methodological flaw, the 
purpose of the Delphi is for people to change their voting in response to that of 
others, the limit to which we can reduce the impact of figures of authority in this 
study is limited however by providing this type of feedback. Some COS studies are 
currently investigating the reasons for people changing their voting within a Delphi 
and this will hopefully shed light on the significance of this effect [195, 305]. 
 
A further advantage of the Delphi study is that participation can be done remotely 
using postal or online surveys, and therefore location is of no barrier to 
participation, which means a more diverse and numerous group of individuals can 
participate. COS should apply to as wide a geographical audience as possible and 
so greater geographical diversity of participants is preferential. The Delphi 
technique has therefore become the most popular method for reaching consensus in 
COS studies [117]. 
 
5.7 Application of the COS 
 
It is likely that the COS is transferrable to other SCCHN subsites, and given that 
OPSCC is usually studied as part of larger SCCHN clinical trial, for it to be 
implemented this would have to be accepted, however it must be borne in mind by 
trialists that a COS represents the minimum that should be reported, and, when 
used in other subsites additional outcomes may need to be measured. It is likely 
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that further COS will be developed for other sub-sites, however rather than starting 
from the beginning it may be that the relevance of the OPSCC COS to other sub-
sites could be evaluated by stakeholder working groups for different sub-sites and 
adapted as deemed necessary. None of the outcomes in the COS are specific to 
OPSCC, however outcomes that are likely to be important to other head and neck 
sub-sites are missing; there are no voice outcomes which are likely to be important 
to clinical trials of interventions for laryngeal cancer. 
 
The COS was designed with late phase clinical trials in OPSCC in mind, however 
COS in other clinical areas have been applied to other effectiveness studies, 
research and audit [178], and we would advocate this use. Minimally invasive 
surgical techniques are increasingly used in the management of patients with 
OPSCC, yet there are substantial barriers to conducting randomized trials because 
of the complexity of surgical interventions [306], and no head to head trial 
comparing surgical and non-surgical interventions has been conducted in SCCHN 
or OPSCC. As the complexity of surgical trials has been acknowledged [307, 308], 
research to define the elements of surgical interventions has been conducted with 
the purpose of increasing the homogeneity of interventions, allowing for robust 
comparisons of outcomes in RCTs [306]. It is hoped that such research will be 
conducted for surgical interventions in OPSCC as this is likely to increase the 
acceptability of surgical interventions to researchers and go some way to reduce 
the criticisms levelled at the heterogeneous delivery of interventions within RCTs 
in surgery [309].  
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Chapter 6 
Conclusions and future work 
 
 
6.1 Main conclusions 
 
Survival remains the most important outcome of treatment to healthcare 
professionals, patients and carers irrespective of age, disease stage or HPV status. 
Of the eight outcomes that reached consensus in the Delphi, five of these related to 
disease control and survival, namely local control, regional control, distant 
metastatic control, disease-specific survival and death related to treatment. Late 
toxicities and functional outcomes are important, and were described at length in 
the interviews, however dysphagia was the only functional outcome to make the 
COS. Health-related quality of life also reached consensus, however this was more 
strongly favoured amongst healthcare professionals than patients and carers. In 
contrast to the significant outcomes heterogeneity identified in the systematic 
review, there is strong consensus amongst patients, carers and healthcare 
professionals regarding the outcomes for inclusion in the COS.  
 
This study gathered consensus opinion from major stakeholders regarding the 
outcomes that should be included in a COS for OPSCC. It is the first study, to my 
knowledge, which has sought patient opinion regarding outcome selection in 
clinical trials in OPSCC. The qualitative study described in chapter three, 
reinforces the existing literature, demonstrating that the adverse effects of 
treatment for OPSCC are severe, and in many cases, persistent. The implications of 
these effects are different for patients depending on their age, interests, social 
circumstances and commitments. The advent of HPV driven OPSCC has seen a 
change in the ‘typical’ head and neck cancer patient, and whilst many studies have 
set out to investigate treatment de-escalation strategies, to reduce the incidence and 
severity of long-term treatment related morbidity, the qualitative work in this thesis 
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suggests that those with young children or caring commitments would accept no 
reduction in survival, for functional gains.  
 
Patients, carers and clinicians were consistent in prioritising survival outcomes. 
Whilst this is not unexpected, the interviews conducted as part of this study 
suggested that outcomes such as mouth dryness and fatigue were very important 
issues for patients both in the acute and long term, yet neither reached consensus 
for inclusion. Further research is required to interpret the differences in what 
people say in interviews, compared with how they vote in Delphi studies in COS 
research. 
 
Mixed methods approaches are useful in core outcome set development for 
ensuring that outcomes important to all stakeholder groups are considered for 
inclusion in the COS. The final COS included outcomes extracted from both the 
systematic review of the literature described in chapter two and the qualitative 
interviews described in chapter three. Consensus methods are important; the 
outcomes included in the COS were not the outcomes most commonly measured in 
the trials included in the review, those spoken about at greatest length in the 
interviews, or those prioritised by patients and carers in the interviews when asked 
to rank outcomes. Consensus was strong in this study however, regarding the 
outcomes of greatest importance, and there were no substantial changes in 
consensus outcomes between rounds. Without consensus methods, very different 
conclusions would have been reached regarding the outcomes deemed important to 
health-care professionals (those measured in trials) and those important to patients 
and carers (the outcomes discussed during the interviews). 
 
In the Delphi study I took the approach of presenting more precise outcomes rather 
than outcome ‘domains’ which have been used in other studies. I felt this approach 
would lessen ambiguity in the interpretation of the outcomes by participants, but 
also in interpretation of the final published COS by those using it. The next crucial 
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stage in developing the COS, is in identifying how the included outcomes should 
best be measured. Outcome domains are outcome composites with multiple events 
per domain that could be measured; this will make the process of identifying best 
measurement methods more complex and challenging, and is likely to lead to 
delays in implementation of the COS. We hope that the approach we have taken is 
still inclusive enough and will allow for efficient dissemination and 
implementation of the COS. 
 
The COS has benefited from the involvement of patients, carers and clinicians in 
its development. It is clear from undertaking this exercise that many possible 
outcomes of treatment could be measured, that different outcomes are prioritised 
by different individuals but that ultimately there are outcomes of key importance, 
upon which there was strong consensus.  
 
6.2 Future work 
 
6.2.1 Refining the COS 
 
Work will be ongoing to establish how the included outcomes should be measured, 
whether this be an objective measure or a subjective measure such as a PROM, and 
the validity of these instruments will need to be assessed. As well as establishing 
how the outcomes are measured, definitions, including the events that would be 
measured need to be clarified, whilst ensuring fidelity to the COS as voted for by 
participants.  
 
We will be in consultation with COSMIN regarding this, following guidance set 
out in a joint initiative between COSMIN and COMET on the selection of outcome 
measurement instruments for COS [310]. This will involve 1) Consideration of the 
construct to be measured and the target population 2) A systematic review to 
identify all existing outcome measurement instruments (OMIs) 3) Quality 
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assessment of OMIs (to evaluate measurement properties and feasibility aspects) 4) 
Consensus procedures to agree on the OMIs for each outcome in the COS, 
performed among all relevant stakeholders, including patients. 
 
An important part of this work will be in establishing how the ‘need for further 
interventions as a result of treatment’ outcome will be defined and measured; what 
events will constitute the outcome and how will these be collected in a systematic 
and repeatable way between trials. Heterogeneous measurement, like 
heterogeneous outcomes would impede synthesis of such outcomes, and it is 
possible that a measurement instrument may need to be developed for assessing 
such events.  
 
Since the induction of this research, a general symptom COS for use in adult 
cancer treatment trials has been published [311]. We will need to review this and 
consider how it sits alongside the COS we have developed. The qualitative 
interview transcripts, and Delphi voting will be useful in assessing the applicability 
of this COS to clinical trials in OPSCC. Furthermore, in the interim other research 
groups have made recommendations about OMIs in SCCHN which will have 
relevance in OPSCC and will be considered as part of the process described above 
[190].  
 
6.2.2 Validating the COS 
 
The OPSCC COS was developed with healthcare professionals, patients and carers 
from the UK and US. Further work will be required to establish whether the COS 
is applicable across international settings. As we work towards refining study 
populations for OPSCC clinical trials, the need for multi-centre and international 
trials to recruit adequate numbers will become greater. Therefore, it is of the 
utmost importance that we establish international applicability of the COS. 
Furthermore, refinement of study populations means that we will rely more on the 
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synthesis of data from individual trials. This work is therefore necessary if the COS 
is to have the intended benefit of harmonising cross-trial outcomes measurement 
thus facilitating data synthesis.  
 
Expert panels and conference workshops have been used to achieve international 
consensus by the OMERACT initiative [145], however this was in the design stage 
of the core set, rather than in assessing its applicability to different international 
settings. This is however likely to be a useful process for firstly publicising the 
COS, and secondly opening discussions about whether this has international or 
cross-cultural validity.  
 
Periodic review of the COS will be necessary to ensure that the included outcomes 
remain important to stakeholders and relevant to contemporary clinical practice 
and the changing patient demographic. New outcomes may need to be added and 
there will need to be a process for considering new outcomes in the context of the 
scope of the COS. As part of this process, uptake of the COS and barriers to its 
implementation in relevant trials will need to be assessed and addressed. A process 
for periodic review of the contents of the COS will need to be delivered. 
 
6.2.3 Uptake of the COS 
 
The protocol for the COS was published and was highly accessed at the time of 
publication [74]. It has been accessed 3568 times and cited in 20 publications. It 
has been cited 20 times but only, so far in other COS projects, not related to 
SCCHN or OPSCC. I have, however, had several enquiries about the COS 
showing that SCCHN researchers are interested in using this. 
 
The COS development process has also been presented at a number of national 
meetings, and awareness of the OPSCC COS has grown with increasing awareness 
of COSs in general. Upon publication, the COS will also be presented at large, 
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international meetings such as National Cancer Research Institute (NCRI) cancer 
conference.  
 
COS are under development in other areas of Otorhinolaryngology-Head and Neck 
Surgery (ORL-HNS), which will hopefully increase awareness of COS amongst 
head and neck cancer clinicians and researchers and drive trialists to search for 
COSs when designing OPSCC trials. 
 
This COS is intended for submission to and publication in an open access journal 
with a large readership to ensure wider publicity and invite feedback. The first 
COS was published, for rheumatoid arthritis, in 1994. The introduction of 
regulatory guidance recommending use of the COS by the Food and Drug 
Administration (FDA) in 1996 and the European Medicines Agency (EMA) in 
1998 are thought to have contributed to trials measuring these outcomes. In 
addition to raising awareness of the COS with regulatory agencies we will need to 
engage with organisations such as the European Organisation for Research and 
Treatment of Cancer (EORTC), the United States National Cancer Institute (NCI) 
and the Radiation Therapy Oncology Group (RTOG) to validate the COS more 
widely and ensure its’ implementation in major OPSCC clinical trials. 
 
The promotion of COS by the COMET initiative [175] and references to COS in 
guidelines for trialists [312], by funders [313] and from regulatory authorities [314] 
are expected to accelerate COS uptake in the future. Furthermore, engagement with 
journal editors, funders, Cochrane Review Groups, clinical guidelines developers 
and trial registries will increase COS uptake by incentivising trialists to use them 
[315].  
 
Evaluation of COS uptake is crucial to avoid core outcome sets being developed 
but never used, thereby contributing to research waste [316]. Uptake of the COS 
will be assessed by consultation of trial registries. In a recent review by Kirkham et 
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al. [315] this was shown to provide a reasonable estimate of the uptake of COS and 
is a more efficient and up-to-date approach than examining the outcomes in 
published trial reports or by citation analysis [317]. 
 
Barriers to implementation of the COS should be anticipated and addressed. One 
potential barrier is of difficulty finding the COS. It will be made clear in the title 
and abstract of the publication that this is a COS for OPSCC, as by the COS-STAR 
recommendations [318]; it will be listed in the COMET database and published, as 
described above, in an open access journal.  COS are indexed inconsistently in 
literature databases; research is required to establish best practice for indexing and 
labelling such research. A further barrier to implementation could be that the 
outcomes are difficult or expensive to measure, making it unfeasible to use the 
COS in certain settings. This will be reflected in the uptake of the COS and a 
further systematic review to identify trials not using the COS with exploration of 
the reasons for not doing so may be helpful. 
 
6.2.4 Optimising patient involvement in COS  
 
Patients and carers were crucial in developing the COS, and future co-working 
with patients and carers will be essential as the COS adapts over time.  Nearly 90% 
of ongoing COS studies registered in the COMET database involve patient and 
public involvement (PPI) stakeholders, and COMET have launched the People and 
Patient Participation, Involvement and Engagement (PoPPIE) working group to 
lead and oversee the public participation, involvement and engagement work of the 
COMET initiative [157]. We will use their resources in planning public 
involvement in future work on our COS. 
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6.2.5 Intended publications arising from the work in this thesis 
 
The systematic review described in chapter two is currently being updated and will 
submitted for publication in a head and neck journal. The series of qualitative 
interviews in chapter three and the Delphi study described in chapter four will be 
submitted as a combined paper to a general open access journal, this will outline 
the process of identifying the comprehensive outcomes list, the Delphi study and 
the final COS. A further paper exploring other issues arising from the qualitative 
interviews is currently under consideration. Further publications will arise from the 
research to refine and validate the COS and establish how the outcomes should be 
measured. A systematic review of PROMs in SCCHN is also under way. 
 
6.2.6 Future methodological research 
 
This methodological research is novel and has highlighted a number of important 
considerations for future COS developers, including areas for future 
methodological research.  
 
6.2.6.1 Streamlining the systematic review 
 
We used a Cochrane search strategy and RCT filter to identify outcomes for the 
comprehensive outcomes list. As discussed, a large number of citations were 
retrieved, and this is a problem described in other COS studies, especially those 
searching for other study types. Future methodological research to identify ways to 
streamline this part of the research process would be useful, along with 
consideration to the indexing of COS studies in bibliographic databases. 
 
6.2.6.2 Delphi process 
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The Delphi undertaken as part of this study raised questions about the impact of 
attrition, factors that contribute to this, ideal participant numbers in Delphi studies, 
the effect of greater or lesser investment in the study on responses, the effect of 
panels and how best to analyse the data. Furthermore this study raised questions 
about patient and carer understanding of the process because they consistently 
ranked more outcomes highly and had greater difficulty identifying a core of 
important outcomes. There are ongoing nested methodological studies hoping to 
answer some of these questions and it is hoped that this study will help to inform 
some of this literature.  
 
6.2.6.3 Comparing or synthesising different COS 
 
This research has some overlap with the ICF core set for head and neck cancer, 
and, although the COMET database aims to avoid duplication of COS research it is 
possible that other COS for OPSCC will be developed. COS for other SCCHN 
subsites may also be developed. An important consideration for COS developers is 
how this research can be compared and or synthesised. There is no research that I 
am aware of that is exploring this currently. 
 
6.3 Final summary 
 
This study has identified eight outcomes to be included in a core outcome set for 
clinical trials in oropharyngeal cancer using a mixed methods approach, requiring 
involvement of patients, carers and healthcare professionals in identifying the 
outcomes and subsequently prioritising these using iterative consensus techniques. 
The methods used in this study have been effective in reaching strong consensus 
and I have identified areas for further methodological research. COS are growing 
in number, and a concerted effort is required amongst those involved in clinical 
research to make sure that the most appropriate outcomes are measured and 
included in COS which are consistently applied and reported in clinical trials. The 
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selection of better outcomes provides more robust evidence for the effectiveness of 
interventions, this should, in turn, inform clinical practice and clinical guidelines 
and, ultimately, lead to improvements in patient care.  
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Appendix 2 Pubmed search strategy 
Search criteria Search terms 
Oropharyngeal squamous cell carcinoma 
 
 
 
Cancer 
 
 
Oropharynx 
 
 
 
 
 
 
 
 
Randomized controlled trials (Cochrane 
Highly Sensitive Search Strategy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To exclude systematic reviews 
1. “Oropharyngeal Neoplasms”[Mesh] 
2. (“Head and Neck Neoplasms”[Mesh:NoExp]) 
3. “Otorhinolaryngologic Neoplasms”[Mesh:NoExp] 
4. “Pharyngeal Neoplasms”[Mesh:NoExp] 
5. “Neoplasms”[Mesh] 
6. (cancer* OR carcinoma* OR neoplas* OR tumor* 
OR tumour* OR malignan* OR SCC) 
9. (#5 OR #6) 
10. “Oropharynx”[Mesh] 
11. (238arbogen238x* OR mesopharyn* OR tonsil* 
OR“head 
and neck” OR “head neck” OR “head-neck” OR 
“head-and-neck” OR “tongue base” OR “soft palate”) 
12. (#10 OR #11) 
13. (#9 AND #12) 
14. (HNSCC ORSCCHN OR OP-SCC OR OPSCC) 
15. (#1 OR #2 OR #3 OR #4 OR #13 OR #14) 
16. ((((Randomized Controlled Trial[ptyp])) 
OR((Controlled Clinical Trial[ptyp])) OR ((Clinical Trial 
[ptyp])) OR (“Clinical Trials as Topic”[Mesh]) 
OR (“Clinical Trials, Phase III as Topic”[Mesh]) OR 
(“Clinical Trials, Phase IV as Topic”[Mesh]) OR 
(“Controlled Clinical Trials as Topic”[Mesh]) 
OR (“Clinical Trial”[Publication Type]) OR (“Controlled 
Clinical Trial”[Publication Type]) OR (“Clinical 
Trial, Phase III”[Publication Type]) OR (“Clinical 
Trial, Phase IV”[Publication Type]) OR (“Multicenter 
Study”[Publication Type]) OR (“Multicenter 
Studies as Topic”[Mesh]) OR (“Random Allocation”[ 
Mesh]) OR (“Double-Blind Method”[Mesh]) 
OR (“Single-Blind Method”[Mesh]) OR (“Cross- 
Over Studies”[Mesh]) OR (“Placebos”[Mesh]) OR 
(controlled[tiab] AND (trial[tiab] OR trials[tiab] 
OR study[tiab] OR studies[tiab])) OR (blind[tiab] 
OR blinding[tiab] OR blinded[tiab] OR mask[tiab] 
OR masking[tiab] OR masked[tiab] OR placebo 
[tiab] OR placebos[tiab] OR rct[tiab] OR random 
[tiab] OR randomised[tiab] OR randomized[tiab] 
OR randomly[tiab] OR randomisation[tiab] OR 
randomization[tiab]) OR (factorial[tiab]) OR (divided 
[tiab] AND (group[tiab] OR groups[tiab])) OR 
(crossover[tiab]) OR (“cross over”[tiab]) OR 
(multicentre[tiab] OR multicentred[tiab] OR multicentric 
[tiab]) OR (versus[ti] OR vs[ti]) OR (“treatment 
arm”[tiab]) OR (“phase III”[tiab] OR “phase three” 
[tiab] OR “phase 3”[tiab]) OR (“latin square”[tiab]) 
NOT ((“Animals”[Mesh] OR mouse[ti] OR mice[ti] 
OR pig[ti] OR pigs[ti] OR rat[ti] OR rats[ti] OR 
rabbit*[ti]) NOT ((“Animals”[Mesh] OR mouse[ti] 
OR mice[ti] OR pig[ti] OR pigs[ti] OR rat[ti] OR rats 
[ti] OR rabbit*[ti] OR cadaver[ti] OR cadavers[ti]) AND 
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(“Humans”[Mesh]))))) 
17. (#15 AND #16) 
18. ““Cochrane Database Syst Rev”“[Journal] 
19. (“systematic review” OR “meta analysis”) 
20. (#19 OR #18) 
21. (#17 NOT #20) 
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Appendix 3 Characteristics of included studies 
 
Author Country 
Randomized 
patients 
Arm A 
intervention 
Arm B intervention 
Arm C 
intervention 
Number of 
outcomes 
Outcomes measured 
Adelstein, 
2003 [1] 
USA 295 RT alone RT + Cisplatin 
RT (Split Course) 
+ Cisplatin/ 5FU 
5 AT, OS, CRR, DSS, RP 
Asif R, 2003 
[2] 
India 60 RT alone RT + Cisplatin   2 AT,R 
Grau, 2003 
[3] 
Multinational 478 RT RT + Mitomycin C   5 AT, LT, OS, LRC, CanSS 
Olmi, 2003 
[4] 
Italy 192 Conventional RT 
Split-course 
accelerated 
fractionated RT (S-
AHF) 
Conventional RT 
+  concomitant CT 
5 AT, LT,OS, DFS, EFS 
Smid, 2003, 
Zakotnik, 
2007 [5, 6] 
Slovenia 114 Surgery + RT 
Surgery + RT + 
Concomitant MMC + 
Bleomycin 
  7 
AT, LT, OS, LRC, DFS, DM, 
SPM 
Bernier, 
2004 [7] 
European 334 
Radical Surgery + 
RT 
Radical Surgery + RT + 
Cisplatin 
  7 
AT, LT, OS, PFS, DM, Rel, 
SPT 
Cooper, 
2004, 
Cooper, 
2012 [8] [9] 
USA 459 Surgery + RT 
Surgery + RT + 
Concurrent Cisplatin 
  6 AT, LT, OS, LRC, DFS, CauSS 
Fountzilas, 
2004 [10] 
Multinational 128 RT alone 
RT + Concomitant 
Cisplatin 
RT + Concomitant 
Carboplatin 
5 AT, OS, CRR, DurCR, TTP 
Huguenin, 
2004, 
Ghadjar, 
European 224 RT + Chemo RT alone   7 
AT, LT, OS, TTF, CanSS, 
TLRF, TDMR 
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2012 [11, 
12] 
Olasz, 2004 
[13] 
Hungary 38 
Bleomycin, 
Vincristine, 
Methotrexate + 
Surgery 
Bleomycin, 
Vincristine, 
Methotrexate, 
Cisplatin + Surgery 
  10 
AT, OS, R, DFS, DM, SPM, 
LR,RR, LRR, PR 
Budach, 
2005 [14] 
German 384 
Hyperfractionated 
Accelerated RT 
Hyperfractionated 
Accelerated CRT 
  6 AT, LT, OS, LRC, PFS, FDM 
Ezzat, 2005 
[15] 
Egypt 60 
Conventioal RT 
5F/week 
Accelerated RT 
6F/week 
Accelerated RT + 
Mitomycin C 
7 AT, LT, OS, LRC, R, DM, LC 
Haffty, 2005 
[16] 
USA 128 
Concurrent CRT + 
MC 
Concurrent CRT + POR   8 
AT, LT, OS, DFS, CauSS, 
MFS, LRRFS, LRFS  
Hitt, 2005 
[17] 
Spain 387 
Induction cisplatin 
and 5FU + CRT 
Induction paclitaxel, 
cisplatin and 5FU + 
CRT 
  6 AT, OS, TTF, OPR, OCR, TRS 
Mendenhall, 
2005 [18] 
USA 101 RT alone RT + Carbogen   7 
AT, OS, LRC, LC, CauSS, 
MFS, PBCB 
Sanguineti, 
2005 [19] 
Italy 226 
Surgery + 
conventional 
fractionation RT 
Surgery + accelerated 
RT 
  4 AT, LT, OS, LRC 
Soo, 2005 
[20] 
Singapore 119 
Concurrent CRT 
(Cisplatin/5FU) +/- 
salvage ND 
Radical Surgery + 
adjuvant RT 
  3 AT, OS, DFS 
Bensadoun, 
2006 [21] 
France 171 
Cisplatin + 5FU + 
concomitant 
twice-daily RT 
Twice-daily RT alone   12 
AT, LT, OS, LRC, R, DFS, 
PFS, LC, ED, GT, SS, SC 
Bonner, 
2006, 
Curran, 
2007,  
Multinational 424 RT alone RT + Cetuximab   8 
AT, LT, OS, LRC, R, PFS, HR-
QOL, S 
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Bonner, 
2010 [22-
24] 
Bourhis, 
2006 [25] 
France 268 Accelerated RT Conventional RT   6 AT, LT, OS, LRC, DFS, H 
Mitra, 2006 
[26] 
India 180 
Induction Cis + 
5FU > RT 
RT alone   6 AT, LT, OS, R, DFS, LC 
Posner, 
2007 [27] 
TAX 324 501 TPF + CRT PF + CRT   5 AT, LT, OS, R, PFS 
Vermorken, 
2007, van 
Herpen, 
2010 [28, 
29] 
European 
EORTC 
24971/TAX 
323 
358 
TPF (Docetaxel, 
Cisplatin, 5-fu) +/- 
RT 
PF +/- RT   8 
AT, LT, OS, R, PFS, HR-QOL, 
TTF, DurR 
Argiris, 2008 
[30] 
USA 76 Surgery + RT 
Surgery + RT + 
Carboplatin 
  4 AT, OS, DFS, PoF 
Ghoshal, 
2008 [31] 
India 290 
Concomitant 
boost RT 
Conventional RT   6 AT, LT, LRC, R, DFS, PoF  
Racadot, 
2008 [32] 
France 146 Surgery + RT 
Surgery + CRT 
(Carboplatin) 
  6 AT, LT, OS, LRC, MCR, PF 
Sarkar, 2008 
[33] 
India 72 
Conventional RT + 
Cisplatin 
Conventional RT + 
Vinorelbine 
  3 AT, LT, R 
Suwinski, 
2008 [34] 
Poland 279 
Surgery + 
Conventional RT 5 
days/week 
p-CAIR, Surgery + 
conventional RT, 7 
days a week 
  6 AT, LT, OS, LRC, MFS, SCFS 
Gupta, 2009 
[35] 
India 105 
Induction 
Cisplatin + 5FU > 
low dose weekly 
cisplatin 
CRT   4 AT, OS, R, DFS 
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Rasch, 2010, 
Ackertsaff, 
2009, 
Ackertaff, 
2012 [36-
38] 
The 
Netherlands 
and New 
Zealand  
239 
Inta-aterial 
cisplatin, standard 
RT 
Intra-venous cisplatin, 
standard RT 
  9 
AT, OS, LRC, R, DFS, HR-
QOL, LC, MFS, DSS 
Grazia, 2010 
[39] 
Italy 164 RT 
RT + Concurrent daily 
low dose carboplatin 
  6 AT, LT, OS, R, DFS, LRRFS 
Rischin, 
2010 [40] 
Multinational 861 RT + Cisplatin 
RT + Cisplatin and 
Tirapazamine 
  6 
AT, LT, OS, HR-QOL, FFS, 
TLRF 
Rodriguez, 
2010 [41] 
Cuba 106 
RT + 
Nimotuzumab 
RT + placebo   5 AT, HR-QOL, CRR, Imm, SB 
Bourhis, 
2011 [42] 
France 109 
Very accelerated 
RT 64Gy/ 32 
frctns of 2Gy in 23 
days (2Gy/ frctn 
BD) 
RT-CT 62-64 Gy/5 
weeks and 31-32 
frctns (1/52 rest after 
each Rx week and 
2Gy/frctn BD) 
  5 AT, LT, OS, EFS,H 
Hamed, 
2011 [43] 
Egypt 52 
RT + Concurrent 
paclitaxel 
RT + Concurrent 
cisplatin 
  6 AT, OS, LRC, R, PFS, LRFS 
Nutting, 
2011 [44] 
UK 94 Conventional RT IMRT   6 
AT, LT, OS, HR-QOL, X, 
LRPFS 
Quon, 2011 
[45] 
USA 371 RT RT + Cisplatin   7 AT, LT, OS, R, FFS, LO, NT 
Zackrisson, 
2011 [46] 
Sweden 750 
Conventional 
fractionation RT 
alone 
Accelerated 
fractionation RT alone 
  8 
AT, LT, OS, LRC, HR-QOL, 
CauSS, IVDVD, VODS 
Bourhis, 
2012 [47] 
European 840 
Conventional CRT 
(carboplatin 
+5FU) 
Accelerated CRT 
(carboplatin +5FU) 
Very accelerated 
RT 
6 AT, LT, OS, PFS, DM, LRP 
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Gupta, 2012 
[48] 
India 62 3D-CRT IMRT   6 AT, LT, OS, LRC, PoF, ASGT 
Halim, 2012 
[49] 
Egypt 216 
RT + Concomitant 
weekly low dose 
gemcitabine 
RT + Concomitant 
weekly low does 
paclitaxel 
  5 AT, LT, OS, R, PFS 
Haddad, 
2013 [50] 
Multinational 145 
Induction CT  > 
concurrent CRT 
Concurrent CRT   3 AT, OS, PFS 
Skladowski, 
2013 [51] 
Poland 345 
Concomitant 
accelerated boost 
Continous accelerated 
irradiation 
  6 AT, LT, OS, LRC, DM, SPM 
 
Abbreviations:  
Toxicity outcomes ASGT= acute salivary gland toxicity; AT= acute toxicity; GT= gastrostomy tube; LT= late toxicity; LO= laryngeal oedema; H= 
Hospitalisation; NT= nutritional toxicity; OPR= organ preservation rate; S= safety; X= xerostomia 
Survival outcomes CanSS= cancer-specific survival; CauSS= cause-specific survival; DFS= disease-free survival; DSS= disease-specific survival; 
FFS= failure-free survival; ED= early death; EFS= Event-free survival; LRFS= local recurrence-free survival; LRPFS= loco-regional progression-free 
survival; LRRFS= loco-regional recurrence free survival; MFS= metastasis-free survival; OS=overall survival; PFS= Progression-free survival; SB= 
survival benefit; SCFS= second cancer-free survival; SS= specific survival 
Disease control CRR= complete response rate; DM= distant metastases; DurCR= duration of complete response; DurR= duration of response; 
FDM= freedom from distant metastases; LARR= local and regional recurrence; LC= local control; LR= local recurrence; LRC= loco-regional 
control; LRP= loco-regional progression; MCR= metastasis control rates; OCR= overall control rate; RP= recurrence patterns; R= response; Rel= 
relapse; RR= regional recurrence; SC= systemic control; SPM= second primary malignancy; SPT= second primary tumour; TDMR= time to 
distant metastatic relapse; TLRF= time to loco-regional failure; TTF= time to treatment failure; TTP= time to progression  
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Quality of life HR-QOL= health-related quality of life;  
Other PBCB= Identification of parameters that might predict a benefit from carbogen breathing; Imm= Immunogenicity; IVDVD= Influence of 
variations in dose–volume distributions in targets and critical organ volumes on the outcome regarding both disease and morbidity; PF= 
prognostic factors; PoF= patterns of failure; PR= pathological response; TRS= time to radical surgery; VODS= Variations in outcome in different 
sub-sites and stages with respect to treatment type 
References for systematic review studies 
1. Adelstein, D.J., et al., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in 
patients with unresectable squamous cell head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology, 2003. 21(1): p. 92-98. 
2. Asif, R., et al., Concurrent cisplatin and radiotherapy in advanced head and neck cancer. Indian Journal of Otolaryngology and Head and Neck 
Surgery, 2003. 55(2): p. 94-96. 
3. Grau, C., et al., Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: Results of the IAEA multicentre 
randomised trial. Radiotherapy and Oncology, 2003. 67(1): p. 17-26. 
4. Olmi, P., et al., Locoregionally advanced carcinoma of the oropharynx: Conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. 
concomitant radiotherapy and chemotherapy - A multicenter randomized trial. International Journal of Radiation Oncology Biology Physics, 2003. 
55(1): p. 78-92. 
5. Smid, L., et al., Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma. 
International Journal of Radiation Oncology Biology Physics, 2003. 56(4): p. 1055-1062. 
6. Zakotnik, B., et al., Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant 
irradiation with Mitomycin C and Bleomycin. International Journal of Radiation Oncology Biology Physics, 2007. 67(3): p. 685-690. 
7. Bernier, J., et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.  The New England 
journal of medicine, 2004. 350(19): p. 1945-1952. 
8. Cooper, J.S., et al., Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. New 
England Journal of Medicine, 2004. 350(19): p. 1937-1944+2019. 
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Appendix 4 Outcomes identified in the systematic review 
1 Acute salivary gland toxicity (grade 2 or worse) 
2 Acute toxicity 
3 Cancer-specific survival 
4 Cause-specific survival 
5 Complete response rate 
6 Disease-free survival 
7 Disease-specific survival 
8 Distant metastases 
9 Duration of complete response 
10 Duration of response 
11 Early death 
12 Event free survival 
13 Failure-free survival 
14 Freedom from distant metastases 
15 Gastrostomy tube 
16 Hospitalization 
17 HR- QOL 
18 Identification of parameters that might predict a benefit from carbogen breathing 
19 Immunogenicity 
20 Influence of variations in dose–volume distributions in targets and critical organ volumes on the 
outcome regarding both disease and morbidity 
21 Laryngeal oedema 
22 Late toxicity 
23 Local and regional recurrence 
24 Local control 
25 Local recurrence 
26 Local recurrence-free survival 
27 Loco-regional control 
28 Locoregional progression 
29 Locoregional progression-free survival 
30 Locoregional recurrence-free survival 
31 Metastasis control rates 
32 Metastasis-free survival 
33 Nutritional toxicity 
34 Organ preservation rate 
35 Overall control rate 
36 Overall Survival 
37 Pathological response 
38 Patterns of failure 
39 Prognostic factors 
40 Progression-free survival 
41 Recurrence patterns 
42 Regional recurrence 
43 Relapse 
44 Response 
45 Safety 
46 Second cancer free survival 
47 Second primary malignancy 
48 Second primary tumours 
49 Specific survival 
50 Survival benefit 
51 Systemic Control 
52 Time to distant metastatic relapse 
53 Time to locoregional failure 
54 Time to progression 
55 Time to radical surgery 
56 Time to treatment failure 
57 Variations in outcome in different sub-sites and stages with respect to treatment type 
58 Xerostomia 
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Appendix 5 Telephone script MDACC 
Hello <<participant name>>, 
I would like to introduce myself. My name is Aoife Waters and I believe <<Kate 
Hutcheson>> told you I would call to discuss the research we will be conducting at the 
MD Anderson?  
Before we proceed is this a good time to speak? 
If no; 
Could you tell me when would be a good time to speak? 
<<Make arrangements for further call>>  
If yes; 
I would like to start off by thanking you for agreeing to speak with me about my research. 
I understand that <<Kate Hutcheson>> sent you an information leaflet. 
Have you had a chance to look at this?  
Do you have any questions? 
<<Answer any questions about study>> 
I also understand that she sent you a copy of the consent form; do you have any 
questions about any of this? 
Taking all of these things into account do you think you would like to go through with the 
interview? 
If no; 
Do you mind if I ask if there any particular reasons for not wanting to take part or if there 
is anything we could have done differently? 
Thank you for your time. I would just like to reassure you, as I’m sure <<Kate>> did, that 
your decision will have absolutely no impact on your follow up or clinical care.  
If yes; 
Thank you for agreeing to participate in this research, we hope it will help those affected 
by oropharyngeal cancers. <<Kate>> will be in touch with the details of the time and 
place for the interview. Before the interview we will go through any further questions 
you have and ask you to sign a consent form to say you are happy to take part. Please 
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remember you are free to pull out of the research at any time, without explanation, and 
this will have no impact on your follow up or clinical care. 
If in the meantime you have any questions, please contact <<Kate Hutcheson>> who will 
answer your question or put you in touch with someone who can. 
 
Thank you for your time, goodbye. 
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Appendix 6 Interview topic guide 
    
 
The CONSENSUS Study 
Squamous Cell Carcinoma of the Oropharynx: Late Phase Clinical Trial Core Outcomes 
Topic Guide for interviewing patients 
This topic guide outlines the questions and prompts that may be used during the interviews. 
This will be adapted as the study proceeds according to the need/preferences of each 
participant, feedback from The Mersey Head and Neck Cancer Patient and Carer Research 
Forum and the emerging analysis.  
Introduction  
I’ve come to talk to you about what life has been like since your treatment for cancer and 
your thoughts and feelings on this because what you think is very important to me and my 
research.  
This is my voice recorder so that I can remember what we talk about today - is it OK for me 
to record? 
Everything we talk about today is private, only me and a professional secretary will listen to 
the recording and when we write about the project we don’t mention your name or any 
place names or anything like that. You don’t have to answer all the questions – please tell 
me if you would like to move on to a different subject. 
If you feel uncomfortable while we are talking or you may need a break for a drink or need 
to go to the toilet, just let me know and we can stop for a while. We are probably going to 
talk for about an hour and a half. I have plenty time so if it takes longer that’s absolutely fine 
with me, as long as you’re happy too.  
I will keep my phone here- I need to check in with work at 1pm to tell them where I am. 
There are no right or wrong answers– I’m just interested in hearing about your views and 
experiences. 
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I’ll jot down some note as we go along and refer to the questions but don’t be distracted by 
that. 
Do you want to ask me anything before we start? 
Main Discussion 
General 
1. I’d like to get a picture of what life’s like for you at the moment, could you tell me a 
bit about that? 
2. How are you getting along at the moment? With regards to…  
a) Are there things that you need help with on a daily basis? What are these? 
What kind of help do you need? Who helps you with this? 
3. Since your diagnosis and treatment has life changed for you? What ways has life 
changed? 
4. Do you still have good days and bad days? 
5. What’s a good day like for you? 
6. What’s a day like for you when things are not so good? 
7. Are there things you’d like to do since your treatment but can’t, could you tell me 
about that? 
8. Some people have said that their sleep has been affected by the treatment; have you 
found this to be the case? What impact has this had on your life? 
Diagnosis 
9. Thinking about your feelings around the time that you got diagnosed, how have these 
changed as time has gone by? 
10. On reflecting back now on that time, is there anything you would have changed? i.e. 
would you have made any different decisions? 
11. Did you feel clear about what your options were?  
12. Tell me about any symptoms you had prior to starting treatment, how have these 
changed, if at all? 
13. What was/is your relationship like with the clinical team? 
14. How do you feel about the care they gave you… did you ever have any doubts about 
aspects of the care 
15. What things helped you through your treatment? 
16. Is there anything that you think should have been done or provided to help you 
during your treatment that wasn’t? 
Treatment 
 
17. Thinking about your treatment, in general how did you find it? 
a) Was your response to treatment as you expected? 
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18. When you think about your treatment and the side effects- which were the most 
difficult side effects of your treatment to deal with?  
a) Which of the side effects that you described are you still having trouble with? 
19. Was there any point at which you thought that it wasn’t worth it or that the side 
effects were too much to handle? 
***IF HPV-POSITIVE AND AWARE OF THIS***  
a) How did you feel when you were told that your cancer was related to a virus? 
20. Are there any problems that have arisen that haven’t been addressed? 
Relationships 
21. All relationships have their ups and downs – could you tell me a little about how you 
get along together? 
22. Has your illness and treatment affected your relationships with those close to you? 
Could you tell me a bit about that? 
23. Some people have said that the treatment has had an impact on the physical or 
intimate side of their relationships. Has it had any impacts on your relationships in 
this way? [prompt what about your your sex-life – has it affected that side of life?] 
24. Has the diagnosis and treatment changed the way you feel about yourself 
a) Mentally and physically 
Socialising 
25. Tell me about your social life [prompt- has this changed?] 
a) Did you find it difficult to do the things you would usually do? Did that 
change much during your treatment? 
26. What do you like to do in your spare time? 
a) Are you still able to do activities/pastimes that you enjoy? 
b) What are the things that make it easier/harder for you to do these pastimes?  
27. Some people have mentioned that they find it difficult to do the sports they used to- 
have you found this to be the case? [lack of energy or get up and go or mouth dryness 
being a problem] 
Work 
28. Have any problems arisen at work linked to your cancer treatment? 
Worries and concerns 
29. Do you have any particular worries or concerns? 
30. What (if anything) helps with dealing with these worries or concerns? 
31. How was your mood during your treatment? How is it now? 
The Future 
32. How do you feel about the future? 
33. What would you say your priorities are in life at the moment?  What would you have 
said if I’d asked that question before your illness and treatment? 
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Other issues 
34. As we discussed previously, the purpose of this research is to find out which 
outcomes of treatment are important and should be measured when we’re 
considering how effective a new treatment is. Today you mentioned difficulties 
with….. what would you say are the most important outcomes to you, could you list 
these in order? Are there any other outcomes that you think are important? 
35. Is there anything else that is important to you that we haven’t talked about today? 
36. Is there anything else you’d like to say 
………………………………………………………………………………………… 
Closing interview 
Thank you for spending time with me today. 
[Give out my contact details]
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Appendix 7 Patient and carer responses to interview questions, coding and categories 
‘Since your diagnosis and treatment has life changed for you? What ways has life changed?’ 
 
Respondent How has life changed Outcome or outcome domain Delphi question 
C3 Erm, no, not really, only cos I’ve thought 
I wouldn’t let it change you know… 
obviously me eating and things like that 
have changed, but I’ve tried to get 
everything back going to how it was 
before.  
Maintaining usual routine 
 
 
 
 
 
Difficulty eating and drinking 
 
 
The long-term impact of a 
treatment on the ability to carry 
out normal activities (e.g. 
hobbies, exercise, socialising or 
holidays) 
 
The risk of long-term difficulty 
swallowing associated with 
treatment (e.g. difficulties with 
propulsion of food, nasal 
regurgitation, aspiration or 
pharyngeal stenosis) 
 
The long-term impact of a 
treatment on diet 
 
C6 I haven’t got as much saliva as I did 
before.  My mouth opening, um, I have 
got a wonky smile, which ((laughs)) 
which I actually think is quite funny.  Um, 
and, you know, I get, like today, if I feel 
all here in my shoulders, from the 
Mouth dryness 
 
 
 
 
Trismus 
The risk of long-term mouth 
dryness and thickened 
secretions/saliva associated 
with a treatment 
 
The risk of long-term difficulty 
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treatment.  It gets stiff at times, and the 
scar itself can be quite, just stiff, not so 
much…  So you get reminded of it, but it's 
nothing to what it was.   
 
 
 
 
Asymmetrical smile 
 
 
 
Shoulder stiffness 
 
 
 
Scar 
 
 
 
 
 
 
Reminders of treatment 
opening the mouth or of pain in 
the jaw associated with 
treatment 
The long term risk of treatments 
altering a person’s physical 
appearance 
 
The long-term impact of a 
treatment on neck and shoulder 
movement and functioning 
 
The risk of permanent skin 
changes associated with 
treatment (e.g. pigmentation 
changes, telangiectasia, 
scarring, acne or 
photosensitivity) 
 
Multiple outcomes in this case 
are reminders, questions 
related to composite parts, no 
generic ‘reminder of treatment’ 
outcome 
C10 socially it’s practically non-existent, um, 
apart from family. Um, because I can’t eat 
and drink, um, so, er, we hardly, well we 
hardly go anywhere.    
Social isolation 
 
 
 
The long-term impact of a 
treatment on the ability to carry 
out normal activities (e.g. 
hobbies, exercise, socialising or 
259 
 
 
 
 
Um, and, um, it’s just, it is totally 
different because I loved eating and I 
loved drinking wine.   
I can’t eat with other people because it’s 
such a difficult thing.  And I certainly 
can’t talk when I'm eating.  
 
 
Um, the rest of it I still do what I used to 
do before, apart from exercise, because I 
used to run, um, I used to walk to work, 
um; I haven't got a job now.  I mean, life 
has changed.  Completely.  Um ((coughs)) 
but I still try and do most of the things 
that I used to do.  Um, but my mouth is so 
dry most of the time. 
 
 
 
Difficulty eating and drinking 
 
Loss of enjoyment of food 
 
Socialising with food 
 
Things going down the wrong 
way 
(triangulated from field notes 
and comparison with other 
responses, aspiration if 
eats/drinks and talks) 
 
Difficulty exercising because 
of mouth dryness 
 
 
 
 
 
 
 
 
 
Longer-term impact of 
holidays) 
 
The long-term effect of a 
treatment on the ability or 
desire to eat or drink in public 
and participate in social 
occasions that involve food 
 
The risk of long-term difficulty 
swallowing associated with 
treatment (e.g. difficulties with 
getting food down, or food 
going up or down the wrong 
way) 
 
The risk of long-term mouth 
dryness and thickened 
secretions/saliva associated 
with a treatment 
 
The long-term impact of a 
treatment on the ability to carry 
out normal activities (e.g. 
hobbies, exercise, socialising or 
holidays) 
 
The long-term impact of a 
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treatment on ability to return 
work 
 
Life has changed completely 
 
treatment on the ability to 
return to work 
 
Multiple outcomes in this case 
have been life changing, 
questions related to composite 
parts, no generic ‘life 
changing’ outcome 
C17 I’m on Megace for eating because I can’t 
eat if I don’t take Megace. And one of the 
side effects of Megace is insomnia.  
 
So I get up in the mornings and I’m 
fatigued but I can usually kind of get my 
act together and go do what I need to do. 
And I might be fine for 4, 5 hours and it’s 
like I hit a wall and then I just need to go 
to bed. Or I go to bed and I lay in bed 2 or 
3 hours, the frustration for that is I’ve 
always been an extremely athletic, active 
person playing in a tennis league, doing 
all sorts – I cannot plan to consistently do 
anything that requires a commitment of 
my energy and time. Physically can’t do it 
and I’m still in that boat of some fatigue 
every day, so that’s [whispers] REALLY 
ANNOYING!  
Long term impact of a 
treatment on appetite 
 
Difficulty maintaining weight 
 
 
 
 
 
 
 
Interrupted sleep 
 
 
 
 
 
 
 
The long-term impact of a 
treatment on appetite 
 
The long-term impact of a 
treatment on weight and the 
ability to maintain a steady 
weight 
 
The requirement for supportive 
treatment measures 
 
The long-term impact of a 
treatment on sleep (e.g. sleep 
interruption because of mouth 
dryness, altered secretions, 
pain or discomfort in the neck 
or shoulder or worries or 
concerns 
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Fatigue 
 
 
 
Loss of physical strength 
 
 
Purpose 
 
The risk of long-term fatigue or 
tiredness associated with 
treatment 
 
The long-term impact of a 
treatment on physical strength 
 
The long-term impact of a 
treatment on the ability to carry 
out normal activities (e.g. 
hobbies, exercise, socialising or 
holidays) 
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‘As we discussed previously, the purpose of this research is to find out which outcomes of treatment are important and should  be 
measured when we’re considering how effective a new treatment is. Today you mentioned difficulties with [name outcome(s)] what 
would you say are the most important outcomes to you, could you list these in order? Are there any other outcomes that you think are 
important? 
 
Respondent Outcomes of importance Outcome or outcome 
domain 
Delphi question 
C1 Saliva sucks, swallowing is awkward. 
Numbness not a big deal, it’s just there I 
mean I touch here and I feel it over there. 
So if I could rank them saliva. Saliva and 
fatigue. Those are the two. 
 
Mouth dryness 
 
 
 
 
Difficulty swallowing 
 
 
 
 
 
Numbness of skin 
(Triangulated from field 
notes, pointed to neck scar) 
 
Fatigue 
The risk of long-term mouth 
dryness and thickened 
secretions/saliva associated with a 
treatment 
 
The risk of long-term difficulty 
swallowing associated with 
treatment (e.g. difficulties with 
getting food down, or food going 
up or down the wrong way) 
 
The risk of long-term numbness 
of the skin of the ear/neck 
associated with treatment 
 
The risk of long-term fatigue or 
tiredness associated with 
treatment 
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C3 The dryness in me mouth is the biggest 
issue… as I said to you before, when you 
go out and you’re eating in company, you 
gotta be careful what you eat, that can be a 
bit embarrassing that’s erm… me arm and 
me shoulder 
 
Mouth dryness 
 
 
 
 
 
Difficulty swallowing 
 
 
 
 
 
Socialising with food 
 
 
 
 
 
 
Shoulder stiffness 
The risk of long-term mouth 
dryness and thickened 
secretions/saliva associated with a 
treatment 
 
The risk of long-term difficulty 
swallowing associated with 
treatment (e.g. difficulties with 
getting food down, or food going 
up or down the wrong way) 
 
The long-term effect of a 
treatment on the ability or desire 
to eat or drink in public and 
participate in social occasions 
that involve food 
 
 
The long-term impact of a 
treatment on neck and shoulder 
movement and functioning 
C14 Well I mean to surviving, and to get 
through, you have got to have nutrients 
haven't you to sort of like, to make you 
better.  Um, so I am pleased I had the PEG 
in 
 
Survival 
 
PEG 
How well the treatment prevents 
death from the cancer 
 
Some treatments are very toxic 
and carry a risk of death, how 
important is it that this risk from 
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treatment is measured? 
 
The effect of a treatment on the 
need for long-term regular 
enterostomy tube feeding 
 
C11 That’s the worst bit I think.  Talking to you 
I think my mouth’s dried up again.  Can 
you not tell my mouth’s, my speech is 
funny? 
Well I haven’t got any saliva… it means I 
don’t get a good night’s sleep.  Because 
when you wake up you imagine when 
((coughing)) (inaudible 41.39) and they 
say people stuck in the desert and their 
tongue’s stuck to their throat and there’s 
dryness everywhere and there’s nothing, 
and that’s just what it’s like.   
 
Mouth dryness 
 
 
 
Speech changes 
 
 
Interrupted sleep 
The risk of long-term mouth 
dryness and thickened 
secretions/saliva associated with a 
treatment 
The long-term impact of a 
treatment on speech and voice 
 
The long-term impact of a 
treatment on sleep (e.g. sleep 
interruption because of mouth 
dryness, altered secretions, pain 
or discomfort in the neck or 
shoulder or worries or concern 
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Appendix 8 Patient and carer information sheet (interviews, UK)
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Appendix 9 Patient interview consent (UK) 
 
                                        <<INSERT HOSPITAL HEADER HERE>> 
 
The CONSENSUS Study 
Squamous Cell CarcinOma of the OropharyNx: Late PhaSE CliNical TrialS; Core OUtcomeS 
Patient consent form: Interview 
 
    Please initial box 
1. I confirm that I have read and understand the information sheet dated ………. (Version 
…….) for the CONSENSUS study. I have had the opportunity to consider the 
information, ask questions and have these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving a reason, and without my care or legal rights being affected.   
 
3. I understand that audio-recordings of my interview will be used for the CONSENSUS 
study. I understand that brief quotations will be made as part of this study and that 
nobody will be able to identify any participants in these reports.  
 
4. I agree to the typed records of my interview being stored at the University of 
Liverpool for up to 10 years after the end of this study for checking purposes. I 
understand that these will be held securely and marked with a number only.  
 
5. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the University of Liverpool, from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking part in 
this research. I give permission for these individuals to have access to my medical 
records. 
 
6. I understand that the information gathered for this study may be looked at again in 
the future to help us answer other study questions. If so, an ethics committee will first 
review the study to ensure the information is used ethically. I give permission for 
future researchers to have access to this information. 
 
7. I would like to receive a summary of the findings at the end of the study.  Yes No 
8. I agree to take part in the above study.   
 
     
Name of participant 
 
 
 Date  Signature 
Name of researcher            Date            Signature 
 
When completed, 1 for participant, 1 for researcher’s file, 1 original to be kept in medical notes. 
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Appendix 10 Delphi letter of invitation 
 
 
[Patient address] 
[Date] 
Dear [Insert name], 
I hope this letter finds you well. It was lovely to speak to you on the phone this afternoon. 
Following on from our conversation, please find enclosed a copy of the questionnaire 
that I mentioned along with consent forms. 
We have conducted interviews with over thirty patients and carers, both in the UK and 
the USA and have found out lots about what things are important to people who, like 
you, have had oropharyngeal cancer. The survey we ask you to complete will help us 
figure out which are the top most important things to consider when testing out new 
treatments for oropharyngeal cancer. 
I wonder if you would mind having a look at the information sheet, survey and consent 
form included. If you are happy to complete this could you do so in the next couple of 
weeks and return the questionnaire to me, along with the signed consent form in the 
stamped, addressed envelope. 
Alternatively you could complete an online version of this survey if you would rather, if 
this is the case, please email me at aoife.waters@liverpool.ac.uk and I can send you a link 
to complete the questionnaire online. 
If you have any questions at all or would like to discuss anything either before or after 
completing the questionnaire, please don’t hesitate to get in touch at 
aoife.waters@liverpool.ac.uk or [phone number].  
I look forward to hearing from you and thank you again for taking part in this important 
research that we really hope will improve life for future patients being treated for 
oropharyngeal cancer. 
 
Best Wishes, 
 
Aoife  
Aoife Waters 
Clinical Research Fellow 
University of Liverpool
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Appendix 11 Delphi Patient and carer information sheet   
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Appendix 12 Delphi patient consent 
            
                              
CONSENSUS Study 
Squamous Cell CarcinOma of the OropharyNx: Late PhaSE CliNical TrialS; Core 
OUtcomeS 
Patient Consent Form: Delphi Survey 
Please initial box 
1. I confirm that I have read and understand the information 
sheet dated ………. (Version …….) for the CONSENSUS study. 
I have had the opportunity to consider the information, ask 
questions and have these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving a reason, 
and without my care or legal rights being affected.   
 
3. I understand that the information gathered for this study 
may be looked at again in the future to help us answer 
other study questions. If so, an ethics committee will first 
review the study to ensure the information is used 
ethically. I give permission for future researchers to have 
access to this information. 
 
4. I understand that relevant sections of my medical notes 
and data collected during the study may be looked at by 
individuals from the University of Liverpool, from 
regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give 
permission for these individuals to have access to my 
medical records. 
 
5. I would like to receive a summary of the findings at the end 
of the study.  
Yes No 
6. I agree to take part in the above study.   
 
     
Name of participant 
 
 
 Date  Signature 
Name of researcher            Date            Signature 
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Appendix 13 Delphi round one patient and carer survey 
 
 
Thank you for agreeing to take part in the CONSENSUS study, we value your contribution 
We would like to know which outcomes of treatment you feel are important, and should be 
measured in clinical trials for oropharyngeal cancer to discover which treatments are best.  
We appreciate that there are a huge number of short-term side-effects that may affect you during 
treatment and in the weeks to months following treatment, such as  neck, mouth and throat burns, 
bowel upset, loss of taste, difficulty swallowing, fatigue and nausea and vomiting, however these are 
generally well recorded in studies. Our main focus here is to find out about which long-term 
outcomes are important, i.e. those that last for years or even for the rest of your life, although we 
also ask about short-term effects below. 
To find out which outcomes are currently measured and important to patients and carers, we have: 
 looked at previous clinical trials and  
 conducted interviews with over 30 patients and carers  
When we did this we found the 50 outcomes listed below. Fifty outcomes would be too many for 
researchers to measure in clinical trials. In order to come up with a smaller list we now want to find 
out what people think are the top most important outcomes to measure.  We would like you to: 
 read through the list  
 consider the question at the start and then  
 score the importance of each outcome to you 
 
It should take about 15 minutes to complete the survey. 
 
Please remember that there are no right or wrong answers – it is your own opinion that we’re 
interested in. 
Even if you have never experienced the outcome, please try and think about how important knowing 
about this would have been in helping you make a decision about treatment. 
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There may be other outcomes that you think are important. If you would like to add any outcomes 
to the list please add them in the space provided at the bottom of the page.  
 
We have used plain English to describe outcomes with the medical language version in italics below, 
(if one exists). For some of the outcomes you can see a further explanation. 
 
Please provide the following details in order for us to contact you about the 2nd round of the 
survey 
Title  
Name  
 
Email 
address 
(or home 
address if 
you 
would 
like to 
complete 
a paper 
copy) 
 
 
Phone 
number 
 
 
Type of 
treatment 
 
 
 
Date 
treatment 
ended 
 
 
 
CONSENSUS Delphi Survey 
Please score all outcomes using the scoring system below. You may have no experience of many of 
the outcomes however we ask that you score how important you think these would be in helping 
you to decide between treatments.  
Scores range from not important (1) to critically important (9). Shade the box that you feel is 
appropriate. If you feel unable to comment, please select ‘Unable to score’.  
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Scoring system 
 
 
 
 
 
 
If you are unsure about what to do please contact aoife.waters@liverpool.ac.uk or [Phone number]. 
CONSENSUS Delphi Survey 
How important is it, on a scale of 1-9, that we measure the following outcomes in clinical trials of 
treatments for oropharyngeal cancer? 
 
1 2 3 4 5 6 7 8 9
Outcome
Importance
Not important Important but not critical Critical
Unable 
to score
This should be measured in 
clinical trials
This is important but it is not 
critical that it is measured in 
clinical trials
You are not concerned if this 
is measured in clinical trials
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1 2 3 4 5 6 7 8 9
Plain English 
term
The risk and severity of early side-effects 
associated with a treatment 
Explanation
There are a huge number of short-term side-
effects associated with treatment, how 
important are these in helping people to 
decide between treatments?
Medical term
The incidence and severity of early side-
effects  associated with a treatment (e.g. 
acute toxicities or complications)
12
Plain English 
term
Having to go into hospital to help deal with 
side-effects during treatment or when 
recovering from treatment 
13
Plain English 
term
The effect of a treatment on a person’s 
ability to carry out their own personal care 
(e.g. washing, dressing, meal preparation)
Plain English 
term
The long term risk of treatments altering 
how a person looks
Explanation
Sometimes people find that their 
appearance is altered following treatment, 
they may have lost weight, their neck may be 
thinner or they may have scars, one shoulder 
may sit lower than the other or they may 
have a facial droop
Medical term
The long-term risk of altered cosmesis, 
physical deformity or disfigurement 
associated with treatment 
Plain English 
term
The long-term impact of a treatment on hair 
growth
Explanation
Some people notice that their hair grows 
back thinner or a slightly different colour 
following treatment
Plain English 
term
The risk of permanent skin changes 
associated with treatment (e.g. redness or 
altered colour, broken veins, scarring, acne, 
increased sensitivity to the sun)
Medical term
The risk of permanent skin changes 
associated with treatment (e.g. pigmentation 
changes, telangiectasia, scarring, acne or 
photosensitivity)
Plain English 
term
The risk of long-term difficulty swallowing 
associated with treatment (e.g. difficulties 
with getting food down, or food going up or 
down the wrong way)
Medical term
The risk of long-term difficulty swallowing 
associated with treatment (e.g. difficulties 
with propulsion of food, nasal regurgitation, 
aspiration or pharyngeal stenosis)
Plain English 
term
The effect of a treatment on the need for 
long-term regular tube feeding 
Explanation
Sometimes people need long-term feeding 
through a tube in the nose or stomach wall 
following treatment
Medical term
The effect of a treatment on the need for 
long-term regular enterostomy tube feeding 
19
Plain English 
term
The long-term effect of a treatment on being 
able to/ wanting to eat or drink in public and 
take part in social occasions involving food 
Number
11
14
15
16
17
18
Terminology Outcome
Importance
Not important Important but not critical Critical Unable 
to score
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1 2 3 4 5 6 7 8 9
Plain English 
term
The long-term impact of a treatment on 
appetite
Explanation
Wanting to eat the same amount as before 
treatment
Plain English 
term
The long-term impact of a treatment on diet
Explanation
Being able to eat and drink the same things 
as a person did before treatment
22
Plain English 
term
The long-term impact of a treatment on a 
person’s enjoyment of food
Plain English 
term
The risk of long-term problems with mouth 
ulcers associated with treatment
Medical term
The risk of long-term problems with oral 
ulcers associated with treatment
Plain English 
term
The long-term effect of a treatment on the 
ability to breath normally
Explanation
Sometimes a person requires a tracheostomy 
or other surgery to help them breathe 
following treatment
Plain English 
term
The risk of long-term mouth dryness and 
thicker secretions/saliva associated with a 
treatment
Medical term
The risk of long-term xerostomia  and altered 
secretions associated with a treatment
Plain English 
term
The risk of long-term infection in the jaw 
bone associated with treatment
Explanation
Sometimes people can suffer from chronic 
infection and poor healing in the jaw bone 
that may require surgery
Medical term
The risk of osteoradionecrosis  associated 
with treatment
Plain English 
term
The risk of long-term difficulty opening the 
mouth or of pain in the jaw associated with 
treatment
Medical term
The risk of long-term trismus  or pain in the 
jaw  associated with treatment
28
Plain English 
term
The long-term impact of a treatment on 
tongue movement
29
Plain English 
term
The long-term impact of a treatment on 
speech and voice
Plain English 
term
The long-term impact of a treatment on 
sensation in the mouth and throat
Explanation
Sometimes people find that they are very 
sensitive to certain textures, flavours, spices, 
fizzy drinks and alcohol following treatment
25
26
27
24
30
21
23
Number
20
Terminology Outcome
Importance
Not important Important but not critical Critical Unable 
to score
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1 2 3 4 5 6 7 8 9
Plain English 
term
The long-term impact of a treatment on the 
skin that lines the mouth
Explanation
Sometimes people find that the skin lining 
the mouth is very sensitive following 
treatment and can become damaged very 
easily e.g. by eating a crispy baguette
Medical term
The long-term impact of a treatment on the 
integrity of the oral mucosa and lips
Plain English 
term
The long-term effect of a treatment on taste 
Explanation
Sometimes people find that their sense of 
taste never returns to normal
33
Plain English 
term
The risk of long-term fatigue or tiredness 
associated with treatment
34
Plain English 
term
The long-term impact of a treatment on 
physical strength
Plain English 
term
The long-term impact of a treatment on neck 
and shoulder movement and functioning
Explanation
Sometimes people find that they have 
stiffness of the neck and/or shoulder 
following treatment, this may give rise to 
weakness in the shoulder and/or difficulty 
using the arm
36
Plain English 
term
The long-term impact of a treatment on 
weight and the ability to maintain a steady 
weight 
Plain English 
term
The risk of long-term indigestion associated 
with treatment
Explanation
Sometimes people find that they get 
heartburn or that food doesn’t agree with 
them
Plain English 
term
The risk of long-term ear problems 
associated with treatment
Explanation
Sometimes treatments can cause fluid to 
build up in the ear which may occasionally 
lead to discomfort or pain, ear infections or 
hearing difficulties
Medical term
The risk of long-term Eustachian tube 
dysfunction  associated with treatment 
(causing glue ear +/- hearing difficulties)
Plain English 
term
The risk of permanent damage to the nerves 
which can lead to numbness and tingling, 
burning, stabbing or shooting pains in the 
hands or to hearing loss
Medical term
The risk of long-term neurotoxicity 
(peripheral neuropathy and ototoxicity) 
associated with treatment
Plain English 
term
The long-term impact of a treatment on 
eyesight
Explanation
Some people find that their eyesight 
fluctuates a lot during and after treatment
31
32
35
37
38
39
40
Number Terminology Outcome
Importance
Not important Important but not critical Critical Unable 
to score
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1 2 3 4 5 6 7 8 9
Plain English 
term
The long-term effect of a treatment on 
memory and cognition
Explanation
Some people find that their memory is 
poorer and that they have more difficulty 
taking information on board or organising 
their thoughts
Plain English 
term
The long-term impact of a treatment on 
psychological well-being
Explanation
Some people find that their mood can be 
quite low or they can be depressed, or they 
can become more anxious or emotional or 
find that they are more short-
tempered/irritable
Plain English 
term
The long-term impact of treatment on sleep 
Explanation
Sleep interruption because of mouth 
dryness, altered secretions, pain or 
discomfort in the neck or shoulder or 
because of worries or concerns
Plain English 
term
The risk of long-term neck swelling 
associated with treatment
Explanation
Some people find that fluid builds up in the 
neck following treatment as it does not drain 
normally
Medical term
The risk of long-term cervical lymphoedema 
associated with treatment
45
Plain English 
term
The risk of long-term numbness of the skin 
of the ear/neck associated with treatment
Plain English 
term
The risk of long-term hypothyroidism 
associated with treatment
Explanation
Following treatment the thyroid gland 
sometimes doesn’t work as well, this can 
make a person feel that their energy levels 
are very low
Plain English 
term
 The long-term impact of a treatment on 
body temperature
Explanation
Some people find that they can be either too 
hot or too cold and have difficulty controlling 
their body temperature following treatment
Medical term
The long-term impact of a treatment on 
thermoregulation
48
Plain English 
term
The long-term impact of a treatment on the 
ability to return to work
49
Plain English 
term
The long-term impact of a treatment on the 
ability to carry out normal activities (e.g. 
hobbies, exercise, socialising or holidays)
50
Plain English 
term
The long-term impact of a treatment on 
relationships (e.g. emotional, physical and 
sexual relationship with spouse or partner 
and relationships with other people)
47
46
44
43
42
41
Number Terminology Outcome
Importance
Not important Important but not critical Critical Unable 
to score
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Additional outcomes 
 
If there are other outcomes that you feel are important and missing from this list, please add them 
in the box below and score their importance on a scale of 1-9. 
 
 
Other comments 
 
 
 
Thank you for completing the survey. We will contact you by email or post in the next 6 
weeks or so to complete the second survey. We ask that you return this as soon as possible. 
 
Please note it is very important that you complete both rounds - your opinion really matters 
and cannot be counted if you only complete the first questionnaire. Having said that, you are 
free to pull out at any time and this will have absolutely no impact on your clinical care. 
Please return the completed questionnaire in the stamped, addressed envelope to: 
Dr Aoife Waters 
Department of Biostatistics 
University of Liverpool 
1st floor Duncan Building 
Daulby Street 
Liverpool, L69 3GA 
If you have any questions at all, please contact aoife.waters@liverpool.ac.uk or [Phone number]. 
1 2 3 4 5 6 7 8 9
Unable 
to score
Outcome
Importance
Not important Important but not critical Critical
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Appendix 14 Delphi patient and carer email invitation 
Dear [Insert name], 
 
 
 
 
 
 You have been contacted about this survey because you have had or are close to someone who 
has been treated for oropharyngeal cancer (cancer of the tonsil, tongue base or soft palate) 
 
 We would like to survey your opinions about which outcomes matter and should be measured 
in clinical trials of new treatments for oropharyngeal cancer. Your opinions will help us to 
improve clinical trials on oropharyngeal cancer  
 
 If you would like to take part in the survey or find out more about it, please follow the link [Insert 
link] and register. You will find more information about the CONSENSUS study and will be able to 
complete the survey 
 
You can find more information about outcomes and similar research at the COMET initiative 
website www.comet-initiative.org  
 
If you have any questions please contact Aoife Waters or Professor Terry Jones at 
aoife.waters@liverpool.ac.uk or T.M.Jones@liverpool.ac.uk  
 
Many thanks in advance for your contribution to this important research. 
Best Wishes, 
Aoife 
Aoife M I Waters MRCS DOHNS 
Clinical Research Fellow 
North West Hub for Trials Methodology Research 
University of Liverpool 
 
On behalf of the CONSENSUS Study Team (Drs Aoife Waters and Catrin Tudur-Smith and Professors 
Bridget Young and Terry Jones) 
 
       
 
You are invited to participate in a 15-minute online survey as part of the 
CONSENSUS study 
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Appendix 15 Development of Delphi Survey 
 
Comprehensive outcomes list 
Relates to 
Delphi 
question 
(number) 
Delphi Survey (Round 1) 
Acute toxicity 11 
1.       The effect of a treatment on controlling local disease 
recurrence 
Altered diet 11,21 
How well the treatment stops the cancer coming back in the same 
place e.g. tonsil, tongue base 
Altered secretions 11 
2.       The effect of a treatment on controlling regional disease 
recurrence 
Altered sensation in throat 30 
How well the treatment stops the cancer coming back in the lymph 
nodes in the neck 
Altered taste 32 
3.       The effect of a treatment on controlling distant disease 
recurrence 
Angular stomatitis 16 
How well the treatment stops the cancer coming back in other parts 
of the body e.g. lungs, brain, liver 
Anxieties/ concerns 42 4.       The effect of a treatment in preventing death from cancer 
Aspiration 17 How well the treatment prevents death from the cancer 
Asymmetrical smile 14 5.       The risk of death from treatment 
Avoiding oral sex because of HPV 50 
Some treatments are very toxic and carry a risk of death, how 
important is it that this risk from treatment is measured? 
Bad breath 25 6.       The effect of a treatment on the risk of death from any cause 
Being able to care for yourself 13 7.       The effect of a treatment on health-related quality of life 
Being able to look after children 49 The impact of a treatment on a person’s general quality of life 
Bowel upset 11 
8.       The requirement for dental extractions in the course of 
treatment 
Cancer spreading 4 
The requirement for unhealthy teeth to be removed in the course of 
treatment 
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Cataracts 40 
9.       The requirement for supportive treatment measures (e.g. 
analgesics, antibiotics, feeding enterostomy, tracheostomy) 
Cough 4 
The need for additional treatments to get a person through the 
cancer treatment e.g. pain killers, antibiotics, tube feeding, 
tracheostomy 
Death from treatment 25 
10.   The need for additional surgery or invasive procedures as a 
consequence of treatment (e.g. pharyngeal dilatations, further 
reconstructive surgery) 
Dehydration 5 
The need for additional surgery or invasive procedures as a 
consequence of treatment (e.g. throat stretches, further surgery to 
treat complications) 
Dental extractions 11 
11.   The risk and severity of early side-effects associated with a 
treatment (e.g. acute toxicities or complications) 
Depression 8 
The risk and severity of early side-effects associated with a 
treatment 
Difficult recalling words 42 
(There are a huge number of short-term side-effects associated with 
treatment, how important are these in helping people to decide 
between treatments?) 
Difficulty breaking up food 41 
12.   The need for hospitalisation to help deal with side-effects 
during treatment or recovery from treatment  
Difficulty breathing 
8, 
25,27,28 
13.   The effect of a treatment on a person’s ability to carry out their 
own personal care (e.g. washing, dressing, meal preparation) 
Difficulty controlling blood sugars 11,24 
14.   The long-term risk of altered cosmesis, physical deformity or 
disfigurement associated with treatment 
Difficulty eating and drinking 17 
The long term risk of treatments altering a person’s physical 
appearance 
Difficulty exercising because of fatigue 17 
(Sometimes people find that their appearance is altered following 
treatment, they may have lost weight, their neck may be thinner or 
they may have scars, the shoulder may sit lower than the other or 
they may have a facial droop) 
Difficulty exercising because of mouth 33,49 15.   The long-term impact of a treatment on hair growth 
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dryness 
Difficulty maintaining weight 25,49 
(Some people notice that their hair grows back thinner or a slightly 
different colour following treatment) 
Difficulty swallowing 36 
16.   The risk of permanent skin changes associated with treatment 
(e.g. pigmentation changes, telangiectasia, scarring, acne or 
photosensitivity) 
Disease-free survival 1,2,3,4 
The risk of permanent skin changes associated with treatment (e.g. 
redness or altered colour, broken veins, scarring, acne, increased 
sensitivity to the sun) 
Disease-specific survival 4 
17.   The risk of long-term difficulty swallowing associated with 
treatment (e.g. difficulties with propulsion of food, nasal 
regurgitation, aspiration or pharyngeal stenosis) 
Early death 5 
The risk of long-term difficulty swallowing associated with treatment 
(e.g. difficulties with getting food down, or food going up or down 
the wrong way) 
Emotional relationship with partner 50 
18.   The effect of a treatment on the need for long-term regular 
enterostomy tube feeding  
Event free survival 1,2,3,4,5,6 
The effect of a treatment on the need for long-term regular tube 
feeding  
Fatigue 11,33 
(Sometimes people need long-term feeding through a tube in the 
stomach wall following treatment) 
Feeling dizzy 11 
19.   The long-term effect of a treatment on the ability or desire to 
eat or drink in public and participate in social occasions that involve 
food  
Feeling ill 11 20.   The long-term impact of a treatment on appetite 
Fluctuating vision 40 (Having the desire to eat the same amount as before treatment)  
Food coming up later 17 21.   The long-term impact of a treatment on diet 
Food intolerance 11,30 
(The ability to eat and drink the same things as a person did before 
treatment) 
Food sticking 17 22.   The long-term impact of a treatment on the enjoyment of food 
Gastrostomy tube 11,18 23.   The risk of long-term problems with oral ulcers associated with 
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treatment 
Glue ear 38 
The risk of long-term problems with mouth ulcers associated with 
treatment 
Hair loss 11,15 
24.   The long-term effect of a treatment on the ability to breath 
independently 
Having blood taken  9,10 
(Sometimes a person requires a tracheostomy or other surgery to 
help them breathe following treatment) 
Heightened sensitivity in mouth 11 
25.   The risk of long-term xerostomia and altered secretions 
associated with a treatment 
Hospitalisation for symptom control 12 
The risk of long-term mouth dryness and thickened secretions/saliva 
associated with a treatment 
Hospitalization 12 
26.   The risk of long-term osteoradionecrosis associated with 
treatment 
HR- QOL 7 
The risk of long-term infection in the jaw bone associated with 
treatment 
Hypothyroidism 46 
(Sometimes people can suffer from chronic infection and poor 
healing in the jaw bone that may require surgery) 
Impact on carer 50 
27.   The risk of  long-term trismus or pain in the jaw associated with 
treatment 
Interrupted sleep 43 
The risk of long-term difficulty opening the mouth or of pain in the 
jaw associated with treatment 
Jaw ache 27 28.   The long-term impact of a treatment on tongue movement 
Lack of appetite 11, 20 29.   The long-term impact of a treatment on speech and voice 
Lack of motivation 33 
30.   The long-term impact of a treatment on sensation in the mouth 
and throat 
Laryngeal oedema 11 
(Sometimes people find that they are very sensitive to certain 
textures, flavours, spices, fizzy drinks and alcohol following 
treatment) 
Late toxicity 
7,10,14-
47 
31.   The long-term impact of a treatment on the integrity of the oral 
mucosa and lips 
Less patient 42 The long-term impact of a treatment on the skin that lines the 
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mouth 
Less sex with partner 50 
(Sometimes people find that the skin lining the mouth is very 
sensitive following treatment and can become damaged very easily 
e.g. by eating a crispy baguette) 
Less strength in jaw to chew 27 32.   The long-term effect of a treatment on taste  
Life has changed completely 49 
(Sometimes people find that their sense of taste never returns to 
normal) 
Local and regional recurrence 1,2 
33.   The risk of long-term fatigue or tiredness associated with 
treatment 
Local control 1 34.   The long-term impact of a treatment on physical strength 
Loco-regional control 1,2 
35.   The long-term impact of a treatment on neck and shoulder 
movement and functioning 
Locoregional progression 1,2 
(Sometimes people find that they have stiffness of the neck and/or 
shoulder following treatment, this may give rise to weakness in the 
shoulder and/or difficulty using the arm) 
Locoregional recurrence-free survival 1,2 
36.   The long-term impact of a treatment on weight and the ability 
to maintain a steady weight  
Longer-term impact of treatment on ability 
to return work 
48 37.   The risk of long-term indigestion associated with treatment 
Longterm oral ulcers 23 
(Sometimes people find that they get heartburn or that food doesn’t 
agree with them)  
Long-term skin changes 16 
38.   The risk of long-term Eustachian tube dysfunction associated 
with treatment (causing glue ear +/- hearing difficulties) 
Loss of confidence 42 The risk of long-term ear problems associated with treatment  
Loss of earnings 48 
(Sometimes treatments can cause fluid to build up in the ear which 
may occasionally lead to discomfort or pain, ear infections or 
hearing difficulties) 
Loss of enjoyment of food 22 
39.   The risk of long-term neurotoxicity (peripheral neuropathy and 
ototoxicity) associated with treatment 
Loss of libido 50 
The risk of permanent damage to the nerves which can lead to 
numbness and tingling, burning, stabbing or shooting pains in the 
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hands or to hearing loss 
Loss of physical strength 34 40.   The long-term impact of a treatment on eyesight 
Low mood 42 
(Some people find that their eyesight fluctuates a lot during and 
after treatment) 
Lymphoedema 44 41.   The long-term effect of a treatment on memory and cognition 
Maintaining usual routine  48,49 
(Some people have found that their memory is poorer and that they 
have more difficulty taking information on board or organising their 
thoughts) 
Medication to counter medication 9 
42.   The long-term impact of a treatment on psychological well-
being 
Metastases 3 
(Some people find that their mood can be quite low or they can be 
depressed, or they can become more anxious or emotional or find 
that they are more short-tempered/irritable) 
More difficulty organising tasks 41 
43.   The long-term impact of a treatment on sleep (e.g. sleep 
interruption because of mouth dryness, altered secretions, pain or 
discomfort in the neck or shoulder or worries or concerns) 
More easily agitated 42 
44.   The risk of long-term cervical lymphoedema associated with 
treatment 
More emotional 42 The risk of long-term neck swelling associated with treatment 
More sensitive to the cold 47 
(Some people find that fluid builds up in the neck following 
treatment as it does not drain normally) 
Mouth dryness 11,25 
45.   The risk of long-term numbness of the skin of the ear/neck 
associated with treatment 
Mouth surface raw 31 
46.   The risk of long-term hypothyroidism associated with 
treatment 
Mucositis 11 
(Following treatment the thyroid gland sometimes doesn’t work as 
well, this can make a person feel that their energy levels are very 
low) 
Nasal regurgitation 17 47.   The long-term impact of a treatment on thermoregulation 
Nausea and vomiting 11 The long-term impact of a treatment on body temperature 
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Neck discomfort 35 
(Some people find that they can be either too hot or too cold and 
have difficulty controlling their body temperature following 
treatment) 
Neutropenic sepsis 11 
48.   The long-term impact of a treatment on the ability to return to 
work 
NG feeding/ drinking shakes 9 
49.   The long-term impact of a treatment on the ability to carry out 
normal activities (e.g. hobbies, exercise, socialising or holidays) 
Numbness ear/face 45 
50.   The long-term impact of a treatment on relationships (e.g. 
emotional, physical and sexual relationship with spouse or partner 
and relationships with others) 
Nutritional toxicity 11 
 
Oesophageal stricture  10,17 
 
Opioid dependance 9 
 
Oral candida 11 
 
Oral hygiene 25 
 
Oral pain 11 
 
Organ preservation rate 17,25 
 
Osteoradionecrosis 26  
Overall control rate 6 
 
Overall Survival 6 
 
Passing HPV on to partner 50 
 
Pathological response 1,2 
 
PEG 18 
 
Poorer concentration 41 
 
Poorer healing 16  
Poorer memory 41 
 
Progression-free survival 1,2,3,4 
 
Purpose 49 
 
Quality of life 7 
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Radiation dermatitis 11 
 
Recurrence 1,2,3,4 
 
Reduced oral intake 11 
 
Reflux 37 
 
Regional recurrence 2 
 
Relapse 1,2,3 
 
Reminders of treatment 10,14,16 
 
Response 1,2,3 
 
Scar 14, 16 
 
Shoulder ache 35 
 
Shoulder asymmetry 14,35 
 
Shoulder weakness 35 
 
Smell of tumour breakdown 11 
 
SNHL 11,39 
 
Social isolation 11,50 
 
Socialising 49,50 
 
Socialising with food 19 
 
Speaking exhausting 25 
 
Speech changes 29 
 
Spottier skin 16 
 
Suicidal ideation 11 
 
Support from others 50 
 
Surgical clips 11 
 
Survival 4,5,6 
 
Taking a long time to eat 17 
 
Things going down the wrong way 17 
 
Thinner hair 14 
 
Thread veins 16 
 
Throat discomfort 30 
 
Throat feels smaller 30 
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Time to progression 1,2,3 
 
Time to treatment failure 1,2,3,4 
 
Tongue protrusion reduced 28 
 
Tracheostomy 11,24 
 
Treatment not being invasive 10 
 
Trismus 27 
 
Voice deeper 29 
 
Voice quieter 29 
 
Weight loss 11,14,36 
 
Wound dehisence 11 
 
Wrinkles 16 
 
Mouth dryness 25 
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Appendix 16 Distribution of scores for all outcomes 
 
